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Worldwide millions of elderly and their relatives suffer from the devastating effects of dementia, 
with Alzheimer’s disease (AD) as its most common cause.1 Age is its main risk factor, and as the 
worldwide average life expectancy is increasing, the incidence of dementia is expected to rise. 
Clinically, AD is characterized by a progressive loss of episodic memory in combination with 
impairment in other cognitive domains and behavioral changes. Eventually severe loss of 
cognition leaves the patient completely dependent, with death occurring on average nine years 
after manifestation of the first symptoms. As a result, AD represents an important socio-
economic and public health concern.2 Unfortunately, an effective therapy is currently not 
available, which is due to our incomplete understanding of the pathogenesis of AD. Our inability 
to detect the disease at its early stages prevents furthering our insight into the pathogenesis 
on the one hand, and on the other it prevents us to detect the disease at a stage early enough 
to expect a beneficial effect of treatment. Nowadays, a definitive diagnose of AD still requires 
an autopsy. Therefore, novel diagnostic methods are warranted that are capable of obtaining 
a definite diagnosis during life and preferably as early in the disease process as possible.
Pathogenesis
Microscopic examination of AD brain tissue typically reveals the presence of both extracellular 
deposits of fibrillar amyloid-β peptides and intracellular neurofibrillary tangles in the medial 
temporal lobe structures and cortical areas of the brain in combination with a deterioration of 
neurons and synapses. (Figure 1.1) These changes are assumed to play a vital role in the 
pathogenesis of the disease.
Neurofibrillary tangles
Neurofibrillary tangles (NFTs) consist of abnormally phosphorylated tau proteins that 
predominantly accumulate in neurons. Normally, tau proteins promote the assembly of 
microtubule and their stability, and as such they are involved in structural and regulatory 
functions of the cytoskeleton.3,4 However, when tau becomes hyperphosphorylated it exerts 
the exact opposite effect, leading to the disassembly of the same microtubules. The resulting 
Figure 1.1 Neuropathological 
characteristics of Alzheimer’s 
disease
AD is neuropathologically hall marked 
by the cortical deposition of amyloid-β 
peptides into amyloid or senile 
plaques that are surrounded by 
neurofibrillary tangles present in the 
axons and neuronal cell bodies.
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loss of neuronal structure impairs axonal transport, thereby disturbing proper synaptic and 
neuronal signaling.3 In addition, as hyperphosphorylated tau tends to aggregate into insoluble 
filaments, it becomes sequestered into NFTs deposited in neurons and neuronal processes, 
also known as neuropil threads. These NFTs further disrupt normal neuronal function and 
eventually lead to neuronal death. 
Although tau-pathology is observed within several neurodegenerative disorders3, its 
characteristic topographical spreading observed in AD led to the description of a histological 
staging of the disease by Braak and Braak.5 This AD staging sequentially describes the 
involvement of the transentorhinal and enthorhinal cortex (stage I and II), the hippocampus 
(stage III and IV), and finally the isocortex (stage V and VI). Of all pathological hallmarks, tau 
pathology has shown the best clinicopathological correlation in AD patients.6 However, the 
pathophysiological role of hyperphosphorylation and tangle formation is still incompletely 
understood.
Deposition of amyloid-β
Amyloid-β (Aβ) peptide is generated by proteolytic cleavage of a transmembrane protein, 
amyloid precursor protein (APP), by β- and γ-secretase to form predominantly Aβ1-40 or Aβ1-42. 
Under normal conditions, cerebral Aβ is either degraded or cleared from the brain by a balanced 
process of influx and efflux across the blood-brain barrier (BBB). According to the amyloid 
cascade hypothesis, AD is initiated by an imbalance in Aβ production and clearance.7,8 This is 
supported by observations in familial AD, accountable for < 5% of all cases, in which mutations 
in the genes encoding for APP or parts of the secretase complexes cause Aβ overproduction. 
In the majority of cases, so called sporadic AD, a failure of Aβ clearance is thought to gradually 
increase cerebral levels of Aβ over time. 
Its fibrilogenic nature causes high local concentrations of Aβ1-42 to aggregate, first into soluble 
oligomers. These eventually cluster into larger insoluble Aβ fibrils that allow the formation of 
β-sheet structures characteristic for amyloid. Serving as a seeding point this triggers the 
misfolding of other Aβ species, including the more soluble Aβ1-40. 
Histologically, Aβ deposits in the brain parenchyma can be classified into two distinct types: 
non-neuritic (diffuse) or neuritic (senile) Aβ plaques. Diffuse plaques typically only show up on 
Aβ immunohistochemistry, whereas no amyloid structure is detected by Congo red of Thioflavin 
staining.9 In contrast, senile plaques consist of an amyloid core of predominantly Aβ1-42 
surrounded by a neuritic corona baring degenerative synaptic endings with hyperphosphorylated 
tau, together with activated astrocytes and microglia.9
In addition, deposits of amyloid, mainly Aβ1-40, can also be found in the cerebral vessel wall 
where it leads to a loss of structure and rigidity. This so-called cerebral amyloid angiopathy 
(CAA) can occur by itself without any parenchymal involvement, and is considered a major cause 
of cerebral microbleeds, hemorrhages and cognitive loss. In 90% of all cases, however, AD and 
CAA are concomitant.10
Similar to tau, the presence of Aβ deposits can be staged based on the spread of cortical 
involvement: (A) only basal portions of the isocortex; (B) throughout the isocortex except the 
primary cortices and with the hippocampus mildly affected; (C) the entire isocortex.5 A correlation 
between cerebral Aβ accumulation and cognitive status has been shown, albeit less significant 
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in comparison to tau. However, the soluble pool of (oligomeric) Aβ are thought to contribute 
more to Aβ-mediated pathology than the histological insoluble Aβ deposits; and the occurrence 
of oligomers has been shown to correlate better with the cognitive status.11
Hypothetical models
Based on observations in large-scale post-mortem studies in the general aging population, the 
AD induced neurodegeneration is estimated to start two decades before clinical onset and is 
thought to have reached a plateau at the time of clinical presentation.12,13 (Figure 1.2) The exact 
underlying pathogenesis responsible for the Aβ imbalance, the hyperphosphorylation of tau 
and their intimate association remains one of the major unresolved questions regarding AD. 
What triggers their formation and is their presence a cause or only a consequence of the 
disease? Besides the aforementioned amyloid cascade hypothesis, some claim that the 
dyshomeostasis of cerebral iron plays an intricate and crucial role. Increased cortical 
accumulation of iron is often found within the premises of the amyloid plaques. As its presence 
is known to lead to formation of reactive oxygen species that induce neurotoxicity, this could 
eventually lead to neuronal cell death and loss of cognitive function. Interestingly, not only APP 
and Aβ but also tau is involved in the chelation and transport of cerebral iron. Others go one 
step further: as iron is essential for the enzymes responsible the maintenance of myelin 
structure and integrity, they have suggested that a mismatch in de- and remyelination might 
change iron homeostasis leading to increased iron deposition, which, subsequently, could lead 
to increased production of Aβ and tau.14 However, as yet no clear single explanation regarding 
the pathogenesis of AD has been found.
Diagnosis
At present, the definite diagnosis of AD can only be made based on microscopical detection of 
Aβ and NFTs in brain tissue, which in general happens at autopsy. Clinically, the diagnosis 
“probable AD” can be made at best based on criteria set by the Diagnostic and Statistical Manual 
of Mental Disorders (DSM IV) and the NINCDS-ADRDA (National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association).15 These criteria require a detailed (hetero) anamnestic assessment of the type and 
course of symptoms, while other somatic causes of dementia, such as cerebral infarcts, 
neoplasms or hypothyroidism, have to be excluded. Clinically, AD is characterized by progressive 
loss of memory and gradual decline of other cognitive domains affecting social and occupational 
functioning. Typically, the symptoms start with isolated short-term memory loss. Over time, 
long-term memory becomes involved too. Characteristically for AD, long-term memory loss 
occurs in a retrograde manner with early memories being preserved longer than recent ones. 
Apart from memory loss, apathy occurs as well as cognitive loss in other domains resulting in 
difficulties in speech (aphasia), practical skills (apraxia), recognition (agnosia) and/or executive 
functions. As a result, patients become restricted in their activities of daily living (ADL) and lose 
their ability to safely support themselves, which eventually leaves them fully dependent on 
family or institutionalized care. 
The criteria developed by NINCDS-ARDA provide a clinical diagnostic tool with a relatively high 
sensitivity and specificity (>80%) to distinguish AD patients from elderly people without dementia. 
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Figure 1.2 A theoretical model of the natural progression of cognitive and biological markers of Alzheimer’s disease 
(reprinted and adapted with permission13) 
(A) Regarding cognition the memory tests are among the first to change (1). As they quickly reach their maximal level of 
impairment (2), they are useful for diagnosis at MCI, but are less adequate to track disease progression (3). Later in the 
disease, the language comprehension starts to change with mild or no impairment during MCI (4), and a steep increase 
during dementia (5). (B) Amyloid markers, e.g. [Aβ42] in the cerebral spine fluid and amyloid PET, represent the earliest 
detectable changes in AD, but plateau at the MCI stage. Metabolic and functional biomarkers, like 18F-FDG PET and fMRI, are 
abnormal at the MCI stage, and continue to change far into the dementia stage. Cerebral atrophy appears later and follows 
a temporal pattern mirroring the deposition of tau pathology.
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Using these criteria, the distinction between AD and other neurodegenerative dementias 
however is less accurate (23–88%).16 In an earlier stage of the disease when objective memory 
complaints are present but daily functioning remains normal and other cognitive domains are 
still intact, subjects qualify for the diagnosis mild cognitive impairment (MCI). However, not all 
MCI subjects are believed to have AD and to develop dementia later in life. (Figure 1.2) 
The role of imaging biomarkers in AD
Although its precise etiology remains unknown, the onset of AD is assumed to start two decades 
before the induced neuronal damage has reached a sufficient level to lead to noticeable clinical 
symptoms.12,13 Our incomplete understanding of the pathophysiology of AD is partly to be 
blamed on our inability to detect the early phases of the disease reliably in vivo, and our lack 
of understanding of the pathophysiology of AD is a major hurdle in developing effective 
treatment. Apart from being instrumental to the development of AD treatment, having early 
markers of the disease is also relevant since it would allow distinguishing among elderly 
individuals with memory loss between those in whom this symptom is an early manifestation 
of AD and progression to dementia can be expected from those in whom functional loss is not 
expected to spread to other cognitive domains or when other diseases than AD play a role. 
Furthermore, once effective treatment will be available, it would be useful to detect even earlier, 
preferably presymptomatic, stages of the disease, in order to have a wider time window for 
treatment. Finally, a test that would allow for detection of the early stages of the disease would 
also be a very useful tool to assess the efficacy of candidate treatment in trials. 
In general such a diagnostic method or so-called biomarker refers to an objectively measurable 
physiologic, biochemical, or anatomic parameter that represents a (patho)physiologic process 
or a therapeutic response.17 In search of a biomarker for AD major efforts have been made to 
develop methods that allow non-invasive in vivo detection of AD-specific changes using 
neuroimaging techniques. 
Structural, functional and metabolic neuroimaging techniques
Initially CT and MRI scans of the brain were just used in patients with dementia to detect possible 
treatable causes of the symptoms, such as subdural hematomas and meningiomas, but not 
for the detection of the more prevalent neurodegenerative disorders in such patients. Later, 
these techniques were used to detect radiological manifestations of these neurodegenerative 
diseases. In AD patients structural MRI studies revealed specific patterns of regional cerebral 
atrophy. Severity of atrophy was observed to correlate well with loss of cognitive function as 
well as with post-mortem Braak staging. Of all putative biomarkers, volumetric measures of 
hippocampal and medial temporal lobe atrophy showed the best correlation with the severity 
of clinical symptoms. According to the dynamic biomarker model (Figure 1.2), however, brain 
atrophy is a late stage event, and therefore structural MRI may not be the method of choice for 
early or pre-symptomatic diagnosis.
In addition to brain atrophy, the feasibility to detect the histological hallmarks of AD using MRI 
has also been explored. In general these efforts have focused on detecting individual amyloid 
plaques. Recently it was demonstrated that increased iron accumulation in amyloid plaques 
combined with the aggregated protein itself induce a magnetic susceptibility effect, visible as 
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hypointense foci on T2*-weighted or susceptibility-weighted (SW) MRI in the cerebral cortex of 
transgenic AD mouse models and in human post-mortem brain slices.18-20 The high magnetic 
field strengths needed to obtain these results only recently became available for in vivo human 
use. These high field whole body human MRI systems (≥7 Tesla) may offer new possibilities to 
specifically detect these neuropathological hallmarks of AD; perhaps even at an earlier stage 
than the traditional MRI biomarker of brain atrophy.
Besides these conventional MRI techniques the versatile character of MRI offers additional 
possibilities to study changes caused by AD, as has been extensively reviewed elswhere.21-23 
In short, functional MRI (fMRI) reflects brain activation when a specific task is performed, and 
in subjects at risk to develop AD fMRI discovered areas of hyperactivation following specific 
tasks. Using task-free resting state fMRI a decrease in activity of the brain’s default functional 
network was seen in AD subjects. Additionally, specific regions of cerebral hypoperfusion were 
found in relation to AD using non-invasive arterial spin labeling MR perfusion techniques. 
Whereas microstructural changes due to AD may not be directly visible, their effect on bulk MR 
signal could allow detection by quantitative MRI techniques, as shown by initial studies using 
magnetic transfer imaging (MTI), diffusion tensor imaging (DTI) and MR relaxometry. Finally, 
changes in brain metabolites have been observed in AD subjects as MR spectroscopy revealed 
a consistent decrease in myo-inositol combined with elevated levels of N-acetylaspartate (NAA). 
Although these MRI techniques just recently gained much interest, currently none has been 
characterized and validated well enough yet to be included as a neuroimaging biomarker for 
AD.  
Molecular imaging techniques
Direct visualization of the histological hallmarks of AD has been attempted by the application 
of molecular imaging strategies. These strategies aim for the in vivo imaging of specific molecular 
or cellular signatures of the disease with the aid of targeted contrast agents. Thus far two 
molecular imaging strategies have been developed for AD: detection of glucose hypometabolism 
using 18F- fluorodeoxyglucose (FDG) PET, and visualization of cerebral amyloid load by radioactive 
PET ligands. FDG-PET reflects brain metabolism, which in general is a function of neuronal or 
synaptic activity. Typically for AD is a decrease in FDG uptake in the lateral temporal-parietal, 
posterior cingulate and precuneus regions that indicates impaired neuronal activity in these 
areas.12 Even when corrected for brain atrophy these patterns of glucose hypometabolism were 
seen. Despite the fact that these patterns of glucose hypometabolism occur prior to the 
development brain atrophy detectable on neuroimaging, following the amyloid cascade 
hypothesis their specificity is limited and they are considered a relatively late phenomenon. 
Therefore major efforts have been made to develop imaging agents that specifically bind to 
AD’s neuropathological hallmarks. Based on known histological amyloid dyes, like Congo Red 
and Thioflavin, various radioactive contrast agents have been synthetized for the in vivo detection 
of cerebral amyloid by either PET or SPECT imaging. The initial in vivo breakthrough came with 
the development of Pittsburgh Compound B (PiB), a neutral 11C derivative of Thioflavin.24 Despite 
many in vivo human studies its broad applicability is hampered by its short radioactive half-life 
(<20min), requiring the availability of a cyclotron and therefore its application is mainly limited 
to research. Another limitation of PiB PET imaging is the inability to distinguish between Aβ 
CHAPTER 1
16  |.
deposits in parenchymal plaques and in the vessel wall (as in CAA). Thus, Aβ targeting imaging 
techniques are needed that can be performed on widespread neuroimaging platforms and 
that are able to discriminate between the different types of Aβ deposits.
Aim of this thesis
This thesis is aimed at the development of innovative diagnostic imaging techniques to detect 
the histological signatures of AD using emerging ultra-high field MRI technologies and molecular 
imaging strategies. The work in this thesis comprises two complementary parts.
Part One aims at developing novel MRI techniques for the in vivo detection of cortical changes 
in AD exploiting innovative ultra-high field MRI technology (7 Tesla). Initially, we focused on 
developing techniques optimized for tissue iron detection at ultra-high magnetic field. Then we 
strived to obtain a better understanding of the source of native MRI contrast changes specific 
for AD neuropathology by studying post-mortem AD tissue at experimental MRI systems with 
optimized MR techniques and by systematically comparing MRI and histological data.
The main objective of Part Two is the detection of Aβ deposits using targeted contrast agents. 
Firstly, we aimed at developing imaging probes that allow distinguishing specific types of Aβ 
deposition, e.g. vascular versus parenchymal, based on llama antibody fragments.  Secondly, 
we aimed at improving small amyloid binding molecules to serve as in vivo imaging probes for 
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Abstract
Over recent years, magnetic resonance imaging (MRI) has become an essential tool for the 
investigation of human brain disease. This chapter describes some of the principal MRI methods 
that are currently used for neuroimaging: T1, T2, susceptibility-contrast, diffusion and 
magnetisation transfer imaging. The mechanisms underlying the sensitivity of these techniques 





The present review will be restricted to the most common and for this thesis relevant 
applications of magnetic resonance imaging (MRI) in the brain, namely the depiction of 
hydrogen nuclei (protons) of mobile water molecules. The utility of MRI with respect to disease 
lies in the sensitivity of the technique to both micro- and macroscopic molecular motions. 
Nervous tissue consists of 70-80% water by weight, these water molecules being distributed 
through a variety of microscopic environments and physiological compartments. It is possible 
to generate MR images whose contrast reflects, amongst other factors, random molecular 
rotational motions (T1 and T2), random translational motion (diffusion), exchange with 
macromolecular protons (MTC) and blood flow (perfusion). The concentration and mobility of 
water molecules is modified in many pathologies and this is the basis of the high sensitivity of 
MRI to cerebral disease processes.
Furthermore, MRI contrast agents can also change these parameters allowing detection. In 
recent years this led to the emerging field of molecular and cellular imaging, where contrast 
agents targeted against disease-specific hallmarks or cells labelled with such agents are explored 
for early diagnostics and therapy follow-up. Also within the field of experimental neuroimaging 
this has taken a leap. A more extensive review is given in Chapter 7.
Biophysical background and methods
Some important principles are discussed here to provide a background for the rest of this 
article. For a more detailed introduction to MRI the reader is refer to various excellent 
textbooks.1,2  Protons possess a nuclear magnetic moment (or ‘spin’). In the absence of an 
external magnetic field these magnetic moments are randomly distributed in every direction. 
In the presence of a magnetic field however, a thermal equilibrium is achieved between spins 
oriented parallel and antiparallel to the magnetic field. The result is a net macroscopic magnetic 
moment, the bulk magnetisation (M0), orientated in the direction of the external field 
(conventionally taken to be the z-axis). The individual spins precess around the z-axis at 
the Larmor frequency (ω, rad s-1), which is proportional to the external magnetic field (B0, Tesla):
ω = γB0                                                                                                             [2.1]
where γ is a constant called the gyromagnetic ratio (26.751 107 rad T-1 s-1 for protons). 
Relaxation 
M0 is proportional to the total number of protons present in the sample, and hence is also 
called the proton density. To be able to distinguish the magnetisation M0 from the external 
magnetic field, M0 is rotated by 90° into the transverse (xy) plane using a radiofrequency (RF) 
pulse at the Larmor frequency. Immediately following this 90° pulse, the initial magnetisation 
level can be detected. In time, the thermal equilibrium is restored, and the magnetisation vector 
returns to the z-axis. The characteristic times involved in this process are the spin relaxation 
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times: longitudinal relaxation time (T1) for the restoration of the magnetisation along the z-axis, 
and the transverse relaxation time (T2) for the decay in the xy-plane. (Figure 2.1)
T2 and T2* 
The transverse relaxation time T2 is also called the spin-spin relaxation time, referring to the 
molecular interactions behind the transverse relaxation process. The protons experience 
intramolecular dipolar interactions between two protons within the same molecule, as well as 
intermolecular interactions with protons of neighbouring molecules. This interaction becomes 
more efficient when the contact time between protons is relatively long, e.g. in viscous media. 
When the rotational correlation time of the molecules is short, as is the case for free water 
molecules, T2 is relatively long (~ 3 sec). Water molecules interacting with macromolecules or 
solid surfaces generally have slower tumbling rates, which leads to a reduction in the relaxation 
time. Because water mobility often varies substantially between tissue types, and changes in 
situations of cellular stress, T2-dependent contrast is very commonly used in MRI studies.
In addition to these spin-spin interactions, the transverse magnetisation is also perturbed by 
small local magnetic field differences. This results in different (local) Larmor precession 
frequencies of the spins under observation and thus in a loss of phase coherence causing a 
faster decay of the magnetisation in the xy-plane. The corresponding apparent relaxation time 
is called T2* to distinguish it from the intrinsic transverse relaxation time T2. 
Figure 2.1 Schematic representation of the nuclear magnetic resonance principle
(A) The sample magnetisation M0 arises from the uneven distribution of the spins (black arrows) between two different states, 
either parallel or anti-parallel to the main magnetic field B0. The spins precess around the main magnetic field direction with 
the Larmor frequency ω. (B) After the application of a 90° pulse, the original distribution is shifted into the horizontal plane 
and phase coherence is established (the spins are all aligned along the same axis). The result is a sample magnetisation M⊥. 
(C) The spins return to the original distribution through T1 relaxation. The loss of phase coherence is called T2 relaxation. 









This field-disturbing effect can be exploited as a source of contrast in tissue, since such magnetic 
field inhomogeneities typically occur at interfaces of structures with differing magnetic 
susceptibilities, like soft tissue and bone, or tissue and blood. T2* contrast is of specific 
importance in blood oxygenation level dependent (BOLD) imaging, which is widely used in 
functional MRI investigations.3 The paramagnetic nature of deoxygenated blood generates 
magnetic field gradients in blood vessels and surrounding tissues, leading to signal loss in T2* 
weighted images. Fast T2* weighted imaging is performed continuously to track transient 
changes in the magnetic field disturbances associated with the balance between oxyhemoglobin 
and deoxyhemoglobin in the blood, thus providing information on local neuronal activity. The 
second important application of T2* contrast is its use in contrast enhanced MRI.4 Specific 
exogenous (super)paramagnetic contrast agents, analogous to the tracers used in nuclear 
medicine, are being developed continuously in order to target specific areas or molecules, thus 
providing a means to map molecular events in vivo. Most commonly used T2/T2* contrast agents 
are iron oxide particles, causing hypo-intensities on the corresponding images by lowering T2/
T2*, hence the name ‘negative’ contrast agents.
T2 and T2* measurements 
Measuring relaxation times rather than making weighted images allows the quantification of 





























Figure 2.2 Spin echo MRI sequence
(A) Diagram showing the fanning out and refocussing of magnetisation in the course of a spin-echo sequence. (B) After the 
application of a 90° pulse, the original distribution is shifted into the horizontal plane. (C) The loss of phase coherence is 
primarily due to T2* effects. (D) The 180° pulse flips the spins in the xy-plane, and the magnetisation refocusses along the 
y-axis. (E)The attenuation of the net magnetisation vector is due to T2 relaxation.
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90° into the xy-plane. The ensuing loss of phase coherence due to T2* effects can be reversed 
by the application of a series of 180° RF pulses following the initial 90° RF pulse, forming the 
so-called Spin-Echo (SE) sequence. The restoration of coherent magnetisation between the 
180° pulses is called an echo. The amplitude of this echo is only attenuated by T2 relaxation. 
(Figure 2.2)
T2* can be measured by means of gradient echoes. In the spin-echo sequence the 180° pulse 
reverses the effects of local field inhomogeneities, whereas in a gradient echo sequence the 
echo is generated by reversing a magnetic field gradient. The main difference between a spin 
echo and a gradient is that the gradient echo does not refocus the dephasing due to field 
inhomogeneities, and therefore the echo is weighted according to T2* rather than T2. In addition 
to its use in T2* imaging, gradient echoes are commonly used in rapid imaging sequences, as 
the echo time can be made much shorter than in spin echo sequences.
T1
The other relaxation time must be considered is the longitudinal relaxation time T1, also referred 
to as the spin-lattice relaxation time. The mechanisms behind this relaxation are complex, but 
it is facilitated by the presence of microstructures (macromolecules, membranes etc.), also 
called the lattice, that via dipolar interactions can absorb the energy of the excited protons. 
This energy transfer is most efficient when the rotational correlation rate of the molecules is in 
the same range as the Larmor frequency. In practice this means that T1 becomes shorter as 
the molecular mobility decreases, but increases again for very slow molecular motion, as in 
solids. Both T1 and T2 reflect the properties of the physical micro-environment of water in tissue, 
albeit not in exactly the same way. Commonly used paramagnetic contrast agents (e.g. 
gadolinium or manganese-containing particles) decrease the longitudinal relaxation time T1 
leading to positive contrast. 
T1 measurements
The most well-known sequence to measure T1 is the inversion recovery sequence. This sequence 
starts with a 180° RF pulse causing inversion of M0, which then gradually recovers to its 
equilibrium. To detect the amount of magnetisation left, a 90° pulse is applied after a range of 
delay times. This rotates the magnetisation into the xy-plane, where it can be detected. (Figure 
2.3) From the different delay times and the corresponding residual magnetisation levels, T1 can 
be calculated.
Diffusion 
Up to now, the translational motion of individual water molecules has not been considered. 
However, all molecules in a fluid are subject to Brownian movements, the extent of this motion 
depending on the temperature and the viscosity of the fluid. When an ensemble of molecules 
is followed in time, the root mean square displacement (x, m) shows a √t dependence:  
x=√2dDt     [2.2]
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where D is the bulk diffusion coefficient of the fluid (m2 s-1), t is the displacement time (s) and d 
(= 1, 2, or 3) is the dimensionality of the diffusion displacement. Normally, the displacement 
distribution of all molecules is Gaussian, where the mean displacement distance increases with 
increasing displacement times. However, if the molecules encounter barriers to diffusion, e.g. 
cell membranes, these determine the maximum displacement. These boundary restrictions 
imply that the displacement distribution is no longer Gaussian and is going to depend on the 
diffusion time. As a result, the measured apparent diffusion coefficient (ADC) is smaller than 
the intrinsic D. This ADC value is sensitive to the number of barriers, their geometry and their 
permeability: in other words to the tissue microstructure.
The above is true if isotropic diffusion can be assumed, i.e. diffusion that exhibits no directionality. 
Many biological tissues have a microstructure that favors molecular motion in a certain direction. 
In the brain, diffusional anisotropy occurs primarily in white matter tracts, caused by the myelin 
sheaths and other structures surrounding the nerve fibers, which restrict diffusion perpendicular 




























Figure 2.3 Inversion recovery MRI sequence
(A) Diagram showing the magnetisation changes during an inversion recovery sequence. (B) The 180° pulse inverts the 
magnetisation M0. (C) In time, the magnetisation returns to equilibrium due to T1 relaxation. (D) 90° pulses are applied to 
detect the residual magnetisation at a number of time points. After each 90° pulse, a waiting time is introduced to let the 
magnetisation return to equilibrium, after which the next cycle of 180° - 90° pulses is performed.
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occurs more readily than along another is defined by a diffusion tensor, and diffusion tensor 
imaging (DTI) is the term used for measurements of the full diffusional properties of the sample 
in all three dimensions.5
 Diffusion measurements
The ADC can be measured using a pulsed field gradient (PFG) experiment. In this experiment 
a sequence of two pulsed magnetic field gradients of equal magnitude but opposite sign and 
separated by an interval ∆ temporarily change the resonance frequency of the observed spins 
(Eqn. 2.1) as a function of their position. If the spins remain at exactly the same position, the 
effects of the opposing gradient pulses compensate each other. However, as soon as 
translational motion occurs, the gradients induced frequency shifts do not exactly compensate 
each other anymore and a phase shift occurs. Because diffusion is random in all directions, no 
net phase shift results, but phase coherence is partially lost, resulting in attenuation of the echo 
amplitude. (Figure 2.4) The amount of this attenuation is determined by the length, amplitude 
and separation of the gradient pulses, summarised in the so-called b factor, and by the mean 
translational distance travelled during the interval ∆, which depends on the ADC. The signal 
intensity in a diffusion-weighted image (DWI) can therefore be described as: 
Sb = S0 e-b.ADC     [2.3]



























Figure 2.4 The principle of diffusion weighted MRI
(A) Water diffusion for three different spins within a sample. (B) Two diffusion gradients are applied with opposite sign and 
a delay time τ between them. (C) Diffusing spins experience different phase shifts (dependent on their position in the direction 
of the applied diffusion gradient) and are incompletely refocused, leading to a net loss in signal intensity
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Magnetisation Transfer Contrast 
A certain fraction of protons in tissue exist in a so-called ‘bound’ state, i.e. their motion is 
restricted because they are part either of macromolecules, or of water molecules within the 
hydration layers around macromolecules. These protons posses very short T2 relaxation times 
(<100 µs) and hence are not accessible by standard spin-echo MRI methods. With currently 
available small-bore technology, minimum echo times are of the order of several ms, and hence 
the signal from these protons has already decayed before signal acquisition. While simple 
models for proton relaxation behaviour predict that such a proton population will have some 
influence upon T1 and T2, Wolff and Balaban6 proposed the method of magnetisation transfer 
contrast (MTC) imaging7, as a more direct means of probing these ‘bound’ protons. 
MTC imaging is based on an inverse Fourier relationship between T2 and the range of frequencies 
over which protons respond to RF excitation: protons in the ‘bound’ fraction possess a very 
short T2 and hence exhibit a broad resonance width (~ 20 kHz) in the frequency domain. 
Conversely, bulk water protons have a long T2 with a correspondingly narrow (~10 Hz) frequency 
domain resonance. (Figure 2.5A) This difference can be used to excite the ‘bound’ fraction 
independently from the bulk protons. If RF energy is supplied at a frequency offset from the 
central Larmor frequency (typically 1-5 kHz) the magnetisation in the ‘bound’ fraction will be 
reduced by saturation, while, in the absence of exchange, the bulk water pool would remain 
unaffected. (Figure 2.5B) However, on the time-scale of a typical MRI experiment there is a 
significant exchange of magnetisation between the two proton fractions, either by chemical 
exchange or by magnetic interactions. Since the ‘bound’ proton magnetisation has been reduced 
by the off-resonance irradiation, such exchange also leads to a reduction in both the magnitude 
of the observable bulk water magnetisation and its associated T1. (Figure 2.5C) The degree of 
reduction depends upon both the relative sizes of the two fractions and upon the rate of 
magnetisation exchange between them: both of these factors may be influenced by tissue 
pathology.
MTC measurements
In its most simple form, the MTC imaging experiment involves collecting an image (Ss) which is 
preceded by a long (~ 3 s) saturating off-resonance RF pulse, followed by a second image (S0) 
without a pre-saturation pulse.8 The Magnetisation Transfer Ratio (MTR) is then quantified as: 
MTR = (S0 - Ss)/ S0     [2.4]
A high MTR signifies the presence of a significant proton pool associated with macromolecules 
or cellular microstructure and a significant exchange of magnetisation between these protons 
and those of the bulk water. Reduction of the MTR suggests a disruption of tissue microstructure, 
the most successful application of MTC in experimental neuroscience being the investigation 
of pathological disruption of white matter due to demyelination.
In order to reduce imaging time, selective saturation of the ‘bound’ fraction may also be achieved 
by pulsed methods whereby gradient-echo images with short TR are obtained with a low angle 
excitation pulse preceded by a short (~10 ms) off-resonance pulse.9 If the repetition time is 
sufficiently short (~100 ms) compared to the T1 relaxation time of the ‘bound’ pool, an equilibrium 
is established after a number of cycles, resulting in substantial saturation of the ‘bound’ fraction.
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It should be noted that unless total selective saturation of the bound pool is achieved, a situation 
impossible to achieve in practice, the magnitude of the MTC effect is dependent upon the 
duration, intensity and frequency offset of the off-resonance pulses. Caution is therefore 
required in the quantitative comparison of MTC imaging results obtained using differing 
experimental schemes.
Concluding remarks
The combination of appropriate imaging techniques can greatly elucidate our understanding 
of human brain pathologies. Prior clinical application the use of suitable animal models of 
disease or post-mortem human brain tissue can greatly aid the development of improved MRI 
techniques. This experimental imaging partnership has contributed to the development of novel 
imaging techniques, to the promotion of better diagnostic and prognostic measures, and to 




























Figure 2.5 The principles of 
magnetisation transfer imaging
(A) Macromolecular-bound protons 
possess a very short T2 and hence a 
broad resonance response in the 
frequency domain. Mobile water 
protons conversely exhibit a narrow 
frequency domain line-width. (B) In 
the absence of exchange, the 
application of RF energy at a 
frequency away from resonance 
perturbs only the bound proton 
fraction, causing the magnetisation of 
this pool to reduce towards zero. (C) 
Exchange of magnetisation between 
free and bound protons causes a 
reduction in the magnetisation of the 
mobile pool, and hence an observable 
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Abstract
For the interpretation of magnetic resonance imaging (MRI) abnormalities in brain pathology, 
often ex vivo tissue is used. The purpose of the present study was to determine the pathological 
substrate of several distinct forms of MR hypo-intensities that were found in formalin-fixed 
brain tissue with amyloid-β (Aβ) deposits. Samples of brain cortex were scanned using T2*-
weighted protocols at several resolutions on a 9.4T MRI scanner. High resolution MRI showed 
large coarse hypo-intensities throughout the cortical gray and white matter, corresponding to 
macroscopic discolorations and microscopic circumscribed areas of granular basophilic neuropil 
changes, without any further specific tissue reactions or Aβ related pathology. These coarse 
MRI hypo-intensities were identified as localized areas of absent neuropil replaced by 
membrane/myelin sheath remnants using electron microscopy. Interestingly, the presence/
absence of these tissue alterations was not related to amyloid deposits, but strongly correlated 
to the fixation time of the samples in unrefreshed formalin. These findings show that prolonged 
storage of formalin fixed brain tissue results in subtle histology artifacts which show on MRI as 
hypo-intensities that on first appearance are indistinguishable from genuine brain pathology. 
This indicates that post-mortem MRI should be interpreted with caution, especially if the history 




MR imaging of post-mortem brain tissue offers a valuable research method to study disease 
related changes in image contrast, because the findings can be correlated to histology.1-12 
High resolution ex vivo imaging has been a useful tool in interpreting the MRI features of many 
neurodegenerative disorders, including multiple sclerosis (MS), Alzheimer’s disease (AD), and 
(sporadic) cerebral amyloid angiopathy.1-3,6-9,11,12 However, the MR characteristics of the tissue 
rapidly change in the post-mortem situation due to tissue decomposition and chemical fixation; 
therefore direct translation of the findings to the clinical setting has to be done with caution.13-19 
Firstly, tissue decomposition occurs during the post-mortem interval (PMI), the time period 
between the patient’s somatic death and beginning of the immersion-fixation of the tissue, 
which varies among subjects. Several studies have shown that an increasing PMI leads to a 
reduction of T1 and T2.13,15,20 A more recent study, however, suggested these findings might 
mainly be due to tissue dehydration or the fixative itself. When these effects were minimized, 
proton density, T1 and T2 values all increased with longer PMI.17 Also mean diffusivity and 
fractional anisotropy decrease with prolonged PMI.17,21 
After autopsy, brain tissue will be immersed into a solution containing a chemical fixative, most 
frequently being formalin also known as formaldehyde. These solutions preserve tissue by 
slowly diffusing into it, leading to the cross-linking of proteins and immobilization of water 
molecules, thereby preventing autolysis and tissue decomposition.21-23 By its nature it is to be 
expected that this would affect MR characteristics, which indeed was confirmed by several 
post-mortem brain MRI studies. A reverse in gray matter (GM) / white matter (WM) T1 contrast 
occurs within several days of fixation, merely due to a rapid decline in the latter combined with 
a general decrease in both continuing at least up to three months.18 Similarly, T2 relaxation 
declines with prolonged fixation affecting both GM and WM, reaching a stable plateau as shown 
by consecutively imaging up to six months fixation.13-15,18
All of the above has led to important considerations on the correct method to obtain and 
interpret post-mortem MR images.13,15 
However, similar studies investigating the effect of long fixation periods (> 6 months) on the 
MR characteristics have not yet been published. Nevertheless, this question is important, 
especially when using rare material from tissue archives, which are stored using fixatives like 
formalin for periods ranging from several years up to decades. In a recent study using archival 
tissue with prolonged fixation times, we noticed unusually large coarse hypo-intensities, 
especially apparent on high resolution T2*-weighted images, in several brain samples regardless 
their pathological diagnosis. We hypothesized that these coarse hypo-intensities were the result 
of the extended formalin fixation period. 
The purpose of the current study therefore was to investigate the occurrence of these T2* 
changes with respect to their formalin fixation time in brain samples with different pathologies. 
To this end, MR images were obtained of eighteen samples with fixation times ranging from 3 
months to several decades. Subsequently the samples were evaluated both macroscopically 
and microscopically to identify the occurrence and the microscopic substrate of tissue changes 
due to prolonged fixation. 




We used brain tissue of six patients with AD, four patients with Hereditary Cerebral Hemorrhage 
with Amyloidosis, Dutch type (HCHWA-D), two patients with Down’s Syndrome (DS), two patients 
with sporadic Cerebral Amyloid Angiopathy (CAA) and four control brains. (Table 3.1) The brain 
tissue had been routinely immersed in buffered 10% formalin for several weeks up to 6 months 
after which the wet tissue was archived in sealed plastic bags with a small excess of 10% 
formalin. Total fixation times varied from 4 months to 42 years. From a subset of subjects, 
several samples of the exact same brain had also been paraffin embedded at the beginning of 
their fixation process, normally within one month post-mortem. This allowed a direct comparison 
of structural changes with tissue from the same patients that was archived in formalin and 
embedded in paraffin several years later. (Table 3.2)  
MRI
A slice of 20x15 mm brain tissue was selected from each subject and cut into a 4-mm-thick slice 
using a vibratome (VT1000S, Leica). The 4-mm slice was placed in a custom made tissue holder, 
immersed in a proton-free fluid (Fomblin, Solvay) and positioned in a vertical small-bore 9.4T 
Bruker Avance 400WB MRI system, equipped with a 1 T/m actively-shielded gradient insert and 
Paravision 4.0 imaging software (Bruker Biospin). A 20-mm birdcage transmit/receive coil was 
used (Bruker BioSpin). Several 3D T2*-weighted gradient echo sequences were obtained with 
isotropic resolutions of 40 – 100 – 200 – 400 µm with the number of signal averages respectively 
being 60 – 20 – 20 – 12. TE/TR = 12.26 / 75 ms, FA = 25º. With the matrix size depending on the 
shape of each sample, average scan time per resolution were respectively 28 hrs, 2 hrs 40 min, 
20 min. and 8 min. For quantitative T2* measurements, 100 µm scans were also acquired using 
TE =  8 – 10 – 12.26 – 15 ms.  
Histology
Following MRI, brain slices were paraffin-embedded and serially cut in 8-µm sections. 
Consecutive sections were stained for general microscopic morphology (hematoxylin and eosin 
(HE)), for myelin (Kluver-Barrera), for iron (Perls and a modified Perls DAB)24 (FEIII-DAB, FEII-
DAB)25, copper (Romeis) and immunohistochemistry for Aβ (Dako, 6F/3D)26, and GFAP (Dako, 
6F2).27 To allow correlation with MRI, sections were digitalized using a flatbed scanner (Agfa).
Electron microscopy
Electron microscopy was performed on a subset of subjects as previously described.28 (Table 
3.2) Collection was done on copper grids instead of carbon grids. Sections were examined using 
a JEOL JEM-1011 electron microscope operating at 60 kV and digitalized using a MegaView III 
camera.
Analysis / Scoring
Two sequential MR slices from the 3D data sets at 40 µm resolution were examined for 
“coarse” hypo-intensities defined by large size (120 – 1200 µm), irregular contour and 
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elongated to stellate shape. These coarse hypo-intensities were scored as follows: absent: 
0 coarse hypo-intensities, present: 1 – 9 coarse hypo-intensities, extensive: ≥10 coarse 
hypo-intensities. Three HE stained sections from the same level of the two sequential MRI 
slices were used to correlate MR images with histology. To perform these correlations, we 
used Adobe Photoshop 6.0 to visually overlay digitalized histological sections to their 
corresponding MR images. Of each patient the same HE sections were used to score the 
amount of granular neuropil changes as follows: “absent” if no granular neuropil changes 
were found, “present” for 1 – 4 and “extensive” for ≥ 5 neuropil changes in at least one out 
of the three sections.
Subjects with similar score were combined for group analysis (Mann-Whitney) to find significant 
differences (p-value < 0.05) in fixation period and age (SPSS 17).
pH of formalin
Of five patients with widely variable fixation times the pH of the formalin around the brain slices 
in sealed plastic bags, was determined using a logging pH meter (Hanna, H1 98230). (Table 3.3)





















1 88/F AD 0.3 Absent Absent Absent
2 29/M Control 0.3 Absent Absent Absent
3 70/F sCAA 0.5 Absent Absent Absent
4 53/M Control 0.5 Absent Absent Absent
5 53/M Control 0.5 Absent Absent Absent
6 71/M sCAA 0.5 Absent Unknown Absent
7 49/M DS 1 13 Absent Absent Absent
8 64/M AD 6 48 Present Present Present
9 58/M HCHWA-D 6 6 Present Present Present
10 73/M AD 7 9 Present Present Present
11 65/F AD 7 2 Present Extensive Present
12 50/F HCHWA-D 9 21 Present Extensive Extensive
13 45/F HCHWA-D 15 Present Extensive Extensive
14 90/F AD 16 Present Extensive Extensive
15 52/M HCHWA-D 17 1 Present Extensive Extensive
16 62/F DS 19 Present Extensive Extensive
17 62/M Control 26 Present Extensive Extensive
18 58/F AD 42 14 Present Extensive Extensive
M = Male; F = Female; sCAA = sporadic cerebral amyloid angiopathy; DS = Down’s syndrome; AD = Alzheimer’s disease; 
HCHWA-D = hereditary cerebral hemorrhage with amyloid Dutch type; PMI = Post-mortem interval; MRI coarse hypo-
intensities: Absent = 0, Present = 1-10 hypo-intensities in one image, Extensive ≥ 10 hypo-intensities in at least one of the 
two examined images. Granular neuropil changes: Absent = 0, Present = 1-4 changes per section, Extensive ≥ 5 changes 
in at least 1 of the 3 sections.




High resolution T2*-weighted images of eleven subjects showed irregularly contoured, elongated 
and stellate shaped hypo-intensities that were randomly distributed throughout the cortical 
gray matter and to a lesser degree in the white matter. (Figure 3.1) Their typical size (120 – 
1200µm) and characteristic shape allowed clear distinction from possible other brain structures 
known to have a similar effect on T2*, e.g. blood vessels or small roundish hypo-intensities 
caused by amyloid-β (Aβ) plaques, especially when including their spatial orientation. (Figure 
3.4) Based on these characteristics, we defined them as “coarse hypo-intensities” and tissue 
was scored according to their presence. (Table 3.1)
When comparing similar MR images of the same section at decreasing resolution, these coarse 
hypo-intensities became less pronounced and harder to recognize as such. (Figure 3.1) This 
depended on their actual size and shape being affected by partial volume effects due to 
increasing voxel size. High and low resolution data were compared to assess if hypo-intense 
voxels on low resolution scans correlated with coarse hypo-intensities at high resolution. The 
largest coarse hypo-intensities were also visible at the lowest isotropic resolution of 400 µm, 
which is comparable to the in vivo MRI resolution. On quantitative T2* maps, areas containing 
coarse hypo-intensities caused a clearly noticeable decrease in T2*. 
Table 3.2 Granular neuropil changes observed in brain tissue with short and 
long fixation times from within the same subject






< 0.5 yr 9 - 42 yr 
13 45/F HCHWA-D - +
15 52/M HCHWA-D - +
17 62/M Control - +







5 Control 0.5 6.62
12 HCHWA-D 9 6.11
15 HCHWA-D 17 4.98
17 Control 26 5.43






Only in brain tissue with coarse hypo-intensities on MRI, well circumscribed, white discolorations 
with similar size and distribution as the coarse MRI hypo-intensities were observed. (Figure 3.2, 
Table 3.1)
Histology
Microscopically, HE sections of tissue blocks with macroscopic white discolorations showed 
neuropil alterations with a close spatial correlation to the coarse MRI hypo-intensities. 
(Figure 3.3 and 3.4) These neuropil alterations comprised irregular, well circumscribed areas 
of granular, basophilic changes usually with some tissue rarefaction. (Figure 3.5) The corres-
ponding Kluver’s staining within these areas was decreased with respect to surrounding cortex/
white matter suggesting a lower density of myelin. Most of these areas showed birefringence 
under polarized light in the HE that was not seen in unstained sections or the Kluver’s stain that 
excludes the presence of anorganic material. 
A B C
D E
Figure 3.1 Hypo-intensities seen on MRI
Similar T2*-weighted MR images of subject 14 acquired with isotropic resolution of respectively 40 µm (A), 100 µm (B), 200 
µm (C) and 400 µm (D). Many coarse hypo intensities are detected in the higher resolution, but even at the lowest resolution 
(D) hypointense voxels are still discernible (white arrows). (E) shows the calculated T2* map of the section in (B) with confirming 
a decreased T2* relaxation.
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Figure 3.2 Macroscopic correlation
Images from subject 13 showing (A) fixated brain tissue with white discolorations (yellow arrows) and (B) high resolution (40 














Figure 3.3 Histological correlation with MRI hypo-intensities of subject 17
Shown are the corresponding HE (A), MR image (B) and Aβ immunostained (C) sections of subject 17. Comparison of MR 
image with HE staining and Aβ staining correlating the granular neuropil changes with the The hypo-intensities seen on MRI 
correspond to areas of granular neuropil changes, as clearly depicted by the rectangular inserts (1-3) at 10x magnification. 
No Aβ deposition was observed at these locations.
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The areas of basophilic granular neuropil changes were randomly distributed throughout the 
cortex and increasingly present in the white matter of tissue with long fixation times. These 
areas were found around vessels but also apart from vessels. The basophilic granular neuropil 
changes showed no signs of gliosis, hemorrhages or infarcts. Neurons, astrocytes, microglia 
and vessels were normally distributed within these areas and morphologically unaltered. 
Gemistocytes were not present. Furthermore, all histological (immuno)stainings for iron, copper 
and amyloid-β were negative within these areas. (Figure 3.4)
The basophilic granular neuropil changes were not only found in AD material but also in long 
fixated brain tissue of controls. In contrast, these changes were not found in short fixated AD 
material. Apart from the coarse hypo-intensities that co-localized with neuropil degeneration, 
other small roundish hypo-intensities were observed on MRI that did correspond to amyloid 
plaques. (Figure 3.4)
Electron microscopy
Tissue with macroscopic white discolorations showed localized areas with absent neuropil, 
although vessels were often present in these spaces on one-micron-thick, epoxy embedded 
tissue sections stained with toluidine blue. Electron microscopy of immediately adjacent ultrathin 
sections showed that these areas with absent neuropil actually consisted of spaces without any 
neuropil or only little neuropil remnants. (Figure 3.6) However, in these spaces varying amounts 
of lamellar structures were found, which were interpreted as membrane remnants and/or 
swollen degenerated myelin sheaths. Outside these circumscribed areas, we observed variable 
splitting and swelling of myelin sheets ranging from little splitting in otherwise normal myelin 
sheaths around axons, up to swollen myelin sheaths lining small empty spaces within the 
neuropil.
Relation of coarse MR hypo-intensities with fixation duration
The presence of coarse MR hypo-intensities, macroscopic and microscopic abnormalities were 
scored for each subject and the results are shown in Table 3.1 Subjects with similar scores 
were combined for group analysis.
With regard to coarse MR hypo-intensities, fixation periods were significantly shorter when 
scored “absent” compared to “present” (p-value = 0.017 / r = -0.79). Furthermore, with even 
longer fixation periods, the number of hypo-intensities significantly increases when comparing 
“present” versus “extensive” (p-value = 0.018 / r = -0.71). 
Similar results were obtained when comparing groups with different scores for granular neuropil 
changes. While fixation periods of those scored “absent” were significantly shorter as compared 
to those who were scored “present” (p-value = 0.006 / r = -0.82), which was significantly shorter 
as compared to “extensive” cases (p-value = 0.008 / r = -0.80). 
No significant differences in subject’s age between groups were found for either coarse hypo 
intensity, histological or macroscopic score. Furthermore, no correlation was found between 
coarse MR hypo-intensities and presence/absence of disease regardless of type of disease.
In summary, brain tissue showed no changes when fixed for a period of one year or less in the 
same formalin solution, whereas changes were always present in tissue fixed for a period of 6 
years or more tissue, and increasingly so with longer fixation periods.






















Figure 3.4 Another example of MRI hypo-intensities due to granular neuropil alterations
A MR image (A) of subject 18 is shown with its corresponding HE (B) and Aβ immunostaining (C). Granular neuropil changes 
in the white matter are observed without the presence of Aβ. (B1) represents the 10x magnification of the HE staining 
showing the granular neuropil changes in the white matter. The enlarged inserts (C1 and C2, with respectively 10x and 5x 
magnifications) highlights that these changes in the WM are not depending on Aβ as black arrows highlight granular neuropil 
changes without Aβ (C1) and Aβ deposits with and without granular changes in the surrounding neuropil (C2).
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To test the hypothesis that prolonged formalin fixation indeed leads to histological and MR 
detectable changes, brain tissue from the same subject that was formalin fixed for either a 
short or a much longer period was compared microscopically. (Table 3.2) In the long-term fixed 
material, macroscopic white discolorations and granular neuropil changes were present, while 
short-term fixed material of the same subject completely lacked these findings, indeed 
supporting our hypothesis.
To obtain a complete picture, pH measurements were performed, because formalin solutions 
are known to become more acidic over time. pH measurements indeed showed increased 
acidity after longer periods of formalin fixation, as observed in the sealed plastic bags used for 
tissue storage. (Table 3.3) 
 
Discussion and Conclusion
In the present study, “coarse hypo-intensities” on post-mortem brain MRI were seen 
corresponding to localized areas of neuropil destruction with remnants of membranes and 
myelin sheaths as observed by electron microscopy. These coarse hypo-intensities are mainly 
detected at high-resolution MR scans. Although brain tissue from Aβ-related diseases was used, 
the hypo-intensities where not related to deposits of iron, copper or Aβ correlating with these 
neurological diseases. Instead, these hypo-intensities appear to be an artifact associated with 
the duration of fixation within the same formalin. This can be concluded from the findings that 
these hypo-intensities were also detected in control tissue with long fixation times, and were 
not found in disease-related tissue fixated for a short period. 
The exact mechanism of the described storage related artifacts is not known from previous 
studies but formalin solutions are known to become more acidic over time.29 This was 
confirmed by pH measurements of the formalin excess around our sealed fixed brain 
tissue. Possibly neuropil destruction is caused by a local increase of acidity. However, 
continuous exposure to formalin and/or formic acid may form many other compounds 
that possibly play a role in causing artifactual tissue changes.29,30 We were not able to study 
the effect of long term fixation in regularly refreshed formalin, and we can thus not exclude 
prolonged immersion in formalin itself as a cause of local neuropil destruction leading to 
Figure 3.5 Detailed HE staining of 
the granular neuropil alterations 
(20x)
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MR hypo-intensities rather than the increasing acidity or the formation of aggressive 





Figure 3.6 EM examination of the neuropil
Ultrastructure of localized areas of nearly empty spaces on semithin sections in long term formalin fixed tissue with 
macroscopic white discolorations. (A) These areas consisted of spaces without neuropil or only little neuropil remnants and 
often but not always contained a small blood vessel (1200x). (B) Circumscribed area of absent neuropil showing lamellar 
structures and a capillary (arrow) (1200x). (C) represents the lamellar structures in B (15000x). (D) shows myelinated axons, 
some with splitting of the myelin sheath. One axon (arrowhead) shows myelin splitting (large arrow) with little expansion of 
the spaces between the myelin sheaths (small arrow) (15000x). (E) A myelinated axon partly with intact myelin sheath and 
partly with myelin splitting with transition to more laminated structures with increasing spaces between the lamellae.
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For this study, sufficient material fixed for a period of one to six years was lacking. Consequently, 
we can only conclude that neuropil artifacts occur in all tissue stored for a period of at least six 
years within the same formalin, whereas tissue stored for a period of one year or less showed 
no changes.
The coarse hypo-intensities correspond macroscopically to homogenous white discolorations 
in the tissue, and microscopically in 8 µm HE sections to granular neuropil alterations with 
slightly less density than the surrounding neuropil. The ultrathin sections (90 nm thick) used 
for EM revealed that these areas represented absent neuropil with partial filling of the resulting 
spaces by membrane-like structures. We speculate that this degenerated membraneous/
proteineous material with weak birefringence causes hypo-intensities on MRI due to its solid-
state-like properties. 
The low signal intensity on MRI may also result from replacement of formalin solution by proton 
free fluid in these relatively more empty spaces. However, a decrease in proton density would 
not cause a T2* decrease, as was observed in the T2* maps.
With respect to the induced MR changes, previous reports state that formalin fixation causes 
changes in relaxation and diffusion properties, thereby altering MR contrast, even though the 
exact mechanism remains unclear.16 These changes in MR properties, however, occur 
throughout the entire sample and are partially reversible by rehydrating the sample in PBS. 
In contrast, the structural disruptions we found after prolonged formalin fixation are very 
localized and irreversible. Detected changes were furthermore not related to any of the known 
possible changes due to prolonged PMI as described elsewhere.13,15,17,20,21 For this study brain 
tissue of all kinds of PMI periods was used, and no correlation was found with either the tissue 
changes or MRI hypo-intensities. (Table 3.1)
The conclusion of this study suggests that data of several earlier published studies, using post-
mortem brain tissue of patients with Alzheimer’s disease (AD) for MRI 1-12, should be cautiously 
interpret. In these studies, hypo-intense spots were observed on T2*- or T2-weighted scans that 
co-localised with dense amyloid plaques and iron accumulations.1-12 However, brain tissue in 
these studies was collected within a short period, and fixed for a maximum period of a few 
months. 
With regard to the detection of amyloid plaques, we also observed hypo-intense spots on MRI 
that corresponded to the presence of amyloid plaques. However, these did not correlate with 
the larger stellar shape coarse hypo-intensities. (Figure 3.4) The possible Aβ plaque detection 
indicates that the basic mechanisms for MR contrast (iron accumulation, dense protein 
aggregates) are still present. On ultra-high resolution scans, these different hypo-intensities 
can be easily distinguished. However, on scans with a lower resolution, e.g. those comparable 
to resolutions that can be achieved on clinical MRI systems, both forms might become 
indistinguishable, and based upon their size the coarse hypo-intensities due to fixation artifacts 
are more likely to remain visible. (Figure 3.1) In our study, these low resolution images were 
acquired at relatively short echo times; when a stronger T2*-weighting would be used, more 
hypo-intensities would be observable at these lower resolutions. Furthermore, it is important 
to realise that although these neuropil changes are beyond the anatomical resolution of scans 
with clinical resolutions, they could still be visible on such scans because their signal differs so 
strongly from surrounding tissue. 
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Other known sources for hypo-intensities on T2*-weighted images, like calcifications, iron 
deposits, microbleeds or cavernous malformations31 could be easily disregarded within this 
study, while their presence could not be confirmed upon histology. However, especially when 
conducting similar ex vivo MR studies for either one of these pathologies using old brain 
material and clinically relevant resolutions, one should be aware that the described formalin 
fixation artifacts could possibly lead to similar hypo-intensities and thus a misinterpretation 
of the data.
In order to put our findings into a broader perspective, a small survey was conducted among 
eight other brain banks and neuropathology departments regarding their brain storage protocol. 
Three of these centers store their formalin-fixed brain tissue in sealed plastic bags with little 
excess formalin similar to the tissue used in this study, whereas four other centers store fixed 
brain tissue floating in formalin, two without a protocol for regularly refreshing it, one renewing 
formalin “when necessary” and the fourth every few years. The last center stores brains in 
polyethyleenglycol. How the different storage protocols affect the general tissue quality with 
respect to ex vivo MRI research after long term storage remains to be further investigated, but 
this small survey shows that the fixation protocol for our study is common practice among brain 
banks, and therefore the findings will have implications for future research on brain bank tissue. 
In conclusion, our results demonstrate that fixed brain tissue stored for prolonged periods 
gives rise to structural tissue changes that are associated with hypo-intensities on T2*-weighted 
MR images. When brain tissue from pathology archives or brain banks is used to study (rare) 
disorders with ex vivo MRI, it is of vital importance to take the storage protocol into account and 
to check for the macroscopic and microscopic alterations that have been described and 
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High field MRI of single histological slices using 
an inductively-coupled self-resonant microcoil: 
application to ex vivo samples of patients with 
Alzheimer’s disease
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Abstract
A simple inductively-coupled microcoil has been designed to image tissue samples placed on 
a microscope slide, samples which can subsequently be stained histologically. As the exact 
same tissue is used for MRI and histology, the two data sets can be compared without the need 
for complicated image registration techniques. The design can be integrated into any MRI system 
using existing commercial hardware. Compared to a commercial 20 mm diameter birdcage, 
the signal-to-noise was increased by a factor of 3.8, corresponding to a reduction in data 
acquisition time of ~15. An example is shown of ex vivo samples of patients with Alzheimer’s 





MRI is a versatile and powerful tool to study many pathological conditions, both in vivo and ex 
vivo. In order to verify that changes in MRI signal intensity are due to pathology, histology remains 
the gold standard for determining the nature of tissue changes. It is highly challenging to co-
register precisely the data from histological sections and MRI, primarily due to the deformations 
and shrinkage that occur when tissue is processed for histology following MR data acquisition. 
In addition, histological sections would ideally be cut in exactly the same orientation as the 
acquired MRI data, but this is in practice not feasible. To overcome these difficulties one can 
develop image processing algorithms to co-register the histological and MRI data by either 
attempting to correct for 3D deformations or the difference in spatial orientation.1 However, 
even under the most optimal experimental conditions, the very different spatial resolution of 
MRI and histological sections makes direct registration a cumbersome task.
To alleviate most of these difficulties and possible errors, a straightforward solution is to obtain 
MR images directly from the same histological slice that is used for staining. Meadowcroft et 
al.2 have designed and built a highly specialized coil setup for horizontal-bore 3T and 7T 
scanners, which enables direct MRI of histological sections, such as those used for standard 
pathology. The imaged tissue slices were afterwards subject to several histological stains, 
thereby showing it is a worthy addition to study and validate MR contrast changes with respect 
to its pathological substrate, e.g. within Alzheimer’s disease (AD) brain tissue. The Meadowcroft 
coil has excellent sensitivity and performance, but requires relatively specialized expertise to 
construct and test, and is difficult to implement within the very restricted diameter bore of high 
field vertical MR magnets. A simple alternative approach would be to use a small self-resonant 
microcoil placed around the sample, and to inductively couple this coil to the much larger 
volume resonator which is standardly provided with the system. The principles of inductively 
coupling a larger transmit coil to a smaller self-resonant “microcoil” have been covered in many 
publications, with recent comprehensive signal-to-noise ratio (SNR) analyses in articles by Bilgen3 
and Utz4. These analyses show that the loss in sensitivity using an inductively coupled 
arrangement compared to using a microcoil alone is, at most, a few percent. The approach of 
using inductively coupled self-resonant coils for MR microscopy was first shown by Banson5, 
with the approach having been extended by Glover et al.6 to show co-registered optical and MR 
images of epidermal cells of Alium Cepa.
In the following study, we have designed and characterized an inductively coupled “histological 
coil” for a 9.4 T vertical magnet. The coil is placed at the back of a standard microscope slide 
so it completely covers a 60 µm thick tissue sample. Using these easily-produced and replaceable 
coils, high resolution images of histological samples can be acquired with a ~15 fold reduction 
in data acquisition time compared to using a commercial resonator. After MRI, the same sample 
underwent staining. In this case, the samples are from ex vivo human brain tissue from an 
ongoing AD study. After MRI scanning, a double staining was performed by using a new modified 
Perls’ 3,3’-diaminobenzidine (DAB) staining combined with immunofluorescence for amyloid β 
(Aβ).
 




The RF coil was constructed from pure silver 18 AWG wire, shaped into a square with dimensions 
15 x 15 mm, ~20% larger than the histological slices so that areas of inhomogeneous B1 field 
very close to the wires do not cover the sample. (Figure 4.1A) For maximum SNR the microcoil 
should be strongly coupled to the outer birdcage coil. If the microcoil is tuned to 400 MHz, this 
introduces a frequency shift that could not be compensated for by re-adjusting the impedance 
matching capacitors of the birdcage. Therefore, the microcoil should be self-resonant at a 
frequency slightly different from 400 MHz. As outlined by Bilgen3, one can minimize the current 


























Figure 4.1 Design of the inductively coupled microcoil
The self-resonant coil is taped onto the back of a standard 25 mm wide microscope slide such that it covers a 60 µm thick 
brain section, which is mounted on the opposite side in PBS 1X (A). The slide is positioned in a 25 mm diameter commercial 
volume resonator (B) such it achieves the strongest coupling. Impedance matching of the histology coil is performed by 
using the variable capacitors of the birdcage coil (black screws). A schematic cross section of the setup is shown in (C) with 
the coil on one side of the microscope slide and the sample on the other. The arrows illustrate how the B1 field is localized 
due to presence of the inductively coupled coil while applying an RF pulse via the volume resonator. (D) Network analyzer 
S11 plots from, respectively, the commercial resonator alone (left), with the strongly coupled coil (center), and after retuning 
and impedance matched to 50 Ω at 400 MHz.
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and then using the lower of the two split-resonances. A 1-3.5 pF non-magnetic variable capacitor 
(Johansson, Boonton, NY), with a DC breakdown voltage of 1 kV, was used to tune the microcoil 
to the resonant frequency of ~396 MHz. The coil was placed directly onto the back of a 
microscopic slide on which the sample had already been placed. (Figure 4.1A) Next, the slide 
was placed in a 25 mm standard Bruker high-pass birdcage resonator (Figure 4.1B-C), which 
was connected to a network analyzer (Agilent Technologies, Santa Clara, CA). The orientation 
of the slide was adjusted to produce the strongest coupling. The mutual inductance splits the 
resonance frequency into two separate peaks. The low frequency resonance was impedance 
matched to 50 Ohms at 400 MHz by adjusting the variable capacitors of the birdcage coil. 
(Figure 4.1B-D)
Sample preparation
Tissue was obtained from The Netherlands Brain Bank (NBB), Netherlands Institute for 
Neuroscience, Amsterdam. All material has been collected from donors for or from whom a 
written informed consent for brain autopsy and the use of the material and clinical information 
for research purposes had been obtained by the NBB. A 12 x 12 x 10 mm formalin-fixed 
human brain tissue sample was resected from the neocortex and cut into 60 µm-thick sections 
with a vibratome (VT1000, Leica) followed by immersion in 1X phosphate buffered saline (PBS) 
for at least 24 hrs to wash out any residual formalin. The tissue section was mounted on a 
histology slide and a drop of PBS (which had previously been placed under vacuum to reduce 
air bubbles) was applied to the sample to prevent dehydration. Extreme care was taken to 
avoid inclusion of any air bubbles by slowly lowering the coverslip, and the section was sealed 
with nail polish. 
MRI data acquisition
All MRI measurements were conducted on a vertical bore 9.4 T Bruker Avance 400 WB 
spectrometer, with a 1 Tm–1 actively shielded gradient insert, equipped with ParaVision 5.0 
software running with Topspin 2.0. Pulse width calibrations were performed with a 1 ms hermite 
pulse. The B1-field homogeneity of the histology coil was evaluated using the double angle 
method (DAM) as described by Stollberger and Wach7 in which two spin echo images were 
acquired with flip angles = 30º and 60º, TR = 4000 ms, TE = 6.5 ms, 4 signal averages, field of 
view (FOV) = 16 x 16 mm, and matrix size 64 x 64 complex data points. 
Imaging experiments were performed using both gradient- and spin-echo sequences. For all 
sequences, a slice selection pulse was applied to excite a thickness of 2 mm. Scout gradient 
echo images were acquired in 1.36 minutes with a FOV of 50 x 50 mm, flip angle = 25°, TR / TE 
= 75 / 3 ms,  matrix = [128 128] and 10 signal averages. Multiple gradient echo images were 
acquired with flip angle = 22.5°, TR / TE = 75 / 5 -12-19 ms, FOV = 16 x 16 mm, matrix = [256 
256] and 200 signal averages resulting in a one hour scan with in-plane resolution of 62 x 62 
µm. Multiple spin-echo images were obtained in order to calculate T2-maps, with TR / TE = 2500 
/ 10-20-30-40 ms, FOV = 16 x 16 mm, matrix = [128 128] and four averages, obtained in 21 
minutes with 125 x 125 µm2 resolution.
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Studies of brain tissue of patients with AD
Several previous studies have shown that the pathological hallmarks of AD, namely Aβ plaques 
and associated iron deposition, can be detected by MR microscopy.8,9 In this current study, 
brain samples from the entorhinal cortex of a confirmed AD patient were prepared. Multiple 
gradient echo images were acquired with flip angle = 22.5°, TR / TE = 75 / 15 – 25 – 35 - 45 ms, 
FOV = 16 x 16 mm, matrix = [400 400] and 200 averages resulting in a 1 hour 40 minutes scan 
with in-plane resolution of 40 x 40 µm2.
Histological staining
Following MR, the same 60 µm section was double stained using a new modified highly specific 
Perls’ DAB to stain for iron followed by an immunofluorescence Aβ staining. First the free floating 
section was immersed for 30 min in 100 ml of methanol with 1 ml 30% H2O2 and rinsed with 
subsequently 96% and 70% EtOH in PBS 1X to block endogenous peroxidase. A pretreatment 
similar to the one described by Levine et al.10,11  was applied at room temperature via 30 minutes 
of immersion in 1% NaBH4 in PBS followed by 20 minutes in a mixture of 150 µl Proteinase K 
(Sigma), 50 µl Triton-X 100 and 50 ml PBS. After each step the section was briefly rinsed in PBS 
1X before being placed overnight at room temperature in a solution of 7% potassium-
hexacyanoferat(II)-trihydrate and 3% HCl according to Smith et al.12 Following rinsing in aquadest 
and PBS 1X the section was immersed in 100 ml 0.075% DAB (Sigma) with 50 µl 30% H2O2 in 
PBS 1X for 10 minutes after which the reaction was stopped in aquadest.
Next, the same section was immunostained for Aβ using a standard commercial monoclonal 
antibody immunostaining (6F/3D, DakoCytomation). One hour immersion in 85% formic acid 
and 30 minutes in trypsin (Type II-S, Sigma), while rinsing with aquadest and PBS 1X in between, 
was followed by overnight staining in 1 ml 1:10 dilution of Aβ-antibody at room temperature. 
Secondary antibody staining consisted of 2 hours immersion with 1:100 goat-antimouse-
Alexa594 (Invitrogen) for fluorescence microscopy.
Coregistration and image analysis
Histological images were acquired using a Leica DM/RB microscope equipped with a DFC-420c 
CCD camera and Leica LAC software. For immunofluorescence, images were acquired in a 
similar fashion with a XBO xenon lamp and Texas Red filterblock N2.1. All subsequent images 
were taken with a either a 5 or 10 x objective lens allowing automatic photomerging with Adobe 
Photoshop CS2 to reconstruct a larger image field. A single image was formed from the MR 
data by summating all the individual echoes of the MGE sequence. Finally, MR and histology 
data were coregistered based upon matching section outlines and structural features. 
Results
RF coil characterization
The frequency shift when the microcoil was placed in the birdcage coil, oriented for maximum 
coupling, was approximately 10 MHz, as shown in Figure 4.1D, with a very small change in the 
impedance match. The birdcage coil was retuned to 400 MHz using the standard variable 
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impedance matching capacitors, and the resulting Q of the retuned coil was almost identical 
to the birdcage alone. Pulse width calibrations for the 25 mm diameter volume resonator with 
and without the coupled microcoil showed a decrease of 12 dB in power needed for a 90° pulse 
when using the inductively coupled coil. (Figure 4.2A) The SNR was calculated using the MR 
images shown in Figure 4.2B, with a measured SNR increase of a factor 3.8 when using the 
coupled system, which corresponds to a reduction in imaging time of a factor of almost 15. 
The factor of 3.8 is very close to the expected value of 4 based upon the relative 90° pulse 
widths. The images in Figure 4.2B also demonstrate how the B1-field is localized when using 
inductively coupled coils, thereby following the concept shown in Figure 4.1C. While the PBS 
surrounding the brain sample is still seen beyond the edges of the coupled coil in the image 
acquired solely with the volume resonator, this signal is not picked up when using the coupled 
coil due to localization of the B1 field.
The experimentally measured B1-field map shows that excitation is homogenous within the 
strongly coupled coil. (Figure 4.3) The homogeneity measured over a field-of-view of 80% of 
each of the linear dimensions of the coil showed a standard deviation of ~5% in the B1-field. 
Similar to a standard surface coil, this homogeneity quickly drops off at the edges of the coil. 
The excellent homogeneity produced by the coupled coil makes it possible to obtain accurate 
quantitative maps of relaxation parameters, such as T2.
Initial scans to compare the performance of the volume coil versus the coupled system clearly 
illustrate the gain in SNR when similar scans were obtained. Standard gradient echo images 
acquired with the coupled coil shows features that are not distinguishable using the volume 
coil alone. (Figure 4.4) Besides clearly distinguishable areas of gray (GM) and white matter (WM), 
Volume coil
Inductively coupled coil




Pulse width calibrations (on log scale) for the commercial resonator alone (A) and with the coupled histology coil (B) showing 
a 12 dB reduction in power. Identical scout images obtained from a 60 µm brain section with their corresponding profile 
through the horizontal center of the volume resonator without (B-C) and with the histology coil (E-F). Besides illustrating the 
focused B1-field, note the decreased noise in (F) compared to (C).
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smaller structures within the GM are also visible. Similar results were obtained when using a 
standard multiple spin echo sequence at a slightly lower resolution. (Figure 4.5) Besides 
increased SNR and image quality, using the coupled coil allowed the calculation of more accurate 
T2 and T2* maps for obtaining quantitative measurements.
Application to ex vivo human AD tissue
Previous literature has strongly suggested that in human AD brain tissue deposits of Aβ, either 
colocalized with iron or in the absence of any iron, can create hypointense foci upon T2*-
weighted sequences.2,8,9,13  If the spatial resolution of the MRI is sufficiently high, this allows 
direct correlation with histology. Figure 4.6 shows a T2*-weighted MR image of a tissue section 
TE = 5 12 19 ms T2* Map
A. Volume resonator
B. Inductively coupled
Figure 4.3 B1-field map 
Profiles through the horizontal and vertical center 
demonstrate the uniformity of the coil within the 
imaging region of a 60 µm thick brain section.
Figure 4.4 
Multiple gradient echo images and 
their corresponding T2*-map from 
a 60 µm thick brain section obtained 
with the volume resonator without 




from the entorhinal cortex of an AD patient and its corresponding histological images double 
stained with a modified Perls’ stain for iron and immunofluorescence staining for Aβ. Registration 
was simply performed based upon the section’s outline and structural features: the WM 
vasculature in particular could easily be correlated in both image modalities due to the high 
resolution and SNR of the MRI. When examining the complete section, WM and GM are clearly 
distinguishable in both modalities, in agreement with previous work2,9 which ascribed the 
decreased WM signal intensity to an increased iron content of oligodendrocytes and myelin 
sheets within the WM as confirmed by our modified Perls’ staining. Within the MR image, the 
GM shows many small hypointense foci. A similar distribution of dark brown patches in the iron 
staining indicated regions of high focal iron content. (Figure 4.6A-B) Furthermore, the diffuse 
brown background coloration within the GM on the iron stain shows a similar distribution to 
the reduced signal intensity on the MR image. 
In order to allow a more detailed evaluation and a direct correlation between the findings on 
MR and histology, images were zoomed on a selected region outlined by the dashed box. (Figure 
4.6C-E) As depicted by the yellow arrows, many of the MR hypointense foci indeed represent 
a one-to-one coregisteration with these dark brown areas of high focal iron content. However, 
for distinct areas marked by a more diffuse brown colour, suggesting a lower iron concentration, 
a clear direct correlation could not be made. 
When examined carefully, immunostaining for Aβ showed a high Aβ content throughout the 
GM with almost all deposits correlating with some degree of DAB enhancement of the Perls’ 
staining. (Figure 4.6E) On the other hand, while most areas showing an increased iron content 
were surrounded or covered by Aβ, several small roundish foci did not correlate with Aβ. 




Multiple spin echo images and their corresponding T2-map from a 60 µm thick brain section obtained 
with the volume resonator without (A) and with the inductively coupled histology coil (B).
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According to their location and size these might be iron loaded microglia cells. Not all MR hypo-
intensities could be directly correlated with either staining (Figure 4.6, green arrows), suggesting 
another source responsible for creating these contrast changes. Since some of these hypo-
intensities can also be seen outside the tissue section, this suggests they are likely to be caused 
by either small impurities or tiny air bubbles.
 
A  B
C D  E
Figure 4.6 MR microscopy of an Alzheimer’s disease brain section
(A) T2*-weighted image of a 60 µm brain section of the entorhinal cortex of a known Alzheimer’s disease patient. (B) 
Microscopy image of the same section after the new modified Perls’ DAB staining for iron. Dark regions indicate higher iron 
concentration. For more detailed comparison a selected region was enlarged as outlined by the dashed boxes, showing 
respectively the T2*-weighted MR image (C), iron staining (D) and Aβ immunostaining (E) of the same section. Many 
hypointense spots within the MR images clearly coregister with focal iron accumulations (yellow arrows), which further 
colocalizes with Aβ as seen on (E). However not all hypo-intensities could be coregistered with either one of the histological 
stainings (green arrows), which might also be caused by image artifacts, like tiny airbubbles. Scale bars represent 1000 µm 




The results presented here indicate that inductively coupled microcoils provide a simple and 
robust method to acquire high quality MR images of a single histological section in a 
reasonable data acquisition time. This offers an alternative approach to study various 
pathological conditions with MR microscopy allowing contrast changes to be easily validated 
by direct correlation with histology.
Compared to other approaches, these coils are easy to produce, and also to replace if needed. 
Made to fit around a histological section of any shape, they are broadly applicable to both 
horizontal and vertical bore systems, and can be impedance-matched up to frequencies well 
over 1 GHz. Positioned on the back of a microscopic slide, the thickness of the histological 
section can be varied without the need for additional hardware changes. The high resolution 
images obtained in this study show sufficiently high SNR such that slices thinner than the 
current 60 μm should be possible to image, with even better potential correlation with 
standard histology.
In this study, formalin-fixed samples were cut using a vibratome and immersed in PBS several 
hours prior to imaging, rather than cryosectioning frozen tissue as was done in previous work.9 
The formalin fixation procedure is known to change MR parameters, but these are partly 
reversible by PBS immersion.  Any extra steps in the slice preparation protocol could lead to 
additional differences with the in vivo situation, and should therefore best be avoided.9,14,15
The debate on the exact origin of MRI contrast of amyloid plaques is ongoing, but recent work 
by Meadowcroft et al. shows both dense amyloid accumulations and iron deposits appear to 
play a role.9 Within human AD material they showed that focal iron load in amyloid plaques 
registered well with increased transverse relaxation rates. In contrast, in their mouse model 
similar effects were seen even in plaques lacking significant iron accumulation, suggesting the 
interaction of water with the highly compacted amyloid fibril masses as a possible cause for the 
increased relaxation rates. However, they also showed that the standard Perls’ DAB staining is 
not sensitive enough to the levels of iron present, while a modified protocol was able to show 
minute amounts of iron even in some of these murine plaques. Applying these modified 
protocols to 60 µm formalin-fixed human tissue however, high unspecific background staining 
hampered clear interpretation, as observed by Meadowcroft et al.9 and our own studies (data 
not shown). As we were unable to exploit the more sensitive iron staining  in human material, 
several questions remain unanswered, e.g. whether diffuse plaques have any effect upon MRI 
contrast at all, due either to iron or Aβ deposits. Therefore, several adjustments were made to 
previously published modified Perls’ DAB staining protocols focusing on iron accumulation 
within Aβ deposits of AD brain tissue.10,12 To lower non-iron-specific DAB enhancement, 
endogenous peroxidase was blocked using methanol before applying the pretreatment 
described by LeVine et al.10 The Prussian blue reaction, involving binding of iron(II) containing 
ferrocyanide to iron(III) within the tissue, was employed using concentrations as described in 
Smith et al.12 Next, the peroxidase-like H2O2-dependent oxidation of DAB used to enhance the 
iron staining was performed in PBS rather than in aquadest.16 In our hands, the DAB 
enhancement was best if applied for 2 minutes. Employing our modified Perls’ DAB staining on 
AD brain tissue resulted in similar iron plaques-like structures, as previously described by LeVine 
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et al.10, while the low unspecific background staining allows a more accurate registration with 
MR then described previously using the modified Perls’ staining. Besides these high focal iron 
depositions many local iron accumulations, which had previously remained undetected, 
emerged from the background. (Figure 4.6C) The more diffuse iron staining, observed in a 
sublayer of the cortex, could also be detected on the corresponding MR image, in agreement 
with recent findings by Duyn et al. in vivo.17 This global iron distribution should not be mistaken 
for unspecific background staining; in the latter case, the entire cortex would be stained, and 
the MRI findings would not correspond.
Although this modified staining technique improves the ability to correlate MR signal changes 
to focal and diffuse iron concentrations, it has a major disadvantage in that staining for amyloid 
by standard Thioflavin T or S is not possible, probably due to the very dark pigmentation of the 
iron-stained sample. Since Thioflavin T or S is an indicator of amyloid (as opposed to Aβ), a 
correlation between the localization of iron and amyloid is not possible. The immunofluorescence 
stain does detect the presence of Aβ, but without the ability to discriminate between dense 
core amyloid and diffuse plaques containing only fibrilar Aβ. Therefore, using our method we 
obtain much higher iron staining efficiency, but as a consequence we cannot make any 
statements as to whether the MR hypo-intensities correspond only to iron co-localized with a 
specific type of Aβ deposition and/or amyloid. Nevertheless, we can conclude that almost all 
Aβ deposits, whether diffuse plaques or amyloid, contained traces of iron detected by our 
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MR Microscopy of human Aβ deposits - 
 characterization of parenchymal amyloid,  
diffuse plaques and vascular amyloid
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Abstract
Cerebral deposits of amyloid-beta peptides (Aβ) form the neuropathological hallmarks of 
Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA). In the brain Aβ can aggregate 
as insoluble fibrils present in amyloid plaques and vascular amyloid, or as diffuse plaques 
consisting of mainly non-fibrillar Aβ. Previously, magnetic resonance imaging (MRI) has been 
shown to be capable of detecting individual amyloid plaques, not only via the associated iron, 
but also Aβ itself has been suggested to be responsible for a decrease in the image intensity. 
In this current study we aim to investigate the MRI properties of the different cerebral Aβ 
deposits including diffuse plaques and vascular amyloid. Post-mortem 60 µm thick brain sections 
of AD, CAA and Down’s syndrome patients, known to contain Aβ, were studied. High resolution 
T2*- and T2-weighted MRI scans and quantitative relaxation maps were acquired using a microcoil 
on a Bruker 9.4T MRI system. Specific MRI characteristics of each type of Aβ deposit were 
examined by co-registration of the MRI with Congo Red and Aβ-immunostainings of the same 
sections. Our results show that only fibrillar Aβ,  present in both vascular and parenchymal 
amyloid, induced a significant change in T2* and T2 values. However, signal changes were not 
as consistent for all of the vessels affected by CAA, irrespective of possible dyshoric changes. 
In contrast, the non-fibrillar diffuse plaques did not create any detectable MRI signal changes. 
These findings are relevant for the interpretation and further development of (quantitative) MRI 
methods for the detection and follow-up of AD and CAA.
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Introduction
Diagnosis of Alzheimer’s disease (AD) in vivo remains a problematic issue. Despite recent efforts 
to sharpen clinical criteria, a definitive diagnosis still requires histopathological evidence showing 
the cerebral presence of amyloid-β peptides(Aβ) aggregated into amyloid plaques and 
neurofibrillary tangles (NFTs).1,2 Although the precise role of amyloid in AD pathology is still not 
completely understood, accumulation of amyloid plaques is thought to precede the onset of 
the first clinical symptoms by up to two decades.3,4 Clinical imaging techniques capable of 
visualizing and quantifying these early changes might enable early diagnosis.
Thus far the clinical role of magnetic resonance imaging (MRI) has been confined to depicting brain 
atrophy from mid-stage AD onwards.3 However, clinically MRI has not been able to detect earlier 
pathophysiological alterations, despite preclinical evidence that showed detection of individual 
amyloid plaques by MRI was feasible in post mortem human brain tissue5-8 as well as ex vivo and 
in vivo in several AD mouse models.6,9-16 The high magnetic field strength, high resolution and long 
acquisition time used in these studies prohibit a direct translation of appropriate imaging protocols 
to the clinic. Though detection of individual plaques is not realistic in a clinical setting, quantitative 
T2 and T2* measurements could be used to detect relaxation changes associated with amyloid 
plaque accumulation, or associated iron deposits, even at an image resolution that is far lower 
than the dimensions of  amyloid deposits.9,17 Promising as it may be, this requires a full 
understanding of the MRI characteristics of all forms of Aβ deposits that may be present in AD. 
The most renowned type of Aβ deposit in the cerebral cortex is the fibrillar plaque, which is 
one of the neuropathological criteria used post-mortem to confirm the diagnosis of AD. 
However, several other types of Aβ deposits can occur in the brain. Neuropathologically, the 
terminology used to describe the different Aβ deposits is diverse. In line with Duyckaerts et al. 
human parenchymal Aβ deposits can be divided into two main subtypes based on their Aβ 
content: diffuse plaques and focal plaques.18 Although the nomenclature of the different types 
of focal plaques is rather heterogeneous (primitive, classic, neuritic, senile and burn-out plaques), 
they generally contain Aβ peptides aggregated into a typical fibrillar β-sheet pleated conformation 
known as amyloid. For the remainder of this paper this type of fibrillar Aβ deposits are referred 
to as amyloid plaques. The presence of amyloid is presumed to lead to neuronal dysfunction 
and even the complete loss of neurons, and correlations between amyloid plaques and clinical 
symptoms have been reported.18 
In contrast, the so-called diffuse plaques are not specific for AD and although abundant in AD 
and healthy controls, they correlate poorly or not at all with dementia.19-23 They are 
histopathologically defined as large, ill-defined patches of parenchymal deposits of Aβ peptides 
but with hardly to no fibrillar amyloid or dystrophic neurites present.18 
The formation of amyloid may also stretch along the vascular wall of leptomeningeal and 
parenchymal arteries and arterioles, and to a lesser extent the brain capillaries. This vascular 
amyloid is commonly referred to as cerebral amyloid angiopathy (CAA).18,24 Although CAA is 
often found to co-exist with AD, it can also appear as an entity on its own leading to microbleeds 
and severe cerebral hemorrhages.25
Thus far, MRI studies have only examined the Aβ-related MR contrast changes with respect to 
parenchymal amyloid plaques.6,9-16 Observed contrast changes were primarily attributed to the 
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accumulation of iron within the plaques.9,10,12,15 However, similar MRI contrast was also observed 
in amyloid plaques without iron, and therefore it has been hypothesized that Aβ by itself 
contributes to the relaxation changes, presumably due to its hydrophobic nature.6,16
The aim of this study, therefore, was to study the MRI characteristics of these different types 
of human cerebral Aβ deposits. In addition to the known induced MRI contrast changes due to 
the presence of amyloid plaques, we investigated the MRI characteristics of diffuse plaques and 
CAA in post-mortem human brain material. Ultimately, a better understanding of the MRI 
correlates of Aβ deposits may help to interpret the observed relaxation changes in quantitative 




Brain tissue was obtained from the tissue bank of our institution and from the Netherlands 
Brain Bank (NBB). Several hours post-mortem, the brains were resected, serially cut in 1 cm 
coronal sections and stored in 4 % paraformaldehyde. Routine autopsy of the brains included 
histological examination for CAA- and AD-related pathology respectively according to Attems 
et al.26 and Braak et al.27 Based on autopsy-confirmed diagnosis we selected tissue from subjects 
suffering from diseases that are known to be associated with cerebral Aβ. We selected patients 
with AD (N = 5), Down’s syndrome (DS) (N = 1), CAA (N = 6) and clinically non-demented controls 
(N = 3). (Table 5.1) Patient anonymity was strictly maintained. All tissue samples were handled 
in a coded fashion, according to Dutch national ethical guidelines (Code for Proper Secondary 
Use of Human Tissue, Dutch Federation of Medical Scientific Societies). Previously described 
formalin-induced tissue artifacts that might affect MRI signal were avoided accordingly by careful 
visual and microscopic inspection and including material fixed for maximal 32 months.28,29 
 (Table 5.1)
Sample preparation
MR samples were prepared according to methods that have been described previously.7 
In short, from each subject a cortical tissue block of approximately 12 x 12 x 10 mm3 was 
resected based on known predilection sides for the different types of Aβ. To study parenchymal 
deposits samples were obtained from a coronal section that contained a section of the 
hippocampus to enable imaging of the neocortex in the medial temporal lobe adjacent to the 
entorhinal cortex. To investigate the vascular Aβ deposits, tissue blocks were obtained from 
occipital lobe cranial within the sulcus, since the occipital lobe is the site of predilection of CAA. 
Remnants of the dura were removed from the pial surface, and 60-µm-thick tissue sections 
were cut with a vibratome (VT1000S, Leica, Germany). Prior to imaging, any residual formalin 
was washed out by immersion in phosphate buffered saline (PBS) for at least one day to partially 
restore  transverse relaxation times.30 Sections were mounted on a standard microscope slide 
covered with a drop of PBS to prevent dehydration.7 Extreme care was taken to avoid the 
inclusion of any air bubbles by slowly lowering the coverslip, after which the section was sealed 
with nail polish.
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MRI acquisition and post-processing
All MRI experiments were performed on a vertical bore 9.4 T Bruker Avance 400 WB spectrometer, 
equipped with a 1 Tm-1 actively shielded gradient insert. As previously described, a self-resonant 
microcoil was placed directly on top of the sample to obtain MR images of the 60-µm-thick tissue 
sections.7 Multi-gradient-echo (MGE) images were acquired to assess T2* with a repetition time 
(TR) = 750 ms, echo time (TE) = 4-70 ms (12 echoes with 6 ms spacing), flip angle (FA) = 30°, field 
of view (FOV) = 16 x 16 mm2, data matrix [400 x 400] resulting in a resolution of (40 μm)2 with a 
total data acquisition time of 6 hours and 40 minutes. T2 effects were investigated by using a 
multiple spin echo sequence acquired in 4 hours and 26 minutes with TR = 2000 ms, TE = 10-100 
ms (10 echoes with 10 ms spacing), FOV = 16 x 16 mm2, data matrix [200 x 200] giving a resolution 
of (80 µm)2. Post-processing was performed using a voxel-wise linear regression MatLab routine 
(MathWorks, Natick, MA, USA) to calculate quantitative T2* and T2 maps. T2- and T2*-weighted 
images were created as the sum of the third to the tenth echo image.
Despite extreme care in sample preparation, MRI hypo-intensities related to small 
inhomogeneities caused either by external dust particles, or tiny air bubbles were unavoidable. 
These artifacts were present throughout all samples, and were excluded from the analysis 
based on visual microscopic inspection of the sample.
Congo Red staining for amyloid
After MRI acquisition, Congo Red staining was performed for detection of amyloid on the same 
control, DS and AD sections that were analyzed by MRI. After removing the coverslip, the free 
floating tissue section was rinsed in distilled water three times for 10 minutes each. The section 
was counterstained with Harris’ haematoxylin and rinsed in tap water for 10 minutes. After 
pretreatment of 20 minutes with 3% NaCl and 0.01% NaOH in 80% EtOH, the free floating section 
was again immersed in the same solution for 20 minutes with 0.5% Congo Red. The section was 
rinsed briefly in, in turn, 96 – 80 – 70 – 0 % EtOH in distilled water and air-dried prior to mounting 
(Micromount). This additional rehydration step with pure distilled water reversed most non-
uniform shrinkage caused by the ethanol, thereby simplifying subsequent coregistration with 
the MRI data. Directly thereafter the section was digitized using a bright field microscope scanner 
(Pannoramic MIDI, 3DHistech, Hungary). Congo Red stained amyloid was confirmed using 
depolarized light, under which the red stained areas gave a characteristic green birefringence.
Aβ-immunostaining
To detect all isoforms of Aβ, including the diffuse plaques, a standard immunostaining procedure 
using a commercial monoclonal antibody (6F/3D, DakoCytomation, Denmark) was applied.31 
The sections that had previously undergone Congo Red staining had the coverslip removed by 
overnight immersion in xylene, and were rehydrated using 96 – 80 – 70 – 0 % EtOH in distilled 
water. During this process both Congo Red and haematoxylin were completely removed. 
Endogenous peroxidase activity was blocked by applying 0.3% H2O2 in methanol for 20 minutes. 
For antigen retrieval the samples underwent 1 hour immersion in 85% formic acid, rinsing with 
distilled water and PBS, and 30 minutes immersion at 37 °C in 0.1% trypsin (Type II-S, Sigma) 
with 0.1 % CaCl2 at pH 7.4. Next, the floating sections were incubated overnight with a 1:10 
dilution of Aβ-antibody in 1% BSA in PBS at room temperature, and rinsed three times for 10 
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minutes each with PBS before biotinylated RAM secondary antibodies (1:200, DakoCytomation, 
Denmark) in 1% BSA in PBS were added for one hour. Next, the sections were rinsed three 
times with PBS and incubated for 30 minutes with freshly prepared HRP-labeled avidin-biotin 
complex (ABC, Vector Labs, CA, USA). Enhancement was completed by 5 – 10 minutes immersion 
in 100 ml distilled water containing 0.075% 3,3’-diaminobenzidine (DAB) (Sigma) and 15 µl of 
30% H2O2 after which the reaction was stopped in distilled water. The section was then mounted 
and digitized.
Coregistration and ROI analysis
For each section, the processed images were stacked prior to co-registration with their 
corresponding histology using the Cyttron visualization platform (CVP, Leiden, the Netherlands) 
and Adobe Photoshop CS3 (Adobe). Based on evaluation by a neuropathologist (R.N.), the Aβ 
positive areas on immunohistochemistry that were also Congo Red positive were classified as 
amyloid plaques. The poorly-defined larger patches of parenchymal Aβ were classified as diffuse 
plaques based on both their morphology and the lack of Congo Red staining according to the 
previous nomenclature.18 Further analysis included only those areas that clearly contained only 
a single subtype of Aβ deposition. CAA-loaded vessels were selected based on their distinct 
vascular morphology present in the immunostaining. Areas completely devoid of any staining 
were classified as normal appearing gray matter (GM). Based on these classifications, T2*- and 
T2-weighted images were analyzed to detect any corresponding changes in the MRI signal related 
to the specific Aβ-deposits. Quantitative T2* and T2 relaxometry of the different parenchymal 
Aβ deposits was assessed by region-of-interest (ROI) analyses based on the aforementioned 
areas using the Image J software package (National Institutes of Health, Bethesda, MA, USA). 
For amyloid plaques, an ROI of a single voxel was used since this corresponds best to the size 
of the plaques. In contrast, for the areas containing diffuse plaques, the ROI consisted of multiple 
voxels corresponding to the plaque’s outline on histology. To assess normal-appearing GM, 
several ROIs of 100 voxels were selected in anatomically-similar cortical areas. Measurements 
across all samples were combined to calculate averages for each type of Aβ deposit. Possible 
differences in relaxation times for each subtype were tested using a Student t-test, with p-values 




All samples were taken from similar neo-cortical regions of the middle temporal lobe, and 
formalin fixation periods were between 3-24 months. Both diffuse and amyloid plaques were 
present in all samples except for two control subjects 1 and 2, and subject 9, whom only 
contained diffuse plaques. The distribution of both types of parenchymal Aβ, however, often 
co-localized with each other which hampered the selection for further analysis. As we aimed 
to select only those areas containing a single type of deposition, diffuse and amyloid plaques 
could not be scored an all samples. The scored amyloid types and other characteristics of each 
subject are presented in Table 5.1.
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Figure 5.1 Qualitative MRI-histology correlation
Co-registration of (A) Congo Red and (B) Aβ stained section with corresponding (C) T2*- and (D) T2-weighted MR image from 
subject 4 diagnosed with Alzheimer’s disease. The inhomogeneous signal in the cortex appeared to be caused by the deposition 
of Aβ into amyloid plaques: their distribution corresponded to the hypo-intensities as detected on both types of MR images. 
As an example, the more detailed comparison showed several larger amyloid plaques to be co-localized with these hypo-
intensities (arrows). Those smaller in size, or corresponding to a lesser amount of CR staining, were more difficult to discriminate. 
The structural layering of the GM, visible in both MR images, appeared to be independent of the Aβ distribution.
4 mm
400 mm
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Figure 5.2 MRI characteristics of diffuse plaques
Co-registration of (A) Congo Red and (B) Aβ stains with the corresponding (C) T2*- and (D) T2-weighted MR images of subject 
9 diagnosed with Down’s syndrome. Since all Aβ deposits lacked Congo Red staining, they were classified as diffuse plaques, 
which resulted in a relatively homogenous MR image. No Aβ specific changes in MR signal intensity could be discriminated.
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 T2*- and T2 -weighted MRI
On visual inspection of the T2*- and T2-weighted scans by trained observers, only the congophilic 
amyloid plaques were visible as hypointense foci. (Figure 5.1)  Congophilic amyloid plaques 
with smaller diameters than the MRI voxel size were less conspicuous on MRI due to the partial 
volume effect. In general, the signal attenuation was more pronounced on the T2*-weighted 
images; however, the resolution of the T2-weighted images was four times lower than the T2*-
weighted images due to time restrictions. Despite the large amount of Aβ present in the diffuse 
plaques, their presence did not result in any visible change in MRI contrast as compared to the 
surrounding GM in either sequence. This was most strikingly seen on close examination of 
cortical sections of subject 9, who was diagnosed with Down’s syndrome, showing abundant 
parenchymal Aβ deposits but completely lacking fibrillar amyloid. (Figure 5.2) MR images of 
normal appearing GM showed no cortical hypo-intensities apart from tissue preparation-
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Figure 5.3 MRI characteristics of healthy age-matched brain tissue
Co-registration of (A) Congo Red and (B) Aβ stains with the corresponding (C) T2*- weighted image and (E) T2* map, and (E) 
T2-weighted image and (F) T2 map of control subject 2. No inhomogeneous hypo-intensities were found within the GM since 
no Aβ was present. Small circular hypo-intensities were observed both on and next to the section due to the inclusion of 
small air pockets underneath the coverslip.
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Quantitative T2* and T2 relaxation
Similar to the visual assessment, only the amyloid bearing deposits were associated with a 
significant decrease in T2* and T2 relaxation times. (Figure 5.4) Further quantification of these 
findings by ROI analysis demonstrated that cortical areas containing diffuse plaques (T2 =  63.4 
± 3.1 ms (mean ± SD); p = 0.051; T2* = 47.3 ±  6.2 ms; p = 0.28) were not associated with a 
significant difference in either T2 or T2* relaxation when compared to normal appearing GM 
(T2 =  55.1 ± 2.5 ms; T2* = 47.5 ±  4.7 ms). (Figure 5.5) In contrast, focal amyloid-bearing deposits 
showed a significant reduction in T2 and particularly in T2* relaxation times (T2 =  49.9 ± 10.0 






Figure 5.4 Quantitative MRI of parenchymal 
Aβ deposits
Co-registration of (A) Congo Red and (B) Aβ 
stains with corresponding quantitative (C) T2* 
and (D) T2 maps of subject 5. No signal decrease 
was observed corresponding to the outline of 
areas with Aβ lacking CR positivity (white circle). 
In contrast, as an example several but not all 
amyloid plaques highlighted by the presence of 
both CR and Aβ clearly resulted in hypo-
intensities seen on the corresponding MR 
images (arrows). 
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Vascular amyloid
Several subtypes of CAA were present within the subjects which, based upon the Aβ 
immunostaining, could be classified as:  a) “large vessel” CAA without, or b) “large vessel” CAA 
with dyshoric changes (i.e. amyloid extending outside the vascular wall into the parenchyma), 
or c) capillary CAA. (Table 5.1) In four subjects more than one subtype of CAA was present, 
while capillary CAA, which is relatively rare, was only detected in one subject. None of the 
selected occipital sections showed evidence of microbleeds or aneurysms that are known to 
often accompany CAA.
Capillary CAA did not result in any detectable MR contrast change on either the T2*- or T2-
weighted images. However, the large CAA-bearing vessels themselves were observed as 
hypointense structures in both scans, irrespective of accompanying dyshoric changes. 
(Figure 5.6) These findings were, however, not consistent for all large CAA vessels, as we also 
observed CAA vessels with a similar histological appearance, but without any signal attenuation 
on MRI. These large variations in appearance on MRI combined with the low number of subjects 



































s) Figure 5.5 T2*  and T2 values of 
parenchymal Aβ deposits
Bar graphs of average (A) T2* and (B) T2 
values in milliseconds (ms) resulting for 
ROI analyses of all samples for normal 
appearing GM (N = 21), diffuse plaques (N 
= 26) and amyloid plaques (N = 40). 
*Significant difference of p < 0.05 after an 
unpaired two-tailed Student t-test. Error 
bars represent the standard deviation.
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Discussion
Previous studies have suggested that Aβ, irrespective of associated iron, might induce detectable 
MRI contrast. Our data, however, demonstrate that the mere presence of large amounts of Aβ 
peptides alone is not sufficient to change T2 or T2* relaxation significantly, since diffuse plaques 
are not associated with intensity changes on the MR images. Only when Aβ is deposited in its 
fibrillar amyloid conformation are T2* and T2 relaxation times reduced, which can be observed 
as the punctuate hypo-intensities described in previous studies.5-16 In addition, this study also 





Figure 5.6 MRI presentation of different types of CAA
Detailed Aβ immunohistochemistry with corresponding T2*- and T2-weighted images of several types of CAA: (A) dyshoric 
CAA (subject 14); (B) “large vessel” CAA (subject 12); and (C) both capillary CAA and “large vessel” CAA (subject 13). For (A) and 
(B) the majority of the CAA could be correlated to similarly-shaped hypo-intense structures. In (C) neither “large vessel” nor 
capillary CAA were associated with a change in MRI signal intensity.
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not observed in all CAA-affected vessels. With regard to the cerebral presence of Aβ, this would 
imply that quantitative MRI would depict the cerebral fibrillar amyloid load rather than the 
amount of cerebral Aβ peptides.
The current study used a magnetic field strength and spatial resolutions that are not clinically 
applicable; however, this study of the neocortical Aβ deposits may provide background 
information that can support the development of future clinical (quantitative) MRI methods. 
Currently clinical scans do not allow the detection of individual plaques limited by the maximum 
resolution. We therefore did not aim to colocalize individual amyloid plaques, but tried to 
characterize which types of Aβ deposits produce changes in MRI signal.
Diffuse plaques are hypothesized to be pathologic and are suggested to function as a seeding 
point for amyloid plaques. However, they are not specific for AD, they do not correlate with 
severity of dementia, and clinical evidence regarding their role in the pathogenesis of AD has 
not yet been reported.19-23 In contrast, amyloid plaques are considered to be one of the definitive 
hallmarks of AD, and thus their presence forms one of the diagnostic criteria for AD. Any imaging 
technique aiming at the detection of amyloid should be sure to preclude the assignation of the 
Aβ deposited as diffuse plaques, especially since they are often found to be present in large 
quantities. (Figure 5.4)
The current clinical standard for in vivo amyloid plaque detection uses [11C]-Pittsburgh-B 
compound (PiB) as an imaging tracer for positron emission tomography (PET). Numerous studies 
have demonstrated its specificity and sensitivity for plaque detection, showing that PiB binding 
is highly selective for fibrillar Aβ deposits in AD.32 However, its ability to delineate diffuse plaques 
and even NFTs has also been reported in a post-mortem study.33 Furthermore, in cases of 
patients with other types of dementias, such as Parkinson’s Disease Dementia, and Lewis Body 
Dementia, correlation of in vivo 11C-PiB with post-mortem neuropathology showed that the high 
11C-PiB retention in these patients was primarily correlated to the presence of diffuse plaques.34,35 
Thus, in the setting of these dementias, 11C-PiB PET has insufficient specificity for in vivo diagnosis 
of comorbid AD due to its inability to distinguish between diffuse and neuritic amyloid plaques.34 
In these cases in particular, MRI could provide additional value to confirm the presence of 
amyloid plaque.
In addition to investigating parenchymal Aβ, this study is the first to present findings regarding 
MRI detection of vascular amyloid, another major site of cerebral Aβ deposition. Besides being 
present in the vast majority of AD cases, CAA is an entity in itself and a common age-related 
finding at autopsy.25 CAA leads to local inflammatory responses and loss of vessel wall integrity 
that eventually result in lobar hemorrhages, as well as complete and partial infarcts.24 Thus far, 
only these secondary CAA-related pathologies have been reported to be detectable by MRI, 
but not the vascular amyloid accumulations themselves.36,37 Our results showed that several 
CAA-affected vessels are associated with linear hypo-intensities. As these closely followed the 
outline of the CAA, this suggests that CAA itself in principle should be detectable with MRI.
However, not all CAA-affected vessels resulted in a similar loss of MR signal. Besides having 
vascular amyloid as a common denominator, various differences can be found amongst CAA.24 
These include not only the amount of Aβ deposition but also its position within the vascular 
wall, vasculature fragmentation and loss of structure, formation of fibrinoid necrosis, iron 
accumulation and signs of hemorrhages or microaneurysms. The current study was limited as 
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its current setup did not allow to take these differences into account, though these might explain 
the variation in MRI results found within the present CAA data.
In contrast to amyloid plaques, the usual site for the development of CAA is the occipital lobe 
rather than the medial temporal lobe. Besides differences in clinical appearance, the spatial 
pattern of areas of signal loss might be used for differentiation between parenchymal and 
Figure 5.7 The presence of iron within Aβ 
deposits
Detailed immunofluorescence against Aβ (A) 
with corresponding 3’3-DAB enhanced Perls’ 
iron stain (B) (adapted from ref. 7) In this small 
cortical areas a wide variety of Aβ deposits 
both rich (arrows) and low (arrow heads) in 
iron content is observed. Unable to define 
the diffuse plaques as the fibrillar status of 
each Aβ deposit is unknown, therefore it 
remains unclear whether this might be 
reflected in the iron colocalization.
A
B 200 µm
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vascular amyloid, analogous to the different distribution seen on PiB-PET images in CAA and 
AD patients.38 Additionally, depending on spatial resolution, the typical tubular structure of 
amyloid-laden vessels might be a distinctive feature of CAA.
An effort was made to assess the contribution of capillary CAA to MR signal intensity. Compared 
to the other types, capillary CAA is a rather rare finding but its presence correlates well with 
clinical symptoms such as dementia.39 It was present in only one sample of all our subjects. In 
this sample, direct detection of amyloid on the T2(*) -weighted MRI was hampered mainly by 
the small vessel size and the location of the capillary CAA within or near the stria of Gennari, a 
cortical layer of the occipital cortex known to result in a loss of signal using these sequences.40 
Further MRI studies including more capillary CAA samples will be essential to state with 
confidence whether capillary CAA leads to signal changes on MRI.
The possible effects of chemical fixation of tissue when acquiring post-mortem MRI data should 
always be taken into consideration and form an important limitation in the direct clinical 
translation of these types of studies.28 Known effects such as altered water diffusion properties, 
reduced relaxation parameters and tissue changes due to prolonged fixation can be minimized 
by including only samples subjected to a well-defined, limited, fixation period and by thoroughly 
washing the sample with PBS to partially restore transverse relaxation times.28,30 This cannot, 
however, compensate for possible effects on T2(*) caused by protein cross-linking. In addition, 
tissue iron concentration are known to decrease due to prolonged formalin fixation, which 
influences MRI parameters.26,41 Whether this iron wash-out differs between the distinct types 
of Aβ deposits remains unknown. With regard to this study most samples were fixated for a 
similar period of just over two years, including the controls (Table 5.1), which makes it unlikely 
that the reported differences in MRI signal were induced by differences in fixation.
Future studies may include the use of fresh unfixed tissue as to circumvent these possible 
fixation effects.42 The 60 µm thick sections required for the direct one-to-one correlation as 
performed within this study, however, hampers the use of fresh non-frozen tissue due to 
technical difficulties with sectioning and mounting of the tissue. 
Iron has been indicated to play an important role in the MR contrast of amyloid plaques. 
However, the presence of iron within the different Aβ deposits remains to be further elucidated; 
a significant fraction of amyloid plaques have been reported not to contain any iron43, whereas 
several analytical microscopy  studies showed a high spatial correlation between amyloid and 
an increase iron concentration with respect to the surrounding tissue26,44,45; only one study 
reported the presence of iron within vascular amyloid other than that associated with 
microbleeds46; and as yet no relation of iron with human diffuse plaques has been reported. 
The main focus of this study, however, was to investigate the MR characteristics of the different 
types of Aβ pathology rather than to precisely unravel which constituent is responsible for the 
observed contrast. The potential role of iron within the non-fibrillar diffuse plaques remains an 
interesting one, both as a source of MRI contrast and as a neurotoxic species. In a previous 
study using similar sections, we showed that even within a small cortical area, the iron content 
was highly variable in areas with a relatively similar Aβ load. (Figure 5.7)  Whether this difference 
can be explained by the presence of amyloid fibrils is yet unclear, because despite several 
attempts using different histological stains against fibrillar amyloid, we have not been able to 
perform triple stainings on these thick sections.
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In conclusion, direct MR microscopy of histological sections offers a valuable tool to characterize 
MR changes in relation to different Aβ substrates. The results in this study show that both “large 
vessel” CAA and parenchymal amyloid cause hypo-intensities visible on T2*- and T2-weighted 
MRI. In contrast, diffuse plaques do not cause any MRI signal changes. These findings provide 
relevant background information for the interpretation and further development of specific 
MRI methods for the detection and follow-up of AD and CAA.
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Abstract 
Non-invasive methods to detect AD (AD) in vivo at an early stage are important for increasing 
our still incomplete understanding of the pathophysiology of the disease. Recently, 7T MRI 
systems that generate novel susceptibility-based contrasts in the human cerebral cortex have 
become available. In this study we aimed to assess whether differences in cortical appearance 
could be observed in AD patients using 7T MRI in vivo and to assess the nature of these changes 
by a histological-radiological correlation ex vivo.
In vivo regional cortical differences between probable AD patients (n=14) and healthy control 
subjects (n=15), visible on 7T susceptibility-weighted (SW) images, were analyzed after defining 
a novel scoring method based on the cortical appearance. In addition, post-mortem MRI of 
confirmed AD cases (n=6) was performed to assess the histological correlates of the changes 
observed in vivo in AD patients. 
Diffuse hypointense bands were frequently found in the cortex of the frontal lobes of AD 
patients (57%), but not in controls. Histologic correlation revealed that the pattern of the 
susceptibility-weighted contrast in the cortex of AD patients does not primarily co-localize with 
amyloid plaques or neurofibrillary tangles, but with microglia- and myelin-associated iron 
accumulation and with an altered myelin cytoarchitecture.
Our observation of disturbed iron accumulation and myelin architecture in AD may have 
important implications for future in vivo diagnosis of AD, but also for the understanding of the 
pathophysiological mechanisms underlying this disease.
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Introduction
For the definitive diagnosis of AD (AD) histological post-mortem detection of amyloid plaques 
and neurofibrillary tangles is required. During life, only a probable diagnosis can be made that 
is based primarily on clinical signs and symptoms.1 However, recently it has been proposed to 
use biomarkers based on CSF analysis, structural MRI and amyloid imaging using PET, as 
supporting diagnostic criteria in research settings.2 
Over the past few years, the feasibility of detecting the histological hallmarks of AD using MRI 
has been explored by many research groups. In general these efforts have focused on detecting 
individual amyloid plaques: increased iron accumulation around amyloid plaques induces a 
magnetic susceptibility effect, which is visible as hypointense foci on T2*-weighted or 
susceptibility-weighted (SW) MRI in the cerebral cortex of transgenic AD mouse models and in 
human post-mortem brain slices.3-5 However, these findings have not yet been convincingly 
replicated in vivo in patients, and it is doubtful whether detecting individual amyloid plaques 
with MRI will be possible in a clinical setting given the required high anatomical resolution, 
limited scanning time, and physiological motion of the patient. Furthermore, the central role of 
amyloid in the pathophysiology of AD remains a topic of debate. Although amyloid is still 
considered to be a hallmark as well as an initiating factor in the progression of the disease, 
there is increasing evidence that other primary or interacting causes, including changes in iron 
metabolism, may exist.6,7
Recent advances in human MRI systems operating at an ultra-high magnetic field strength (7 
Tesla and higher) show that the increased sensitivity to susceptibility effects generates iron-
based contrasts in the human brain that have not been observed at lower fields.8 The aim of 
our study was to establish whether 7T MRI allows in vivo detection of differences in the cerebral 
cortex between probable AD patients and healthy age-matched controls. Having observed a 
difference, we then determined the histological substrate of the changes by comparing MRI to 
light- and electron microscopy (EM) of human post-mortem material of AD patients and controls. 
Materials & Methods
In vivo MRI study
Participants 
This study was approved by the institutional review board. In all cases, informed consent was 
obtained according to the declaration of Helsinki. Fourteen probable AD patients (mean age 
76.4 years (range: 68 - 86), 9 males) and fifteen control subjects (mean age 75.1 years (range: 
69 – 80), 10 males) were included. (Table 1) AD patients were recruited from the memory 
outpatient clinic of our institution. Memory outpatient clinic patients were referred to the 
hospital by their general practitioner or a medical specialist. Prior to the 7T MRI study these 
patients all underwent a routine clinical protocol, comprising a whole brain MRI (performed on 
a clinical 3 Tesla platform), a battery of neuropsychological tests, and a general medical and 
neurological examination performed by a neurologist, psychiatrist or internist-geriatrician. 
The diagnosis was made in a multidisciplinary consensus meeting using the National Institute 
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of Neurological and Communicative Disorders and Stroke and AD and Related Disorders 
Association (NINCDS-ADRDA) criteria for diagnosing probable AD.9 Participants with the diagnosis 
‘probable AD’, who were capable of giving informed consent and who had a Mini Mental State 
Examination (MMSE) of ≥19 were selected for inclusion in the 7T study, either retrospectively 
within one year after attending the memory clinic, or prospectively. Healthy control subjects 
were recruited by focused advertisements. Subjects between 69 and 80 years of age, who were 
living independently and had an MMSE of ≥25 and a Geriatric Depression Scale (GDS) of ≤4 
were selected for inclusion. Control subjects with the following diseases were excluded: stroke, 
Parkinson’s disease, diabetes mellitus, rheumatoid arthritis, polymyalgia rheumatica, cancer, 
heart failure, and chronic obstructive pulmonary disease. 
MRI data acquisition
Our study was performed on a human whole-body MRI system operating at a magnetic field 
strength of 7 Tesla (Philips Healthcare, Best, The Netherlands) using a quadrature transmit and 
16-channel receive head coil (Nova Medical, Wilmington, MA, USA). AD-related pathology spreads 
throughout almost the entire brain, but macroscopically typically involves the fronto-temporal 
association cortices.10-12 Participants were scanned using a 2D flow-compensated axial T2*-
weighted gradient-echo sequence which included the frontal lobe for detection of AD pathology 
with a total imaging duration of 10 minutes. Imaging parameters were: repetition time (TR)/
echo time (TE) 794/25 ms, flip angle 45°, slice thickness 1.0 mm with a 0.1 mm interslice gap, 
20 slices, 240 x 180 x 22 mm field of view, 1024x768 matrix size – resulting in an in-plane spatial 
resolution of 0.24 x 0.24 mm2. The bandwidth per pixel was 46 Hz, corresponding to a readout 
length of approximately 22 ms. Frequency and phase encoding directions were along the 
anterior-posterior and right-left axes, respectively. This sequence is very sensitive to image 
artifacts arising from resonance frequency fluctuations within the brain caused by slight patient 
movements, even in areas significantly away from the head, and so a navigator echo was 
Table 6.1 Characteristics of patients and controls and scoring results of the in vivo SWI study
AD Controls p-value
(n = 14) (n = 15)  
Characteristics:
Male / female 9 / 5 10 / 5 0.893
Mean age (range, yrs) 76.4 (68 - 86) 75.1 (69 - 80) 0.497
MSME (range) 22.5 (19 - 26) 29.2 (27 - 30) 0.000
Presence of diffuse band:
Superior frontal lobe 2 / 14 (14.3%) 0 / 15 (0%) 0.224
Middle and inferior frontal lobe 8 / 14 (57.1%) 0 / 15 (0%) 0.001
    
Hypo-intense foci
Superior frontal lobe 0 / 14 (0%) 0 / 14 (0%) -
Middle and inferior frontal lobe 0 / 14 (0%) 0 / 14 (0%) -
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included to correct for these artifacts.13 Shimming up to third order was performed using an 
image based shimming approach.14 Phase images were unwrapped by high-pass filtering with 
a 92x92 kernel size. SW images were constructed by applying four phase mask multiplications.15
Whole brain imaging at this high spatial resolution (0.24 x 0.24 x 1 mm3) however would result 
in an impractically long imaging duration, particularly for AD patients.13 Since susceptibility 
artifacts induced by the temporal bone hampered the imaging of the temporal lobe, the final 
imaging volume focused on the frontal lobe, which is less prone to atrophy than the temporal 
lobe, but is known to accumulate high amyloid loads16, to have a lower metabolic rate17, and to 
have an altered resting state network connectivity in AD.18
Image analysis
Based on previous 7T MRI studies of the human cortex in post-mortem brain specimens of AD 
patients4 and in vivo imaging of healthy volunteers19 we developed a scoring method to capture 
the appearance of the cortex on SW images. We defined a normal cortex based on the following 
criteria: a) a cortical ribbon containing one homogeneous layer with a higher signal intensity as 
compared to the adjacent white matter (WM), b) a cortical ribbon containing two well-defined, 
homogeneous layers, with the superficial layer demonstrating a higher signal intensity compared 
to the deepest layer (the layer adjacent to the WM) and the WM, or c) a cortical ribbon with 
three layers: the same layers as previously described separated by a third thin layer with a lower 
signal intensity than the other two layers. (Figure 6.1) Abnormal cortex was classified as a 
deviation from the normal patterns described above, showing the presence of well-defined foci 
of signal loss (hypointense foci) and/or more diffuse areas with lower signal intensity in the 
superficial layer as compared to the adjacent WM (a diffuse band). (Figure 6.1) Features were 
scored as present or absent per subject in several predefined gyri of the frontal lobe. (Table 
6.1) Uniform window settings were used for all images. Images were scored by two 
neuroradiologists (B.E. and M.L.) who were blinded for the diagnosis in a consensus reading.
Statistics
A Mann-Whitney U-test was used to assess differences in age and MMSE, and a chi-square test 
was used to assess differences in gender between AD and control groups. For each feature 
A B C D
 AD Control
Figure 6.1 The observed variations of in vivo 7T SWI appearance of the human cortex 
Shown are the middle/inferior frontal brain area of an AD patient (A) and healthy elderly controls (B, C, D). An clear example 
of a cortical ribbon containing a hypointense diffuse band is observed in the AD patient (A). Please note the blurring of the 
edges of the layers. (B) shows an example of a cortical ribbon containing one regular layer with higher signal intensity than 
the adjacent WM. In (C) a cortical ribbon is shown containing two well-defined layers. (D) shows a cortical ribbon containing 
three well-defined layers.
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(hypointense foci and/or a diffuse band), a Fisher’s exact test was performed per brain region. 
Positive and negative predictive values of the features to detect AD were calculated per brain 
region. All statistical analyses were performed with the Statistical Package of Social Sciences 
(SPSS 17.0.1; SPSS, Chicago, Ill).
Post-mortem MRI study
Study design
To investigate the histological substrates responsible for the observed in vivo MRI changes at 
7T, we applied similar scan methods on post-mortem material of AD patients and controls using 
a vertical-bore 9.4 T system (Bruker Biospin, Ettlingen, Germany). For each sample high-
resolution (isotropic 40 µm voxels) images were acquired, as well as images with a similar 
resolution (isotropic 200 µm voxels) as were used in the in vivo study. The lower resolution MR 
images were acquired to help translation between the in vivo and ex vivo MR data sets. The 
high-resolution MR images helped to identify the particular MR images that matched best with 
the 8-µm thick histological sections.
Sample preparation
Brain tissue was obtained from the tissue bank of the Department of Pathology at our institution 
and from the Netherlands Brain Bank (NBB, Netherlands Institute for Neuroscience, Amsterdam). 
Following a post-mortem interval of <19 hours, brains were resected and stored in 4% 
paraformaldehyde. At both institutions brain tissue was examined histologically for the presence 
of AD-related pathology and scored using the Braak classification.20 Based on availability six 
samples with a clinical diagnosis of AD by histological confirmation were selected, as well as 
three age-matched non-demented controls. (Table 6.2) Patient anonymity was strictly 
maintained. All tissue samples were handled in a coded fashion, according to Dutch national 
ethical guidelines (Code for Proper Secondary Use of Human Tissue, Dutch Federation of 
Medical Scientific Societies). To avoid formalin-induced artifacts in the MR images only material 
fixed for a period of between three months and two years was used.21 From each subject one 
tissue block of approximately 4 x 15 x 15 mm3 was resected from the medial temporal lobe 
using a vibratome (VT1000S, Leica, Germany). Care was taken to ensure that the samples were 
resected with a similar gyral orientation. Residual formalin was washed out by placing the 
samples in phosphate buffered saline (PBS) for >24 hours to partially restore MR relaxation 
parameters.22 For MRI, each sample was placed in a customized tissue container and immersed 
in a proton-free fluid (Fomblin LC08, Solvay). Air was removed by application of a vacuum for 
several minutes.21
Post-mortem MRI
Scans were acquired on a 9.4 Tesla vertical bore MRI system, equipped with a 1 T/m actively-
shielded gradient insert and Paravision 5.0 imaging software (Bruker Biospin, Ettlingen, 
Germany). A 20-mm diameter birdcage transmit/receive coil was used to acquire T2*-weighted 
3D gradient echo images with TR = 75 ms; TE = 22.5 ms; flip angle = 25° at either 200 μm 
isotropic resolution with 20 signal averages, or 40 µm isotropic resolution with 28 signal 
averages. The average scan time per resolution was approximately 40 minutes (200 µm 
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resolution) or 25 hours (40 µm resolution), with minor differences between samples of slightly 
different sizes. To create SW images comparable to in vivo scans, the 200 µm resolution phase 
images were unwrapped using a k-space Hanning filter with a width set to 50% of the image 
size.23 Final SW images were reconstructed from the original images by four phase mask 
multiplications.15 All data processing was performed with MatLab (MathWorks, Natick, MA).
Post-mortem image analysis
For assessment of ex vivo SW images we used the same criteria as were used in vivo for defining 
normal and abnormal cortex (hypointense bands and hypointense foci). In addition, since the 
ex vivo images showed increased anatomical detail compared to the in vivo scans (due to the 
absence of physiological motion), a third category of abnormal cortex could be added, namely 
diffuse areas with low signal intensity, not extending parallel to the cortical surface (as in healthy 
tissue) but instead expanding locally in an irregular fashion throughout the cortex, a feature 
which we have termed “clouds” (Suppl. Figure 6.1). Window settings were optimized for each 
sample based on the WM and gray matter (GM) histogram. The 200 μm SW images were scored 
blinded for diagnosis by a neuroradiologist (M.v.B) and MR-microscopy expert (L.v.d.W) in a 
consensus reading.
Histology and electron microscopy
All brain samples were paraffin-embedded and serially cut into 8-µm thick sections. Tissue 
morphology was assessed by standard hematoxylin-eosin (HE) staining. Iron was detected using 
a 3’3-diaminobenzidine-tetrahydrochloride (DAB) enhanced Perls’ staining protocol for light 
microscopy and EM which has shown to be the most sensitive to detect iron-positive structures 
in paraffin-embedded human AD brain tissue.24,25 Consecutive sections were (co-)stained for 
amyloid-beta (Aβ), paired helical filament-tau (AT8), myelin (protolipid-protein (PLP)), microglia 
(CD68 and HLA-DR) and activated astrocytes (GFAP). (Suppl. Table 6.1) Endogenous peroxidase 
was blocked by 30 minutes of incubation in methanol with 0.02% H2O2. After these pre-
treatments, non-specific binding was minimized by incubation with 10% fetal calf serum 
(DakoCytomation). Labeling was visualized by DAB staining (DakoCytomation). All sections were 
digitized with a microscope scanner (Panoramic, 3DHistotech, Hungary) for global and 
microscopic evaluation. To assess co-localization of cellular iron with CD68, HLA-DR or GFAP-
positive cells, sections stained for iron as described above were subsequently treated according 
to the previously described immunohistochemical procedures except for using an Alexa647-
labeled secondary anti-mouse antibody for immunofluorescence. (Suppl. Table 6.1) Co-
localization of these antigens with iron was assessed using a confocal fluorescence microscope 
(LSM 510, Zeiss, Germany). Iron-stained ultrathin (100 nm) sections were examined by electron 
microscopy (JEM-1011, JEOL, Germany) to assess the exact localization of the cortical iron in 
the neuropil. 
Histology-MRI correlation
The digitized histological sections were matched with their corresponding high-resolution (40 
µm) MR images by visual comparison of the contour and vascular architecture of each section. 
The corresponding low-resolution SW image that matched best with the histological section 
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could then be identified directly since the two SW image datasets are inherently co-registered. 
To assess the histological substrate of the cortical changes observed on MR images, the digitized 
histological sections were first inspected at low magnification (2x) alongside the corresponding 
low-resolution SW image. Subsequently, these areas were further analyzed microscopically 
at higher magnification (40x) to look for the microscopic changes underlying the MR. 
All observations were independently verified by three neuropathologists (R.N., S.v.D., M.F.). 
Results
The characteristics of the participants for in vivo MRI are shown in Table 6.1. No difference 
in age (p = 0.497) or gender (p = 0.893) was found between patient and control groups. Scores 
for global cognitive functioning (MMSE score) were significantly higher in controls (29.2 points; 
range 27-30) than in patients with AD (22.5 points, range 19-26), p<0.001. 7T SW images of 
the frontal lobe of probable AD patients (n=14) were visually compared to those of control 
subjects (n=15).
We developed a scoring method to rate the cortical appearance based on previous 7T 
observations in normal brain and post-mortem observations in AD patients, distinguishing 
normal-appearing cortical patterns with one or more homogeneous layers from hypo-intense 
foci or hypointense diffuse bands. (Figure 6.1) Clear in vivo differences between AD patients 
and controls were seen in terms of the presence of diffuse hypointense bands on the SW 
i m a g e s .  ( T a b l e  6 . 1  a n d  F i g u r e  6 . 2 ) 






Figure 6.2 In vivo cortical differences seen on SWI in AD patients versus age-matched control subjects 
Regional distribution of the observed variations of in vivo 7T SWI appearance as presented in Figure 6.1, shown in an AD 
patient and a control subject. The left two columns (A and C) show an AD patient and the right two columns (B and D) a control 
subject. The upper row (A and B) shows the superior frontal region, the lower row (C and D) the middle and inferior frontal 
region. In the AD patient a diffuse band is seen in both regions of the frontal lobe and the double arrows show several locations 
containing this band whereas in the control subject this diffuse band is absent and a regular layer (arrow), two-well defined 
layers (arrowhead) and three-well defined layers (small arrow) could be detected.
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Within the frontal lobe, these patterns were found in the middle and inferior frontal gyri in 
eight out of 14 patients, whereas these diffuse bands were not observed in any of the control 
subjects. In these frontal gyri, the diffuse hypointense band was significantly more prevalent 
in AD patients as compared to controls (p = 0.001), with positive predictive and negative values 
of 100% and 71%, respectively. In the superior frontal gyrus, a similar hypointense band was 
observed in only two out of the 14 AD patients and in none of the control subjects: there was 
no significant difference between the two groups (p = 0.224). For this specific cortical region, 
corresponding positive and negative predictive values were 100% and 55%, respectively. Foci 
of signal loss were not observed in the frontal lobe in either AD patients or control subjects.
Post-mortem cerebral cortex samples of six AD cases and three age-matched controls were 
scanned with a similar SWI protocol as for the in vivo MRI. Two of the controls showed a normal 
cortex. The control subject with an abnormal cortex revealed AD-type pathology (Braak stage 
III), despite the absence of an ante-mortem clinical AD diagnosis. We therefore discuss the 
findings in this case separately. 
In all post-mortem AD samples (six out of six), an abnormal cortex was observed on SW images. 
(Table 6.2) Hypointense bands were observed in five out of six AD cases, and in the control 
with Braak III. Due to the lack of physiological movements, the ex vivo images that were acquired 
with a similar resolution as the in vivo images provided more anatomical detail, and demonstrated 
that the hypointense bands did not cover the full width of the cortex, but were located centrally 
in the cortex. (Figure 6.3) Hypointense foci were observed in two out of six AD cases, and in 
the one control specimen with Braak III. In addition to the scoring criteria defined for the in vivo 
scans, in these post-mortem samples a third category of cortical disturbance could be observed, 
consisting of cloud-like areas of low signal intensity with less alignment along, and more 
expansion through, the cortical layers (four out of six AD cases, and in the control subject with 
Braak III). (Suppl. Figure 6.1)
Comparing radiological and histological data of the same sample, the epicenter of the 
hypointense bands and clouds observed on the ex vivo MR images could be localized in cortical 
layer IV. Subsequently, we assessed which of the histological markers (Aβ, tau, iron, and myelin) 
showed a similar distribution over the cortical layers to the hypointense bands and clouds. 
We observed that the hypointense bands and clouds on MRI co-localized with areas 
characterized by an increased presence of iron and changes in myelin structure. (Figure 6.3) 
Figure 6.3 Comparison of post-mortem SWI with histology
The SWI image of the AD patient (Table 6.2 subject 7) showed a midcortical hypointense band (yellow arrows) in addition to 
several focal hypo-intensities, as opposed to a clear homogenous cortex as seen in the control subject (Table 6.2 subject 1). 
For detailed evaluation similar regions of interest of the cortex are shown alongside each corresponding main image and 
the cortical layers have been assigned accordingly. Neither the cortical distribution of Aβ or tau matched the hypointense 
band. Tau typically showed a band-like pattern in cortical layers II – III and V, and so is not co-localized in the layer 
corresponding to MR signal decrease. Both iron and myelin correlated with the observed pattern of band-like hypo-intensities, 
including a diminished staining in the inner cortical layers V and VI. As compared to the control, the iron staining of the AD 
subject showed an increase in cellular deposits and diffuse iron within the neuropil, mainly centered around cortical layer 
IV spreading to both sides with overlap in layers III and IV. The myelin distribution visualized by the PLP-immunostaining 
showed a similar pattern of increased staining in the AD subject resulting from a denser network of thin myelinated fibers. 
Similar to previous reports, in the AD patient the cortex also contained several small roundish areas devoid of myelinated 
fibers suggesting the presence of amyloid plaques based on their morphological appearance.29
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Only cortices that were scored as abnormal on SW images demonstrated these accentuated 
local patterns for iron and myelin on histological examination. Interestingly, no co-localization 
was observed between the hypointense bands and clouds on MRI and areas staining for Aβ or 
tau. Tau pathology typically affected cortical layers II – III and V. Aβ staining was present to an 
equal extent across all cortical layers. Microscopically, some of the hypointense foci observed 
on the ex vivo images corresponded to large amyloid plaques, but these focal signal voids barely 
contributed to the observed hypointense cortical bands. (Suppl. Figure 6.2)
Since the pattern of the abnormalities observed on MRI corresponded best with the patterns 
observed on iron and myelin-stained tissue, we examined these stainings in more detail. 
Microscopically, using higher magnification, four different types of iron accumulation were 
observed in the cortex: 1) diffuse neuropil deposition associated with myelinated fibers, 2) 
dense stellate cytoplasmic iron accumulation in microglial cells, 3) a dense thin line of perinuclear 
iron accumulation in oligodendroglial and microglial cells, and 4) iron associated with amyloid 












Figure 6.4 Characterization of 
intracortical iron distribution in AD 
brain tissue  
Shown are the different types of  cellular 
and neuropilar intracortical iron in the 
medial temporal lobe of an AD patient 
(Table 6.2 subject 7). (A) Indicated by the 
brown color due to the modified 3’3-
DAB enhanced Perls’ iron staining, iron 
is present as perinuclear (arrow head) 
and stellate cellular deposits (arrow), 
and as diffuse iron spread throughout 
the neuropil (asterix). Morphologically 
the cellular iron was attributed to 
oligodendro- or microglia cells. The 
latter was further verified by the co-
localization of iron (black) with (B) CD68 
(red )  and (C )  HLA-DR (red ) 
immunostaining. As indicated by both 
stainings, even in close proximity to 
these iron-bearing microglia, several 
microglia were present that were 
completely devoid of iron. (D) 
Ultrastructurally, as shown by EM, 
neuropil iron was found to be located in 
the myelin sheets folded around an 
axon. (E) A example of iron found 
associated with an amyloid plaque. (F) 
The negative iron staining of a 
consecutive section did not result in any 
DAB enhancement, thereby confirming 
specificity of the iron stain. (axon, ax; 
myelin sheet, my)
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All four types of iron deposits were more abundant in the subjects with an abnormally appearing 
cortex on post-mortem MRI, including the control subject with Braak III. The first three types of 
iron deposits were localized differently in the cortical layers: neuropil iron accumulation was 
centered in layer IV, extending into layers III and V of the cortex; stellate glial aggregates were 
most abundant in the middle cortical layers (layers III and IV), but were also present to a lesser 
extent in the deep cortical layers (layers V and VI), and perinuclear glial iron accumulation was 
most abundant in layers V and VI, followed by layers IV and III. (Figure 6.3) In addition, increased 
microglial and neuropil iron accumulations were also observed in areas characterized by cloud-
like hypo-intensities on MRI. EM analysis revealed that the diffuse iron in the neuropil was 
located predominantly in oligodendrocytic myelin sheaths. (Figure 6.4D)
The association of iron with myelin sheaths in the neuropil led us to examine the cortical myelin 
in more detail using a PLP staining. Interestingly, the intensity of myelin staining also showed a 
Figure 6.5 Structural alterations of 
intracortical myelin
In addition to the observed differences 
in myelin highlighted by Figure 6.3, this 
figure presents a more detailed 
comparison of the intracortical myelin 
of the medial temporal lobe of (A) an AD 
patient (Table 6.2 subject 4) and (B) a 
non-demented age-matched control 
(Table 6.2 subject 1). Shown are 
midcortical regions (layer IV) with a 
comparable orientation assessed by a 
PLP-immunostaining (brown). At this 
higher magnification, the intracortical 
myelin in the AD subjects  was 
characterized by an accentuated PLP 
staining due to changes in myelin 
structure comprising fragmentation, 
increased segmental tortuosity and 
bead-like varicosities. As a result the PLP 
staining of the AD cortex appeared 
disorganized with loss of individually 
discernable fibers and orientation when 
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colocalization with the low signal intensity bands and clouds on MRI. (Figure 6.3) Histologically, 
these areas were characterized by an accentuated PLP staining due to changes in myelin 
structure comprising fragmentation, increased segmental tortuosity and bead-like varicosities, 
centralized in layer IV, but extending to layers III and V in the AD patients. (Figure 6.3 and 6.5) 
Furthermore, as expected, small round plaque-like areas that were devoid of any myelin fibers 
were observed in cortical areas containing a high number of Aβ deposits.
 
Discussion
Using 7T MRI we observed striking differences in vivo in the frontal cortex between AD patients 
and age-matched controls. In patients with probable AD we found a disturbance of the layered 
structure of the cortex. Previous studies in healthy subjects demonstrated that cortical 
lamination at 7T reflects intracortical myeloarchitecture8,19,26, and this normal pattern of cortical 
lamination was attributed to differences in myelin-associated iron and myelin lipids in the 
different cortical layers.19 Our current study shows that in AD patients the cortical areas of 
altered SW contrast co-localize with areas of increased microglia- and myelin-associated iron 
accumulation and also with changes in myelin cytoarchitecture. However, our data also 
demonstrate that the pattern of the changes observed on MRI does not correspond to the 
pattern of amyloid deposits. These observations are not in line with the previous assumption, 
mostly based on animal experiments, that T2*-weighted and SW imaging contrast in AD primarily 
reflects the presence of iron associated with amyloid plaques.3-5,19 Our observations of disturbed 
iron accumulation and myelin architecture have important implications for in vivo diagnosis of 
AD, and also for the understanding of the pathophysiological mechanisms underlying this 
disease.
According to the amyloid hypothesis oligomeric forms of Aβ are the trigger for a cascade of 
events that ultimately results in dementia. However, there is increasing evidence that a range 
of other etiological factors have an important impact on this cascade, presumably by interacting 
with the Aβ aggregates or by subsequent cellular changes which follow it.6,11,27 In our study, we 
found a close correlation between SW MRI contrast changes, myelin changes and increased 
iron accumulation in cortices with AD pathology. Interestingly, changes in iron metabolism and 
myelin breakdown have both been mentioned as potential upstream mechanisms for AD.11,27 
Iron and myelin are closely associated in the brain. Seventy percent of the brain’s iron is located 
in oligodendrocytes. Maturation of oligodendrocytes and myelin synthesis are both dependent 
on the availability of iron.11,28 During demyelination processes in disease, as well as during normal 
myelin turnover, iron is assumed to be released from myelin into the brain tissue.11 Our 
observation of increased iron in microglial cells (which have an important phagocytic role) in 
areas of altered myelin structure suggests that the observed MRI changes are a reflection of 
increased demyelination. 
Cortical demyelination has been observed previously in AD, but mainly as areas of focal myelin 
loss in the immediate vicinity of amyloid plaques.29,30 We also observed this pattern of myelin 
loss in our samples, but it was much less prominent than the more diffuse changes in myelin 
structure (increased fragmentation, tortuosity, and bead-like varicosities) which we report here. 
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To our knowledge, these findings have not been reported before in human AD, but strikingly 
similar myelin alterations were recently discovered in a mouse model of AD.31
Apart from its role in myelin metabolism, iron is an important upstream and downstream 
modulator of several molecular pathways in AD. Recently it was demonstrated that APP plays 
a physiological role in preventing iron-mediated oxidative stress in the brain.32 In AD, zinc 
accumulation in amyloid plaques and loss of soluble tau interfere with APP’s ferroxidase activity, 
causing increased neuronal iron accumulation. Furthermore, there is evidence that APP 
processing through the amyloidogenic and non-amyloidogenic pathways is affected by iron.32,33 
Finally, experimental data have demonstrated that iron may accelerate Aβ oligomerization.34 
Based on these observations, it has been suggested that iron could be an important biomarker 
of AD.35,36
The data presented here show convincing evidence that the cortical myelin cytoarchitecture 
and iron distribution are disturbed in AD patients. Although these changes might not be central 
to the pathogenesis of AD, the ability to visualize them by MRI creates a putative novel biomarker 
with the potential to reflect an as yet underappreciated change that may accompany the 
progression of AD. However, our data are preliminary since they have been generated in a 
limited number of patients and healthy controls, and cover only a limited part of the brain. 
Post-mortem, we observed these changes in SWI contrast in all patients with confirmed AD. In 
vivo, we observed these changes in cortical appearance only in a sub-set of patients; one reason 
for this discrepancy may be that the patients have been included based on a clinical diagnosis 
(NINCDS-ADRDA criteria), which is known to have a limited diagnostic accuracy (77 - 85%).37 
Further studies, comprising larger patient series and additional controls populations of patients 
with different types of dementia are required to assess the potential of the cortical changes we 
observed to constitute true diagnostic biomarkers for AD. There are many other important and 
related questions, such as whether the presence of cortical changes is associated with reduced 
cognitive function, whether the changes appear early in the course of AD, and whether the 
frontal lobes are the best regions in which to detect these early changes. Additional in vivo and 
post-mortem research on the correlation between ultra-high field MRI and pathology will allow 
us to further elucidate the role of iron and myelin in the pathogenesis of AD. Overall, the analysis 
of the cortical changes via visual inspection and simple scoring criteria, without the need for 
quantitative measurements or sophisticated image processing techniques, makes the proposed 
method very attractive as a diagnostic and research tool in a clinical setting. 
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Supplemental
Supplemental Figure 6.1 Cortical hypointense clouds on post-mortem SW images
Examples of “cloud” hypo-intensities (red arrows) on the post-mortem low resolution SW images corresponding to Table 
6.2 subject 2. These represent a third category of abnormal cortex consisting of diffuse areas with low signal intensity, not 
extending parallel to the cortical surface but expanding locally in an irregular fashion throughout the cortex.
Supplemental Figure 6.2 Focal hypo-intensities on post-
mortem SW images
Correlation of Aβ plaques (A) with focal hypo-intensities on the 
post-mortem high (B) and low (C) resolution SW images 
corresponding to Table 6.2 subject 4. Similar to previous studies, 
areas that contain a high amount of large dense core Aβ plaques 
(arrows) typically co-localized with many focal hypo-intensities on 
the high resolution (isotropic 40 µm voxels) SW images. On the 
corresponding lower resolution SW images (isotropic 200 µm 
voxels), however, only some focal hypo-intensities remained 
discernible, mainly due to partial voluming effects. In general, these 
focal signal voids contributed to a very small degree  to the 




CORTICAL CONTRAST IN AD
|  101
Supplemental Table 6.1 Applied immunohistochemistry procedures including primary and secondary antibodies 
and additional pretreatments







(6F/3D, DakoCytomation, Glostrup, Denmark)
1:20 # 1:200 † 38
Anti-PHF-tau monoclonal mouse 
(AT8, Innogenetics, Ghent, Belgium)
1:2000 # 1:200
Anti-protolipid protein 
(PLP) monoclonal mouse (Serotec)
 1:2000 #  1:200
Anti-human CD68 monoclonal mouse 
(KP1, DakoCytomation, Glostrup, Denmark)
1:50 # 1:200 ‡
¥ 1:100 ‡
Anti-human HLA-DR monoclonal mouse 
(Dakocytomation, Glostrup Denmark)
1:30 # 1:200 ‡
¥ 1:100 ‡
Anti-human GFAP monoclonal mouse







# Biotinylated rabbit anti-mouse (DakoCytomation, Glostrup, Denmark) followed by ABC (Vector) prior to DAB-enhancement
¥ Goat anti-mouse Alexa Fluor 647 (Invitrogen)
† Formic acid + Trypsin
‡ Steamed for 20 minutes in citrate buffer (pH 6)
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Abstract 
In the foreseeable future the molecular imaging field could greatly assist neuroradiologists. 
Reporter molecules provide information on specific molecular or cellular events that could not 
only aid diagnosis, but potentially differentiate between different stages of disorders and 
treatments. In order to accomplish this, reporter molecules literally need to pass a barrier, the 
blood-brain barrier, which is designed to repel non-essential molecules from the brain. Although 
this is not a trivial task, several transport systems could be tricked into guiding molecules into 
the brain. 
The non-invasive nature in conjunction with a wide availability makes MRI particularly suitable 
for longitudinal neurological imaging studies. This review explains the principles of MR contrast, 
delineates different types of reporter molecules and describes strategies to transport reporters 
into the brain. It also discusses recent advances in MR hardware, pulse sequences, the 
development of (targeted) reporter probes and future directions of the MR neuroimaging field. 
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Introduction 
Anatomical images have always been the center of gravity in the daily work of radiologists. 
They provide the basis of many diagnoses supplemented by physiological magnetic resonance 
data or metabolic profiling if necessary. Despite the sophistication of these techniques and the 
wealth of information that can be obtained, the diagnostic information often remains non-
specific and evidence regarding the nature of the underlying disease commonly remains 
circumstantial. In contrast to generic contrast agents used in the clinic, the ‘molecular imaging’ 
(MI) field uses reporter molecules tailored for in vivo detection of specific molecular or cellular 
events. Formally, MI encompasses techniques that directly or indirectly monitor and record the 
spatiotemporal distribution of molecular or cellular processes for biochemical, biologic, 
diagnostic, or therapeutic applications.1,2 (Table 7.1) The technique is widely used in pre-clinical 
research and is on the verge of entering the clinical arena. It enables radiologists to add 
molecular or cellular information to their array of diagnostic tools, which will have a tremendous 
effect on the diagnosis of neurological disorders, where invasive diagnostic techniques like 
biopsies can rarely be used.3,4 Radiologists may even be able to detect “pre-disease” or “pre-
symptomatic states” when molecular and cellular changes arise before they lead to anatomical 
or functional disturbances. Following an early diagnosis, MI could closely monitor the 
effectiveness of therapeutic interventions. 
MR imaging is already the imaging technique of choice for neuroradiologists and MR imaging 
systems are widely available. In principle one could collect anatomical and physiological 
information and report the location of reporter molecules in a patient during a single MR imaging 
session. For these reasons this review focuses on MR-based MI of the brain, explaining the 
principles of MR reporter molecules, describing strategies to target them to the brain and 
reviewing the state of the art in CNS MI.
Brain targeting
An important feature of the brain that sets it apart from other organs in terms of MI is the 
presence of the blood-brain barrier (BBB), a selective barrier to the CNS that impedes the influx 
of most compounds from blood to brain. (Figure 7.1A) It permits the passage of metabolic 
compounds and ions to maintain neuronal function, while shielding off possible harmful 
compounds. The effective barrier results from the selective permeability of tight junctions 
between endothelial cells, although the underlying layers and cell types also exhibit great 
influence on its function and permeability. The endothelial cells in the cerebral vasculature differ 
from normal endothelial cells in having low pinocytotic activity, abundant mitochondria, fewer 
fenestrations and specialized junctions to adjacent cells; all these features play a role in the 
impermeability of the BBB.5 
The BBB is generally regarded as a bottleneck for MI imaging of the brain, as it severely hinders 
the delivery of reporter probes to the brain. Designing reporter molecules such that they may 
cross the barrier is not trivial, although a good understanding of BBB physiology has resulted 
in several delivery strategies.6 With paracellular transport sealed off, transmembrane transport 
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through endothelial cells is the only way to gain access to the brain. Several strategies to 
transport MI probes across the BBB can be followed, exploiting different endogenous transport 
systems: passive diffusion, carrier-mediated transport, receptor-mediated endocytosis and 
adsorptive endocytosis.7-10 (Figure 7.1B)
 Small molecules such as oxygen and carbon dioxide readily diffuse into the brain, but the BBB 
is quite restrictive for other compounds. Nevertheless, small non-charged lipophilic compounds 
may be engineered to passively enter the brain.11 However, lipophilic compounds have major 
drawbacks, including enhanced uptake and retention by peripheral tissues, complicating the 
compound biodistribution and pharmacokinetics.12 In practical terms, lipophilic compounds 
are generally not soluble in aqueous solutions. Organic solvents are usually excluded from in 
vivo experiments for toxicity reasons, while others that are in clinical use, such as DMSO, reduce 
the integrity of the BBB, which clearly is not desirable for non-invasive imaging purposes.13 
Metabolites such as glucose, amino acids, nucleosides and neurotransmitters are transported 
into the brain by carrier-mediated transport through proteins in the plasma membrane of 
endothelial cells that catalyze bidirectional transport (blood to brain and vice versa).14 
These pumps operate on both sides of the cell to maintain a nutritional balance. Reporter 
molecules that mimic the structure of a nutrient could trick the transport system to gaining 
entrance to the brain, although efflux pumps on the luminal (blood) side may impede this 
effort.15 Positron emission tomography (PET) has extensively employed this strategy, e.g. by 
using fluorodeoxyglucose as a glucose analog.16 
Larger reporter probes may target internalizing receptors, resulting in receptor-mediated 
endocytosis: following complex formation of the probe and the receptor, the complex is 
internalized, transported to the abluminal (brain) side of endothelial cells and released into the 
brain. The insulin receptor and transferrin receptor are well-known examples.8 This transport 
mechanism is suitable for the translocation of macromolecules and nanoparticles and is 
therefore particularly interesting for MI.7 A prerequisite for this mechanism is a receptor-binding 
ligand, such as a molecular mimic of an endogenous ligand or an antibody against the receptor 
of interest. Evidently, the ligand should be conjugated to a contrast agent or an MR imaging-
detectable nanoparticle to be able to visualize it using MR imaging.
Table 7.1 Definitions
Molecular imaging In vivo imaging of the spatiotemporal distribution of molecular or cellular processes.
Cellular imaging In vivo imaging of the spatiotemporal distribution of cellular processes.
Contrast agent, label Chemical functional group that allows visualization by an appropriate imaging technique. For 
example, Gd chelates or iron oxides are MR contrast agents, 18F atoms are PET contrast 
agents, and fluorophores are optical contrast agents.
Nanoparticle Molecules in the 10-1000 nanometer range that serve as an imaging platform. Examples 
include SPIO particles, liposomes, dendrimers and quantum dots.
Reporter probe, Reporter 
molecule
A molecule or nanoparticle that is used to image particular biological processes. The molecule 
or nanoparticle is a composite of a contrast agent and targeting moiety.
Reporter cell A cell that contains a contrast agent.
Reporter gene A gene that encodes for a protein that (directly or indirectly) is easy to assay. Reporter genes 
are linked to genes of interest to study expression levels.
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Compounds may also be internalized by non-specific interactions with the cell surface. 
Cationized albumin, for example, interacts with the anionic cell surface of the endothelial cells, 
and is then internalized via adsorptive endocytosis.8 This is a general internalization mechanism 
that is not specific for endothelial cells, so with regard to MI this strategy is not very useful, as 
reporter probes would be internalized by a range of cell types, resulting in a high non-specific 
background signal.
It is possible to disrupt the BBB temporarily to gain access to the brain, e.g. through osmotic 
pressure (mannitol). A method that appears relatively safe is the injection of microbubbles into 
the bloodstream followed by focused local ultrasound exposure causing cavitation, leading to 
BBB disruption.17 Such methods may be used for preclinical studies, but will not be suitable for 
clinical use of targeted probes, except perhaps for image-guided drug delivery.
 
Generating MR Contrast
Whatever the object of interest is, the reporter system used to visualize it should contain an 
MR imaging-visible contrast agent. An overview of these agents is provided here below and in 
Table 7.2. Iron oxide particles (SPIO, CLIO and MION) are composed of iron oxide crystals with 
polymer coatings and are often biodegradable. They are synthesized in different forms and 
sizes, ranging from 300 nm to 1.6 μm in diameter, and each size category exhibits different 
pharmacodynamical behavior and relaxation effects.18 All iron oxide particles possess relatively 























Figure 7.1 Blood-brain barrier
(A) Schematic representation of 
the blood-brain barrier(BBB) and 
(B) transport mechanisms for BBB 
passage (see text for details).
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in signal voids or hypointense regions in T2- or T2*-weighted MR images. The fact that SPIOs 
cause ‘negative contrast’ could make them difficult to distinguish from imaging artifacts or other 
susceptibility sources. To overcome this disadvantage, imaging sequences are being developed 
that produce positive contrast using SPIOs, although the generated contrast is still non-specific 
and cannot be exclusively attributed to the presence of iron oxide particles.19 Some SPIOs are 
approved by the FDA, making them popular choices for cellular and molecular imaging, although 
their relatively large size makes them less useful for targets that are not easily accessible, as in 
neurological applications.
Paramagnetic agents (e.g. Gd) have small positive magnetic susceptibilities that cause a modest 
decrease of relaxation times, particularly T1, resulting in ‘positive contrast’ on T1-weighted 
images.20 The positive contrast effect of paramagnetic contrast agents is much weaker than the 
negative contrast effect of SPIOs. Sensitivity could be enhanced by conjugating multiple Gd-
containing chelates to a single probe, such as a dendrimer or protein, but the design of large 
complexes is always a trade-off between sensitivity and molecular weight. The larger (and 
‘brighter’) contrast agents are synthesized, the more difficulties they will encounter to cross the 
BBB. A special class of paramagnetic contrast agents is encompassed by ‘smart’ or ‘responsive’ 
contrast agents. Their relaxation properties significantly change in response to local physiological 
changes, e.g. in pH, temperature or enzyme activity.21,22 Paramagnetic agents are small and 
generally easy to conjugate to probes of interest, which makes them suitable for neuro-imaging, 
although they remain relatively insensitive. 
Chemical Exchange Saturation Transfer (CEST) is contrast mechanism that has been developed 
over the past decade and is based on magnetization transfer through proton exchange.23 
CEST agents contain exchangeable protons with a resonance frequency different from bulk 
water. Upon selective irradiation of this frequency, magnetization is transferred to bulk water 
through chemical exchange, causing a decrease in the signal intensity of bulk water. The contrast 
can thus be switched ‘on’ (by presaturation of the CEST protons) or ‘off’ (no presaturation). The 
efficacy of CEST agents depends on the exchange rate and frequency difference between the 
exchangeable ‘CEST protons’ and bulk water and can be improved by the incorporation of 
lanthanide ions (PARACEST).24 CEST probes can be engineered to work at different excitation 
frequencies, which potentially allows us to study interactions of cells labeled with different CEST 
agents.25 
Table 7.2 MR contrast
MR Contrast  agent Examples Predominant effect MR sensitivity Notes
T1 agent Gd3+, Mn2+ chelates T1 ++ Gd is chelated for
toxicity reasons
T2 agent SPIO, USPIO T2 ++++ Large range of sizes
MION, CLIO
CEST; paraCEST Amino acids, sugars; saturation ++ Pre-clinical stage
Eu-DOTA transfer
Heteronuclei 19F, 31P “Hot spot” + Negligible
 imaging background signal
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Contrast agents described thus far are detected indirectly, in the sense that they affect the 
relaxation properties of water protons. Their effect is registered in the final proton image. A 
more direct approach is heteronuclear MR imaging. In principle any nucleus with a non-zero 
magnetic spin and a large enough ‘magnetic sensitivity’ could be used. Fluorine (19F) is a popular 
choice in the MI field, as it exhibits favorable MR characteristics with a spin-½, a magnetic 
sensitivity close to that of proton and 100% natural abundance. Moreover, there are hardly any 
endogenous fluorine-containing molecules, so fluorine-based reporter molecules do not suffer 
from background signal. Compared with proton imaging, however, the fluorine signal will be 
rather low; fluorine probes accumulate at most in the millimolar range, whereas the water 
concentration in vivo is roughly 40 mol/l. The design of fluorine-based probes is very variable, 
ranging from low-MW molecules with covalently bound fluorine atoms to perfluorocarbon 
molecules measuring hundreds of nanometers.26-28 Low-MW fluorine probes may be designed 
to accumulate in the brain, where they could take full advantage of the ‘hot spot imaging’ 
principle if they locally agglomerate to sufficiently high concentrations. 
Reporter Systems
MR-based MI is used to detect a wide range of biological events, which can be classified in three 
categories (with some overlap between them). Firstly, the presence of specific molecules, such 
as receptors, can be imaged (see “Detecting molecules”). Secondly, specific cells, such as stem 
cells after transplantation (see “Detecting cells”), can be traced, and thirdly, the expression of 
specific genes (see “Reporter genes”) can be visualized. 
Detecting molecules
Molecular reporter probes come in many shapes and sizes, but their principal components are 
a targeting molecule and a contrast agent.  The probe should be targeting a unique hallmark 
of the biological process of interest. Popular target choices are receptors, enzymes and 
cytokines, which are often expressed to much higher levels in pathologies. Once a target is 
chosen, one needs to select a complementary ligand that binds the target with high affinity and 
specificity. Natural ligands, such as receptor agonists, can be used, or specific ligands, such as 
antibodies or peptides, can be developed. 
Reporter probes are synthesized in a wide range of sizes and can be divided in low-MW probes 
and large MW probes or nanoparticles. (Figure 7.2)  Low-MW probes are based on drugs, 
metabolites or inhibitors, in which single atoms or small functional groups are substituted with 
a contrast moiety. For neurological MI applications, low-MW probes most likely find their way 
to the brain via passive diffusion or carrier-mediated transport. A beautiful example is the small 
fluorine-containing reporter probe developed by Higuchi et al.27 This molecule targets amyloid 
plaques, one of the hallmarks of Alzheimer’s disease (AD) and was intravenously injected into 
transgenic AD mice. (Figure 7.3A-C) Using a combination of 19F and 1H MRI, Higuchi showed 
the presence of this probe in the brain of these mice, presumably bound to amyloid plaques.
High-MW reporter probes (with MWs over 5 kDa and diameters ranging from a few to hundreds 
of nm) are based on proteins or nanoparticles to which contrast agents and ligands are 
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conjugated. Some nanoparticles, such as SPIOs or perfluorocarbon particles, generate contrast 
themselves (see section “Generating MR contrast”), while others (such as liposomes and 











































Figure 7.2 Reporter probes and their orders of magnitude
The actual size of reporter molecules ranges from a several Ångstroms (10-10m) to hundreds of nanometers. (A) High-MW 
biomolecules (not drawn to scale), such as peptides or antibodies, that have target affinity could directly be labeled with a 
contrast agent. Reporter molecules based on liposomes or SPIO particles, tens to hundreds of nanometers in size, are 
conjugated to targeting moieties and contrast agents. (B) Low-MW reporter probes are small molecules that contain contrast-
generating labels. They fall in the low nanometer range. The figure shows reporter probe FSB that is able to cross the blood 
brain barrier and bind to amyloid plaques. It is labeled with 19F for MR imaging.27 
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nanoparticles that contain multiple types of contrast agents, which can be visualized by different 
imaging modalities.29 This concept, referred to as multimodality imaging, combines the strengths 
of different imaging techniques, such as sensitive PET tracers with high resolution MR images. 
For example, Kircher et al. set out to aid neurosurgeons visualizing brain tumor margins.30 
They synthesized a long-circulating multimodality reporter molecule, composed of an iron-oxide 
nanoparticle and a near-infrared fluorochrome and injected this into rats bearing gliosarcoma 
that expressed green fluorescent protein. MR imaging confirmed that microglia had sequestered 
the nanoparticle and displayed the tumor as hypointense regions in T2-weighted images. 
Subsequent optical imaging allowed discrimination of tumors from brain tissue, which ultimately 
could be used by surgeons during surgery. 
  
Detecting cells 
Instead of visualizing reporter molecules, it is also possible to label intact cells, allowing cell 
tracking and gaining knowledge on cell behavior, such as migration patterns of immune cells 
following immunotherapy or stem cell survival following transplantation. 
Evidently, cells should remain viable and functional after the labeling procedure. Cellular contrast 
agents should ideally remain within the desired cell type and not dilute with cell division to 
enable reliable longitudinal studies.31,32 SPIO particles are by far the most used MR contrast 
agents used for MR cell tracking. However, a particular confound is that the MR image cannot 
distinguish viable cells from non-viable cells. Additionally, due to susceptibility effects, 
hypointense regions in MR images are significantly larger than the actual cluster of labeled cells, 
which could lead to misinterpretations of the iron source. MR imaging-based cell tracking does 
not exclusively lean on SPIO particles; Gd-based approaches benefiting from positive contrast 
have also been demonstrated, although substantial amounts of lanthanide-based contrast 
agents are required to affect MR images, which increases toxicity issues.33 Phosphorous and 
fluorine imaging have the advantage of a low background and can often be performed in a 
quantitative manner, but they too suffer from sensitivity issues. Finally, CEST imaging is emerging 
as a very useful technique, especially in reporter gene imaging.34 
Cell labeling can be performed in vitro, after which the labeled cells are implanted or the contrast 
agent may be injected systemically, which is then taken up by phagocytotic cells.35 Many cell 
types readily take up contrast agents via phagocytosis, but non-phagocytic cells (including stem 
cells) can be labeled via transfection agents, fluid phase pinocytosis, encapsulation, receptor-
mediated uptake or magneto-electroporation, amongst others.31,32 Cells that have been labeled 
for CNS application include neural stem cells, oligodendrocyte precursors and macrophages.36-38 
Tracking neuronal stem cells empowers us to study the best way to administer the cells 
(intravenous versus intraparenchymal transplantation), estimate the dose (how many cells to 
use), assess the survival rate, evaluate their migration patterns, check if they find their target 
site and home, and optimize the therapeutic time window.32,39 To illustrate this, Hoehn et al. 
transplanted SPIO-labeled stem cells into the contralateral hemisphere of a mouse displaying 
ischaemic stroke.37 T2*-weighted MR images showed the migration of these cells across the 
brain from the implantation site to the edge of an ischaemic lesion. (Figure 7.3D-F) This example 
demonstrates the possibility to follow cells in real time, which may be used to study the 
therapeutic potential of stem cells in the future.
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Reporter genes 
The previous two sections focused on reporting specific molecules or cells; this section addresses 
imaging gene function, which in contrast to cell tracking, exclusively reports on viable cells. 
Reporter gene imaging is a technique in which gene products (i.e. reporter proteins) are imaged 
in vivo.40,41 Essentially, a reporter gene is transcribed to mRNA, which in turn is translated into a 
reporter protein (which are far more abundant in the cell than DNA or RNA). A good reporter 
protein must be easy to assay and must not normally be expressed in the cells of interest or, 
when encoding for endogenous proteins, must be expressed at much higher levels than normal. 
The gene of interest is unlikely to encode an MR-visible protein, although the protein of interest 
may interact with exogenous reporter molecules.42 Often, the gene of interest is teamed up 
with a reporter gene. These genes can be engineered such that they are both driven by the 
same promotor. Upon activation of this promotor (which can be conditional or tissue-specific, 
for example), the expression of both genes is simultaneously enhanced; imaging the reporter 
protein thus ‘reports’ on the expression of the gene of interest. The reporter protein may 
produce endogenous contrast or may be imaged via exogenous reporter molecules.42 
Reporter gene imaging is currently in a preclinical stage, but its potential is enormous. One 
could monitor gene expression, track cells in normal and abnormal development, map dynamic 
protein interactions and check cell transplantation therapy. Taking this one step further, one 
could follow the effects of gene therapy, in which cells are genetically modified to produce a 
therapeutic effect.40,42 Reporter gene imaging is commonly used in the nuclear and optical 
imaging field, with green fluorescent protein43 and luciferase44 as prominent examples, but MR 
imaging starts claiming a place on stage as well, by virtue of its non-invasive nature and whole-
body coverage. 
Needless to say, for MR reporter gene imaging, the reporter protein needs to be MR detectable 
and common strategies are outlined in recent reviews.40,42,45 Reporter genes may encode for 
artificial proteins, which are detectable by CEST imaging (Figure 7.3G-I)34, but most MR reporter 
systems are based on the accumulation of iron, circumventing the administration of exogenous 
contrast agents. When reporter genes overexpress proteins such as ferritin46,47, the transferrin 
receptor48 or MagA49 at high levels, they cause a local build-up of iron, which leads to enhanced 
negative contrast in T2- or T2*-weighted images. This principle has been demonstrated by 
Genove et al.47, who visualized gene expression using genetically modified replication-defective 
adenovirae carrying the genes for the light-chain or heavy-chain subunits of ferritin. They 
injected the adenovirae into the striatum of a living mouse, which lead to the local overexpression 
of ferritin and the accumulation of endogenous iron. This resulted in enhanced negative contrast 
in T2-weighted MR images, which was visible for weeks. 
The field of MR reporter gene imaging is developing at a steady pace, but before it becomes a 
mainstream clinical tool it has to overcome several issues. The efficiency of gene transfer is 
currently very modest, which in combination with low MR sensitivity, makes MR reporter imaging 
a challenge. Reporter gene imaging (in combination with gene therapy) often uses viral based 
vectors to package genes, and a delivery device to pass them to the target organ. In this respect 
the method is not strictly non-invasive. Current applications of reporter gene imaging are 
therefore mostly confined to small animal models, although clinical applications are anticipated 
in the future, most likely as a tool to visualize gene therapy. 
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Current developments
The field of molecular imaging is developing in several directions. Imaging modalities perform 
better, molecular biologists construct ingenious reporter genes and transgenic mice, while 
chemists improve contrast agents and create multimodal reporter molecules.20,50 
There is a continuous effort to increase the field strengths of human scanners, and these high-
field magnets are making their way into the clinic. The most commonly used clinical scanners 
operate at field strengths of 1.5 Tesla, while 3 Tesla is regarded as high-field, but ultra-high field 
magnets at 7 Tesla are also used for patient studies. As the MR signal is proportional to the 
magnetic field strength, using high-field scanners improves the sensitivity and enhances the 
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Figure 7.3 In vivo examples of molecular neuroimaging using MRI 
(A-C) MR images of transgenic mice displaying symptoms of AD. (A) A fluorine containing reporter probe with affinity for 
senile plaques was intravenously injected and imaged by 19F and 1H MRI. (B) Proton MR image before injection of the reporter 
probe; (C) merged proton and fluorine image after injection of the reporter probe, indicating the anatomical locations of the 
reporter molecule in the brain.27 (D-F) Cellular imaging of migrating stem cells in a mouse model of ischaemic stroke. (E) 
Stem cells were labeled with ultra-small SPIO particles and transplanted into the contralateral hemisphere. (F) They migrate 
from the implantation sites along the corpus callosum towards the ischaemic border zone.37 (G-I) In vivo reporter gene 
imaging using CEST reporter proteins. The left hemisphere of a mouse brain was injected with glioma cells expressing LRP 
(lysine rich protein, a CEST agent); the right hemisphere was injected with control tumor cells. (H) Anatomical MR image of 
the brain; (I) CEST signal intensity-difference map superimposed on the anatomical image, indicating the LRP-expressing 
tumorxenograft.34
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also increases the spectral resolution, which is an additional benefit for 1H-MR spectroscopy 
and CEST-based imaging. Unfortunately high-field magnets do not come without expense: 
increased magnetic susceptibility effects, field inhomogeneity and energy deposition pose 
worries and technical challenges, but these are partly overcome by using optimized coils, fast 
and parallel imaging and refocusing flip angles.52,53 
With regard to molecular imaging, high-field scanners are able to detect lower concentrations 
of reporter molecules, which decreases toxicity issues. This is particularly the case for iron 
oxide-based particles, heteronuclear contrast agents and CEST agents. On the other hand, the 
current lanthanide-based contrast agents do not perform as well at high fields, and their 
relaxation behavior should be significantly improved.20 Regardless of the field strength there is 
a continuous effort to tailor and improve pulse sequences, such as ultrafast imaging sequences 
and creating positive contrast for SPIO particles.19 
Outlook
The road to MR-based MI has been a long one. MR-based contrast agents are inherently far 
less sensitive than radiotracers, which makes them more likely to fail due to sensitivity or toxicity 
problems. Nevertheless, the advantage of providing anatomical, physiological and molecular 
or cellular information during a single examination is so great that research in this area is 
booming.  
In the near future we anticipate that fluorine-based reporter molecules in conjunction with MR 
imaging at high(er) fields holds great promise, combining “hot spot imaging” and sensitivity. In 
contrast to fluorine-based radiotracers, MR reporter probes are relatively long-lived and could 
be imaged at a regular basis while avoiding excessive ionizing radiation. While BBB research is 
in fifth gear, MI imaging of the brain is already in use for pathologies with a (possible) 
compromised BBB, such as cerebrovascular diseases, inflammatory conditions and gliomas. 
Without the need to cross the BBB, this approach could take full advantage of current 
developments in the field. 
Also, alternative therapies for neurological disorders, such as gene therapy and stem cell 
transplantation, are active areas of research and we expect that MI will play an essential role 
in the development of these therapies, for example by tracing labeled stem cells or by developing 
a common platform for treatment and diagnostics. Examples for this common approach are 
already known from cancer research, where liposomal particles have been used that target 
tumor sites, contain anti-cancer drugs and MRI-visible contrast agents to monitor the treatment 
response. 
Many radiologists may regard MI as science fiction, but they should be aware that this field 
develops at a fast pace. Although currently most research is applied in animal models, the first 
radiological studies in humans have already been performed. It is generally believed that MI 
based on radiological techniques will be introduced in the clinical arena within the next few 
years. However, the clinical implementation of MR-based MI will only occur when academic 
radiologists are actively involved in research programs in which they master data collection and 
interpretation of MI images. This could be achieved by providing MI courses to residents, 
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organizing postgraduate courses for radiologists and by creating MI fellowships. Radiologists 
could also assist (bio)chemists in the development of reporter probes to advance clinical 
applications. Seeing that MI is on the brink of leaping to the clinic, radiologists should prepare 
themselves now to join that jump in the near future.
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Abstract
Previously selected amyloid-β recognizing VHH affinity binders derived from the Camelid heavy 
chain antibody repertoire were tested for their propensity to cross the blood-brain barrier (BBB) 
using an established in vitro BBB co-culture system. Of all tested VHH, ni3A showed highest 
transmigration efficiency which is, in part, facilitated by a 3 amino acid substitution in its 
N-terminal domain. Additional studies indicated that the mechanism of transcellular passage 
of ni3A is by active transport. As VHH ni3A combines the ability to recognize amyloid-β and to 
cross the BBB, it has potential as a tool for non-invasive in vivo imaging and as efficient local 
drug targeting moiety in patients suffering from cerebral amyloidosis such as Alzheimer’s disease 
and cerebral amyloid angiopathy. 
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Introduction
Alzheimer’s disease (AD) is the most prevalent form of dementia and clinically characterized by 
an irreversible process of cognitive decline.1 Cerebral amyloid angiopathy (CAA), is the main 
cause of non-hypertensive intracerebral hemorrhage in the elderly.2 AD and CAA share amyloid 
beta (Aβ) accumulation and aggregation as one of their primary neuropathologic characteristics.3,4 
Furthermore, a definitive diagnose can only be made with certainty by post-mortem histological 
analysis of brain tissue. Ideally, treatment of AD and CAA patients has to be started before 
significant cognitive loss has occurred. However, this requires novel diagnostic methods, ideally 
non-invasive, allowing the early detection of these diseases. Therefore, several classical 
antibodies, targeted at Aβ, have been developed for detection and treatment of cerebral 
amyloidosis, but their utilization in vivo has been hampered by their size which prevents them 
from crossing the blood-brain barrier (BBB) effectively. 
Camelidae co-express unusually shaped antibodies which are devoid of light chains next to their 
conventional immunoglobulin repertoire. These antibodies, referred to as heavy chain antibodies 
(HCAb), are composed of two identical heavy chains. Their antigen-binding properties are 
therefore only defined by the variable domains of these heavy chains (VHH). Interestingly, these 
VHH by themselves are fully capable of antigen binding.5
VHH have a molecular mass of ~15 kDa with affinities similar to those achieved with conventional 
antibodies.6 VHH rapidly pass the renal filter, resulting in a rapid tissue penetration and fast 
blood clearance.7 Moreover, it was demonstrated that they can cross the BBB: VHH FC5 binds 
to human cerebromicrovascular endothelial cells (HCEC) and transmigrates across an in vitro 
human BBB model.8 Therefore, VHH are considered to have potential as tools for early non-
invasive diagnosis using targeted contrast agents and delivery of therapeutic agents in patients 
with neurodegenerative disorders.
Targeted drug delivery and non-invasive early diagnosis using targeted contrast agents in 
neurodegenerative disorders are complicated by the regulated interface created by the BBB. 
The BBB’s primary function is to maintain homeostasis of the brain and protect it against 
undesirable compounds and cells. For the identification of compounds that can cross the BBB 
the availability of in vitro BBB (co)-culture systems is imperative. Previously, we reported on an 
in vitro BBB co-culture system consisting of bovine brain capillary endothelial cells (BCEC) and 
newborn rat astrocytes. This established BBB model has been studied thoroughly and was 
shown to mimic the BBB in vitro, having small paracellular permeability, expression of various 
transporters and a relatively high transendothelial electrical resistance (TEER).9
In a previous study, we described a panel of VHH which we selected against Aβ by phage display.10 
As a first step toward in vivo application, we here analyzed their propensity to cross the BBB in 
vitro and the influence of three specific amino acid substitutions on this crossing ability. The 
combination of both properties, that is, the ability to cross the BBB and to recognize Aβ, would 
render these VHH promising tools for non-invasive in vivo imaging and efficient local drug 
targeting in patients with AD or CAA.
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Materials and Methods
VHH used in this study
The VHH used in this study were described previously.10 VHH ni3A, ni8B and va2E are selected 
against Aβ. VHH ni3A and ni8B are derived from a non-immune library; va2E is selected from 
an immune library created after immunisation with post-mortem cerebral blood vessels of a 
Hereditary Cerebral Hemorrhage With Amyloidosis – Duchtype (HCHWA-D) patient. VHH FC5 
encoding mRNA and amino acid sequences are deposited in the GenBank no. AF441486 and 
no. AAL58846, respectively and was produced synthetically.
 
Subcloning and Production 
The VHH genes were subcloned into the pUR5850VSV production vector.11 Thereafter, the VHH 
were produced in E. coli and purified from the periplasmic supernatants as described earlier.12 
To test the necessity of the presence of three atypical amino acids in the N-terminus (framework 
1; FR1) of ni3A for its ability to cross the BBB, a chimearic VHH 3A2E was constructed by PCR 
amplification of FR1 of ni3A and the region starting from complementarity determining region 
1 (CDR1) until FR4 of va2E, and subsequent cloning of the chimearic PCR product into the 
pUR5071myc and pUR5850VSV vectors. All vectors were sequence verified (LGTC, Leiden, 
Netherlands). Production was performed as described previously.12
The open reading frame of the similarly sized control protein alpha-synuclein (SNCA) was PCR 
amplified from human brain cDNA, cloned, sequence verified and its encoded product was 
produced in the pET28 production system (Novagen, Madison, WI, USA). Primer sequences are 
available upon request. All proteins were purified using Talon metal affinity resin (Clontech, Palo 
Alto, CA, USA) according to the instructions of the manufacturer.
Immunohistochemistry
Frozen brain tissue sections (8 µm) from the neocortex of neuropathologically confirmed 
HCHWA-D, AD patients and non-demented controls were rinsed in PBS, fixed with ice-cold 
acetone for 10 min, incubated with peroxidase blocking reagent (Dako Cytomation) for 20 min, 
washed in PBS and incubated with the anti-Aβ VHH (20 ng/µl) in 1% BSA/PBS overnight in a wet 
chamber. Thereafter, the sections were rinsed with PBS and incubated with mouse-anti-VSV 
for 1 hour and EnVision+® system labelled Polymer-Hrp anti-Mouse (Dako Cytomation) for 30 
min. Detection was performed with Liquid DAB+ Substrate Chromogen System (Dako 
Cytomation). In addition, hematoxylin counterstaining was performed and the sections were 
dehydrated and mounted in micromount mounting medium (Surgipath, Richmond, IL, USA). 
6E10 (Covance, Princeton, New Jersey, USA) was used as a positive control for Aβ staining.
In vitro blood-brain barrier system
The in vitro BBB model was prepared as described before.9,13 Briefly, brain capillaries were 
isolated from cortices of bovine brain, acquired at a slaughterhouse (de Boer, Nieuwerkerk a/d 
IJssel, The Netherlands). The capillary fraction was prepared by homogenization, captured by 
percolation with nylon meshes and subsequently digested by enzymes. Astrocytes were isolated 
from cortices of brains of newborn Wistar rats (Harlan B.V., Zeist, the Netherlands) and used 
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for co-culture purposes and the preparation of astrocyte conditioned medium. Brain capillaries 
were cultured on collagen and fibronectin coated culture flasks in 50% astrocyte conditioned 
medium to brain capillary endothelial cells (BCEC). The astrocytes were seeded on the bottom 
of the filter. Two days later the BCEC were passaged on collagen coated Transwell polycarbonate 
filters (surface area: 0.33cm2, pore size: 0.4 µm, Corning Costar, Cambridge, MA, USA) and 
cultured to tight monolayers in 50% astrocyte conditioned medium in 5 days. 
In vitro blood-brain barrier transport
Transport studies were performed after 10 days of seeding and subsequently 5 days of seeding 
on the filters in DMEM+ 10% fetal calf serum (Bio Whittaker Europe, Verviers, Belgium) at 37°C. 
Transport studies were initiated by adding 10 µg VHH to the upper chamber of the in vitro BBB 
system. 60 µl aliquots were taken from the bottom chamber at 5 – 15 – 30 – 60  and 90 min. 
As a control a protein with the same size as a VHH (SNCA) was used. Membrane integrity was 
monitored with transendothelial electrical resistance (TEER) measurements, which was shown 
before to be a reliable and sensitive method to rule out paracellular BBB permeability.9 
The threshold was set at a resistance of 400 Ohm x cm2. After 120 min the cells were washed 
3 times 300µl DMEM+S, harvested and lysed with MPER (Pierce Biotechnology, Rockford, IL, 
USA). For determination of the amount of VHH/protein that transmigrated across the model, 
25 µl aliquots collected from the bottom chamber were immobilized on a Ni-NTA HisSorb 96-
well plate (QIAGEN Benelux, Venlo, The Netherlands) diluted in 1% BSA with a final volume of 
200 µl, at 4°C overnight. Plates were washed 4 times with PBS 0.05% Tween (PBST) and incubated 
with anti-c-myc / anti-VSV monoclonal antibody diluted in 1% BSA for 1 hour at room 
temperature. After washing, plates were incubated with polyclonal Rabbit anti-Mouse Immuno 
globulins conjugated with HRP (DakoCytomation). Plates were washed and detection was 
performed by adding 100 μl OPD (3,7 mM o-phenyldiamine, 50 mM Na2HPO4.H2O, 25 mM citric 
acid) supplemented with 0.01% H2O2 to the wells. When the reaction was clearly visible, 50 μl 
1M H2SO4/well was added to stop the reaction. The extinction at 490 nm was measured utilizing 
a Biotec synergy HT plate reader. Statistical analyses were performed by unpaired 2 tailed t-test 
comparing target VHH to control for each time point (Figure 8.3) or 2-way ANOVA followed by 
a Bonferonni post hoc test (Figure 8.4) using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego California USA). Threshold value for statistical significant 
differences was set at 5%. 
Results
Subcloning and purification of specific VHH
Two independent VHH clones, ni3A and ni8B respectively (Figure 8.1B), were chosen for this 
study.10 These VHH were subcloned into the pUR5850-VSV production vector. Ni3A has an 
unexpected intrinsic efficiency in crossing the BBB. (see below, Figure 8.3) In order to investigate 
the necessity of the presence of three, for VHH unusual amino acid residues in the N-terminus 
of ni3A, [R15-D-G-D], with respect to crossing the BBB, chimaeric VHH 3A2E was constructed. 
3A2E consists of the N-terminus from ni3A fused, at the boundary between FR1 and CDR1, with 
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Figure 8.1 Overview single and chimaeric VHH constructs  
(A) Schematic representation of a conventional IgG with two heavy and two light chains (left) and a Camelid heavy chain IgG 
(right). The variable domains, including the VHH domains used in this study are indicated. (B) Schematic representation of 
the VHHs used for the different experiments. First (top to bottom) the monovalent VHHs FC5 (grey), 8B (less grey), 3A (white), 
and 2E (dark grey) are shown. 8B and 3A differ 3 amino acids in framework 1, 13, 14 and 16, depicted with XX-X and ∆∆-∆, 
respectively. 2E is an unrelated VHH that differs from ni3A and ni8B. At the bottom the chimaeric VHH 3A2E, used to investigate 
the influence of the three unusual amino acids (∆∆-∆) of 3A on the transport, is depicted. 3A2E consists of amino acids 1-16 
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Figure 8.2 Immunohistochemistry using chimaeric VHH 3A2E
Shown are adjacent neocortical cryosections of confirmed AD, HCHWA-D and control subjects stained with a commercial 
anti-Aβ antibody (6E10), chimaeric 3A2E or its negative control. 3A2E retains its functionality of recognizing preferentially 
vascular Aβ. On adjacent sections 6E10 showed the presence of large parenchymal deposits, only partially detected by 3A2E 
within the AD subject and completely lacking upon HCHWA-D tissue. Both control and negative control staining showed no 
non-specific staining patterns. Scale bar = 100 µm.
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the C-terminus of va2E and therefore also contains these unusual amino acid residues. VHH 
va2E also recognizes Aβ but was selected from a different phage display library.10 After 
production in E. coli the pure VHH were isolated from the periplasmic fraction and purified by 
immobilized metal affinity chromatography on Talon beads. An overview of the single and 
chimaeric VHH constructs is shown in Figure 8.1.
Immunohistochemistry
Frozen brain tissue sections of AD, DS and HCHWA-D patients showed specific Aβ staining of 
3A2E indicating that the Aβ recognizing propensity of va2E was preserved in this chimaeric 
molecule (HCHWA-D and control sections are shown in Figure 8.2). The specificity of the Aβ 
staining was confirmed by the absence of staining in control brain tissue sections and an 
identical staining pattern was obtained with, the commercially available Aβ antibody, 6E10 in 
all patients. In contrast to 6E10, only vascular staining was observed with 3A2E, equal to ni3A 
and ni8B, as previously described.10
In vitro blood-brain barrier transport
VHH ni3A, ni8B and FC5 were assessed for their ability to transmigrate across the BBB in vitro. 
While FC5 was previously described to cross the BBB as it was selected for this propensity, we 
didn’t anticipate that ni3A showed higher transmigration velocity than FC5.8 Yet, the 
transmigration rate of ni3A and ni8B was significantly higher compared to FC5 (respectively 
p<0.01 and p=0.02). (Figure 8.3) 
Although VHH ni3A differs by 3 amino acids in its N- terminus from ni8B but has furthermore 
identical CDRs, a significantly higher transmigration velocity was observed by ni3A (p<0.05). In 
order to elucidate the capacity of ni3A to cross the BBB system with high efficiency, two 
additional VHH were tested: VHH va2E and chimaeric VHH 3A2E. The difference in crossing 
efficiency between va2E and the unrelated control protein of similar molecular weight (SNCA) 
did not reach statistical significance (p=0.22). Chimaeric VHH 3A2E has the same FR1 as ni3A 
 control 2E FC5 8B 3A 3A2E












Figure 8.3 Transmigration of VHHs across the in vitro BBB system
Transmigration of the control (SNCA) protein and VHHs 2E, FC5, 8B, 3A and the chimaeric VHH 3A2E at 37°C. Measurements 
were taken 5 – 15 – 30 – 60 – 90  minutes after addition of the VHH samples to the system. Data is represented as OD490 
at consecutive time points. *=p<0.05 compared to the control, trending p values are noted in the graph. VHH 8B and VHH 
3A demonstrate significant transport across the in vitro BBB. In addition, the chimaeric VHH 3A2E shows transport relative 
to the control and native 2E VHH.
PART TWO  |  CHAPTER 8
126  |.
and the 2E-specific C-terminus. Chimaeric VHH 3A2E displayed a significantly higher 
transmigration rate compared to 2E (p=0.002), indicating that the 3 amino acids subtracted 
from ni3A facilitate the crossing efficiency of VHH. At 4°C there was no significant passage of 
the VHH ni3A, indicating that the transmigration of ni3A is by active transport. (Figure 8.4) 
Time as well as temperature was a significant determinant of transport speed, as was determined 
by 2-way ANOVA (time p=0.01 and temperature p<0.01, respectively), confirming the 
temperature dependency of the transport of VHH ni3A.  In all experiments TEER was measured 
to rule out paracellular BBB permeability.9
 
Discussion
The availability of effective treatment for neurodegenerative disorders like AD and CAA is 
currently lacking but dearly needed. This lack of available therapy is partly based on our poor 
understanding of the pathogenesis of these diseases. The absence of reliable and sensitive 
biomarkers that permit studying cerebral amyloidosis in its early phases has certainly contributed 
to this situation. Cerebral Aβ accumulation and aggregation is one of the primary neuropathologic 
characteristics of AD and CAA and is assumed to play a key role in the pathogenesis of these 
diseases. Consequently Aβ is considered to be an important biomarker of cerebral amyloidosis.3,4 
Recently, molecular imaging techniques have been developed that permit detection of brain 
amyloidosis in vivo. Currently, positron emission tomography (PET) using amyloid-binding 
radiotracer compounds are being used for detecting cerebral amyloidosis in patients 
worldwide.14-16 However, these agents detect both vascular and parenchymal Aβ, and are thus 
not well suited to differentially recognize AD and CAA. Therefore, the development of imaging 
moieties that can be used to differentiate between vascular and parenchymal amyloid in living 
patients could help detecting CAA and/or AD in vivo.
Previously we reported VHH which differentially recognize vascular and parenchymal Aβ 
deposition.10 In this study we assessed the ability of these recently selected VHH for their ability 
to serve as imaging moieties and vehicles for tissue targeting. These VHH have the potential to 
serve as delivery vectors for efficient local drug targeting and for diagnostic purposes. It is 
believed that VHH have advantages to serve as imaging agents and/or transport moieties behind 
the BBB as they may overcome some of the current hurdles to transmigrate over the regulated 
interface created by the BBB.7,17 In this study, an established in vitro co-culture model of the 












Figure 8.4 Energy-dependence transmigration of ni3A across the 
in vitro BBB
Measurements were taken 5 – 15 – 30 – 60 – 90 minutes after addition 
of the samples to the system at 4°C and 37°C. Data is represented as 
OD490 at consecutive time points. *=p<0.05 compared to the control, 
trending p values are noted in the graph. Transport of 3A is time and 
temperature dependent, as determined by 2-way ANOVA. Significance 
of the separate time points was determined by Bonferonni post hoc 
test.
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BBB was used to test different Aβ recognizing VHH for their ability to cross the BBB. Previously 
it was shown that in order to acquire a high quality in vitro co-culture model of the BBB one 
needs an optimal isolation method of bovine brain capillaries, and specific culture procedures 
for primary bovine BCEC and rat-astrocytes.9 The co-culture systems used in this study are 
superior to other transport systems with respect to paracellular permeability and the 
maintenance of influx and efflux.18
As VHH FC5 was previously reported to cross the BBB in vitro, we compared the crossing 
efficiency of FC5 to VHH ni3A selected against Aβ. To our great surprise, ni3A showed higher 
transmigration efficiency than FC5 at 37°C. It was reported previously that transport of FC5 
across the in vitro BBB was by uptake and transcytosis via clathrin-coated vesicles, via a 
temperature and energy dependent receptor-mediated endocytosis (RME).19 The first step 
towards elucidation of the mechanism behind the ni3A transport was to test the energy 
dependence of this transport. An experimental observation that would support active transport 
is temperature dependence because energy consumption and active transport processes are 
minimal at 0–4°C while functioning normally at 37°C.20 Although energy dependence can also 
be observed for passive diffusion21,22, the temperature dependency by which a compound will 
diffuse through a medium is neglectable according to the formula: 
D=Doe−EA/RT     [8.1]
(where D is the diffusion coefficient, Do is the “frequency factor,” EA is the activation energy, R 
is the gas constant and T is thermodynamic, or absolute, temperature (i.e. in Kelvins)).23 Thus 
the influence of temperature on diffusion is minimal since the difference between 4°C (=277 
kelvin) and 37°C (=310 kelvin) has a neglect influence on the diffusion coefficient of compounds. 
Therefore transport of ni3A at 4°C and 37°C was compared to investigate temperature and 
energy dependence. At 4°C there was barely passage of ni3A. This indicates temperature and 
energy dependence and suggests that the mechanism of transcellular passage of ni3A is by 
active transport.
Ni3A passes the system with the highest efficiency compared to all other VHH tested. Because 
ni3A is only three amino acids different from ni8B in FR1, and they present different crossing 
efficiencies, we hypothesized that those amino acid residues could potentially be key for the 
crossing propensity. It is interesting to note that these three amino acid diversion of ni3A is a 
special feature that is not present in any germline VHH gene. In order to test this hypothesis, 
VHH 3A2E was constructed, a chimaeric VHH in which we combined FR1 of ni3A with the 
carboxyterminus (CDR1-FR4) of va2E. This affinity binder va2E was selected against Aβ from an 
immune library10 and showed no crossing ability.
In vitro BBB passage of va2E was significantly and positively facilitated by the replacement of 
the three ni3A-specific amino acids. Although the unique amino acids in ni3A are not sufficient 
for efficient transmigration we conclude that they positively affect the transmigration rate. 
Apparently, a combination of N-terminal amino acid substitutions and other ni3A and ni8B-
specific downstream sequences allow ni3A to outperform other VHH in its transmigration 
efficacy. In support, chimaeric 3A2E and ni8B, both having only one of these features, show 
intermediate transmigration efficiencies. The reason for the effect of the three amino acids 
remains to be elucidated. From numerous studies on enhancement of drug transport, it is 
known that positively charged amino acids can increase the BBB permeability and transport 
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into the brain.24 Ni3A has 18 positively charged amino acids and ni8B 17, this could be a reason 
for the enhanced transport. Further analysis of the tertiary structure and the interaction 
between the different molecules is necessary to determine the exact nature of the higher 
transport rate of ni3A.
In conclusion, in this study VHH ni3A shows in addition to a high affinity for Aβ, the ability to 
cross the BBB in vitro. This transport is temperature sensitive and facilitated by three unique 
amino acids. Ni3A has potential as in vivo imaging agent and local drug targeting moiety. Further 
studies will need to focus on its mechanism of transmigration and its application in vivo.
 
IN VITRO BBB PASSAGE OF VHH
|  129
References
1.  Alzheimer, A, Stelzmann, RA, Schnitzlein, HN, et al.  An English translation of Alzheimer’s 1907 paper, “Uber eine 
eigenartige Erkankung der Hirnrinde”. Clin Anat. 1995; 8:429-431.
2.  Revesz, T, Holton, JL, Lashley, T, et al.  Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 2002; 
12:343-357.
3.  Hardy, J and Selkoe, DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to 
therapeutics. Science. 2002; 297:353-356.
4.  van Duinen, SG, Castano, EM, Prelli, F, et al.  Hereditary cerebral hemorrhage with amyloidosis in patients of 
Dutch origin is related to Alzheimer disease. Proc Natl Acad Sci U S A. 1987; 84:5991-5994.
5.  Hamers-Casterman, C, Atarhouch, T, Muyldermans, S, et al.  Naturally occurring antibodies devoid of light chains. 
Nature. 1993; 363:446-448.
6.  Zhang, J, Tanha, J, Hirama, T, et al.  Pentamerization of single-domain antibodies from phage libraries: a novel 
strategy for the rapid generation of high-avidity antibody reagents. J Mol Biol. 2004; 335:49-56.
7.  Harmsen, MM, Van Solt, CB, Fijten, HP, et al.  Prolonged in vivo residence times of llama single-domain antibody 
fragments in pigs by binding to porcine immunoglobulins. Vaccine. 2005; 23:4926-4934.
8.  Muruganandam, A, Tanha, J, Narang, S, et al.  Selection of phage-displayed llama single-domain antibodies that 
transmigrate across human blood-brain barrier endothelium. FASEB J. 2002; 16:240-242.
9.  Gaillard, PJ, Voorwinden, LH, Nielsen, JL, et al.  Establishment and functional characterization of an in vitro model 
of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm 
Sci. 2001; 12:215-222.
10.  Rutgers, KS, van Remoortere, A, Van Buchem, MA, et al.  Differential recognition of vascular and parenchymal 
beta amyloid deposition. Neurobiol Aging. 2009.
11.  van Koningsbruggen, S, de Haard, H, de Kievit, P, et al.  Llama-derived phage display antibodies in the dissection 
of the human disease oculopharyngeal muscular dystrophy. J Immunol Methods. 2003; 279:149-161.
12.  Kazemier, B, de Haard, H, Boender, P, et al.  Determination of active single chain antibody concentrations in 
crude periplasmic fractions. J Immunol Methods. 1996; 194:201-209.
13.  Gaillard, PJ and de Boer, AG. 2B-Trans technology: targeted drug delivery across the blood-brain barrier. Methods 
Mol Biol. 2008; 437:161-175.
14.  Klunk, WE, Engler, H, Nordberg, A, et al.  Imaging brain amyloid in Alzheimer’s disease with Pittsburgh 
Compound-B. Ann Neurol. 2004; 55:306-319.
15.  Small, GW, Kepe, V, Ercoli, LM, et al.  PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 
2006; 355:2652-2663.
16.  Verhoeff, NP, Wilson, AA, Takeshita, S, et al.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 
PET. Am J Geriatr Psychiatry. 2004; 12:584-595.
17.  Muyldermans, S, Cambillau, C, and Wyns, L. Recognition of antigens by single-domain antibody fragments: the 
superfluous luxury of paired domains. Trends Biochem Sci. 2001; 26:230-235.
18.  Prieto, P, Baird, AW, Blaauboer, BJ, et al.  The assessment of repeated dose toxicity in vitro: a proposed approach. 
The report and recommendations of ECVAM workshop 56. Altern Lab Anim. 2006; 34:315-341.
19.  Abulrob, A, Sprong, H, Van Bergen en, HP, et al.  The blood-brain barrier transmigrating single domain antibody: 
mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem. 2005; 95:1201-
1214.
20.  Sugano, K, Kansy, M, Artursson, P, et al.  Coexistence of passive and carrier-mediated processes in drug 
transport. Nat Rev Drug Discov. 2010; 9:597-614.
21.  Lei, YD, Wania, F, Shiu, WY, et al.  HPLC-based method for estimating the temperature dependence of n-octanol-
water partition coefficients. Journal of Chemical and Engineering Data. 2000; 45:738-742.
22.  Tanaka, M, Fukuda, H, and Nagai, T. Permeation of Drug Through A Model Membrane Consisting of Millipore 
Filter with Oil. Chemical & Pharmaceutical Bulletin. 1978; 26:9-13.
23.  Crank, J. The mathematics of diffusion. 2nd ed. Oxford: Oxford Press, 1975:414.
24.  Pardridge, WM. Blood-brain barrier delivery. Drug Discov Today. 2007; 12:54-61.
PART TWO  |  Development of Molecular Imaging strategies
# Authors have contributed to this work equally
1 Department of Radiology, Leiden University Medical Center, Leiden, Netherlands; 
2 Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands; 
3 Nuclear Medicine & PET Research, Radionuclide Center, Free University Medical Center, Amsterdam, Netherlands; 
4 Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA; 
5 Department of Anatomy & Embryology, Leiden University Medical Center, Leiden, Netherlands 




Maaike E. de Backer1
Maarten Rotman2
Brian J. Bacskai4
Mark A. van Buchem1
Silvère M. van der Maarel2
Louise van der Weerd1,2,5
Adapted from PLoS ONE 2012;7(6):e38284
In vivo detection of amyloid-β deposits using 
heavy chain antibody fragments in a transgenic 
mouse model for Alzheimer’s disease
Chapter 9
PART TWO  |  CHAPTER 9
132  |.
Abstract
This study investigated the in vivo properties of two heavy chain antibody fragments (VHH), ni3A 
and pa2H, to differentially detect vascular or parenchymal amyloid-β (Aβ) deposits characteristic 
for Alzheimer’s disease and cerebral amyloid angiopathy.
Blood clearance and biodistribution including brain uptake were assessed by bolus injection 
of radiolabeled VHH in APP/PS1 mice or wildtype littermates. In addition, in vivo specificity for 
Aβ was examined in more detail with fluorescently labeled VHH by circumventing the blood-brain 
barrier via direct application or intracarotid co-injection with mannitol.
All VHH showed rapid renal clearance (10–20 min). Twenty-four hours post-injection 99mTc-pa2H 
resulted in a small yet significant higher cerebral uptake in the APP/PS1 animals. No difference 
in brain uptake were observed for 99mTc-ni3A or DTPA(111In)-pa2H, which lacked additional 
peptide tags to investigate further clinical applicability. In vivo specificity for Aβ was confirmed 
for both fluorescently labeled VHH, where pa2H remained readily detectable for 24 hours or 
more after injection. Furthermore, both VHH showed affinity for parenchymal and vascular 
deposits, this in contrast to human tissue, where ni3A specifically targeted only vascular Aβ.
Despite a brain uptake that is as yet too low for in vivo imaging, this study provides evidence 
that VHH detect Aβ deposits in vivo, with high selectivity and favorable in vivo characteristics, 
making them promising tools for further development as diagnostic agents for the distinctive 
detection of different Aβ deposits.
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Introduction
Besides neurofibrillary tangles, Alzheimer’s disease (AD) is characterized by cerebral deposition 
of β-amyloid (Aβ) in so-called senile or diffuse plaques.1 Similar vascular deposits of Aβ 
associated with cerebral amyloid angiopathy (CAA) lead to loss of vessel wall integrity increasing 
the risk of brain haemorrhages.2 Present in 30% of the non-demented population over 60 years 
of age, CAA co-exists in 90% of the AD patients and forms an important complication in the 
development of immunotherapeutic strategies.3-5 Although, the exact role of Aβ regarding the 
underlying pathogeneses remains unsolved, accumulation is believed to start 20–30 years prior 
to clinical onset.6,7 Distinctive in vivo detection of the different Aβ deposits therefore renders 
important knowledge regarding early diagnosis and preventive therapy development.
Currently, a gross differentiation can only be made based on the occipital predilection of CAA, 
while existing PET ligands, like 11C-PiB, target Aβ in its fibrillar amyloid form rather than specific 
vascular or parenchymal types of Aβ deposits.8
Previously, we have selected heavy chain antibody fragments with high affinity specific for either 
CAA or all types of human Aβ deposits.9 Derived from the Camelid heavy chain antibody 
repertoire, which completely lack light chains, their single N-terminal domain (VHH) is fully 
capable of antigen binding with affinities comparable with those of conventional antibodies.10,11
Blood-brain barrier (BBB) passage was shown to be favorable in an in vitro assay12; therefore, 
this study assessed the in vivo characteristics of two distinct Aβ targeting VHH, ni3A and pa2H, 
for their potential use to differentially detect AD and CAA. First, pharmacologic behaviour and 
biodistribution were examined after administration of radiolabeled VHH into a transgenic AD/
CAA mouse model. Secondly, fluorescently labeled VHH were administered after the BBB was 
circumvented to evaluate their ability to specifically bind Aβ deposits in vivo.
 
Materials and Methods
Production of ni3A and pa2H
VHH ni3A and pa2H were selected from respectively a non-immune or an immune library created 
after immunisation with post-mortem brain parenchyma of a patient with Down’s syndrome. 
VHH were subcloned and produced as previously reported including a myc- or VSV-tag for 
detection and a his-tag for purification.9 Similarly, pa2H free of any additional peptide tags was 
commercially produced by overexpression in yeast (BAC, Leiden, the Netherlands).
Animal studies
All studies were performed using 12 – 16 month old transgenic mice or wildtype littermates 
from a colony set up using the APPswe/PS1dE9 strain (APP/PS1) (JAX), known to accumulate 
vascular and parenchymal Aβ deposits13,  and have been approved by the institutional Animal 
Ethics Committee (DEC) at the Leiden University Medical Center, permit number 09132. Besides 
standard genotyping, after each experiment amyloid pathology was confirmed by standard 
Thioflavin T staining.
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Human material
Human brain tissue was obtained of AD/CAA patients or controls as confirmed by 
neuropathological examination in agreement with the guidelines of the ethics committee of 
the LUMC. Patient anonymity was strictly maintained. All tissue samples were handled in a 
coded fashion, according to Dutch national ethical guidelines (Code for Proper Secondary Use 
of Human Tissue, Dutch Federation of Medical Scientific Societies). 
Murine specificity of the selected VHH
To evaluate appropriate use of the APP/PS1 mouse model, murine cryosections (10µm) were 
stained according previous protocols9,12 with in addition a standard anti-mouse-to-mouse kit 




VHH were labeled according to two different protocols. First, his-tagged VHH were labeled directly 
with technetium-99m (99mTc) using  a previously published protocol.14 Briefly, 20 μl of VHH in PBS 
solution (450-500 ng/µl) was added to 8 μl of an aseptic mixture of 950 mg/l Sn(Cl)2.2H2O and 
2 g/l Na4P2O7.10H2O (Technescan PYP, Covidien, Petten, the Netherlands) in saline. After addition 
of 4 μl of 10 mg/ml of KBH4 (crystalline, Sigma Chemical Co, St. Louis, MO) in 0.1 M NaOH, and 
100 μl of Na[99mTcO4] solution (approximately 200-700 MBq/ml, Technekow, Covidien, Petten, 
the Netherlands) the mixture was gently stirred at room temperature for at least 30 min before 
use. Analysis of the labeling solution, referred to as 99mTc-VHH, yielded a radiochemical purity of 
>95% without detectable unreduced or free 99mTcO4.15
Secondly, untagged VHH were chelated for indium-111 (111In) using diethylene triamine penta-
acetic acid (DTPA). Untagged pa2H was chelated in a total volume of 1.0ml with 20-fold molecular 
excess of p-SCN-Bn-DTPA (Macrocyclics, Dallas, TX) at pH 8.5 in phosphate buffer for 5 hr at 
37.5°C and purified by dialysis using phosphate buffered saline (PBS). 111In chloride (25µl, 111 
MBq/ml, Covidien, the Netherlands) was added to DTPA-pa2H conjugate (0.1ml) in 0.25 M 
ammonium acetate buffer (0.8 ml) at pH 5.5 and incubated for 1 hr at room temperature. The 
reaction was quenched with 50mM ethylene diamine tetra-acetic acid (EDTA) (50 μl) to chelate 
residual non-bound 111In and the radiolabeled antibody was then purified using a Sephadex™ 
G-25 column (PD 10; GE Healthcare) eluted with PBS. Radiochemical purity assessed by instant 
thin layer chromatography (ITLC) yielded a purity of >95%.
Biodistribution and brain uptake
To study the biodistribution, animals were injected intravenously with 0.2 ml radiolabeled VHH 
diluted with saline (5-10 MBq/ml, 10µg/ml). At different intervals (t = 3 – 6 – 24hrs) post-injection 
APP/PS1 (n=4) and wildtype animals (n=4) were sacrificed (Euthanasol, AST Pharma). Similar 
biodistribution experiments using untagged DTPA(111In)-pa2H were only performed at 24 hours 
post-injection for APP/PS1 (n=6) and wildtype mice (n=6). Blood was collected via cardiac puncture, 
and various organs were removed, including the brain, which was divided into the cerebrum and 
cerebellum. All were weighed and counted for radioactivity (Wizard2, Perkin Elmer). After decay 
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correction, radioactivity was expressed as the percentage of the total injected dose of radioactivity 
per gram tissue (%ID/g). Blood/cerebrum ratios were calculated to correct for possible confounding 
effects accountable by residual blood. Similarly, muscle/cerebrum determined target-to-non-target 
ratios. Differences were regarded significant when p ≤ 0.05 using an unpaired one or two tailed 
t-test. Experiments at t = 24hrs were repeated twice using 99mTc-pa2H.
Blood clearance and analysis
Simultaneously, blood half-life was examined by collecting 5 µl tail samples at several time points 
between 3–90 minutes post-injection of radiolabeled VHH into transgenic or wildtype mice 
(n=4-6). Combined with the cardiac blood samples corresponding half-lives were calculated 
using GraphPad Prism.
Similarly, 10 µl samples obtained at 10 and 90 minutes post-injection were mixed with 90 µl 
heparin (34 U/ml saline) and 900 µl PBS. Centrifugation for 10 minutes at 7,000 rpm separated 
plasma from the cell pellet. Radioactivity was measured separately to determine the blood 
distribution of radiolabeled VHH over time.
Specificity of radiolabeled pa2H
Aβ specificity of pa2H-his after 99mTc-radiolabeling was tested by quantitative competition 
autoradiography. Human and murine brain cryosections (20 µm) were blocked with 1% bovine 
serum albumin (BSA)/PBS at 37°C for 1 hour followed by similar application of the labeling 
solution, which was diluted to 1 µg/ml by 1%BSA/PBS with or without additional 1 hour pre-
incubation with excess monomeric or fibrillar Aβ1-40 (rPeptide) at 37°C. Fibrils were produced 
using existing protocols.16
After rinsing 3 times with PBS, radioactivity was counted for 15 minutes by a gamma camera 
(Toshiba GCA7100/UI). A similar region of interest was fitted for each scintigram to assess 
binding of 99mTc-pa2H-his with 0.1 ml of diluted labeling solution as a reference. Binding was 
expressed as the % of radioactivity compared to the section without any competitor. Experiments 
were performed in triplicate.
In vivo Aβ targeting by VHH
Fluorescent labeling
Tagged VHH were fluorescently labeled with Alexa Fluor 594 protein labeling kit (Molecular 
Probes, Invitrogen) according to the manufacturer’s guidelines, except using only half of the 
recommended amount of dye. Briefly spun to remove possible aggregates, extensive dialysis 
removed excess free label. The labeling degree and protein concentration (200–600 ng/μl) were 
determined using the Nanodrop ND1000 (Isogen Life Sciences). Protein integrity was confirmed 
by mass spectrometry.
Immunofluorescence using VHH-Alexa594
To examine whether the fluorescent labeling affected antigen recognition, human and murine 
cryosections (10 µm) were rinsed with PBS, fixed in ice-cold acetone for 10 minutes before overnight 
incubation with VHH- Alexa594 in 1% BSA/PBS in a wet chamber. Washed 3 x 5 minutes with PBS, 
sections were mounted and analyzed using a fluorescence microscope (Leica DMR5500B).
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In vivo Aβ imaging by topical application
Four APP/PS1 animals received permanent cranial windows to allow serial in vivo imaging of the 
brain by multiphoton microscopy. Animals were anaesthetized using 2% isoflurane gas 
inhalation, and the exposed skull was partly replaced by a round glass coverslip glued into place 
using Krazyglue® according to previous surgical protocols.17,18 Prior to fixation of the cranial 
window, a drop of 40-60μl of VHH-Alexa594 (275–400 ng/μl) was applied directly onto the 
exposed brain for 30 minutes and briefly rinsed with PBS. Colocalization with the Aβ deposits 
was based either upon their typical green autofluorescence or by intraperitoneal injections of 
Methoxy-X04 one day prior surgery.16 Animals were imaged immediately following surgery, 
which was typically less than 90 minutes after beginning of the procedure,  and re-imaged under 
isoflurane anaethesia (2%) for several days to study the washout. Images were acquired with a 
Bio-Rad 1024 multiphoton microscope equipped with a Ti:Sapphire laser (Mai Tai, Spectra 
Physics) and external photodetectors (Hamamatsu Photonics). Areas were imaged to 
approximately 200 μm deep in 5 μm steps with a 20x objective (UMPlanFl, NA=0.95; Olympus). 
Maximum intensity projections were reconstructed using ImageJ.
Specific in vivo Aβ binding after BBB disruption 
A systemic approach to study the in vivo behaviour of the VHH throughout a larger area within 
the brain involved intracarotid infusion (60 µl/min) of 100 µl pa2H-his-Alexa594 along with 600 
µl 15% mannitol selectively into the right carotic artery to disrupt the BBB.19 At t = 2 and 24 
hours post-injection., transgenic (n=9) and wildtype animals (n=3) were euthanized (Euthanasol, 
AST Pharma), and perfused with 4% paraformaldehyde (PFA). Resected brains were stored in 
 APP/PS1 Negative control APP/PS1 Negative control 
 Wildtype Negative control Wildtype Negative control
 ni3A pa2H
A B E F
C D G H
200 µm200 µm200 µm200 µm
200 µm200 µm200 µm200 µm
Figure 9.1 Immunostaining on murine APP/PS1 sections using ni3A and pa2H
The upper panels (A - D) show 10x magnifications of the resulting staining with cryosections of aged APP/PS1 mouse brain 
tissue including negative controls, while the lower panels (E - H) show similar staining performed with wildtype littermates.
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4% PFA with 10% sucrose for 4 hours followed by overnight fixation in 4% PFA with 30% sucrose. 
Next, the brains were snap frozen and sectioned completely to obtain consecutive 30 µm thick 
cryosections. Besides standard Thioflavin T staining for amyloid, adjacent sections were 
immunostained for Aβ (6F/3D, DakoCytomation)20 with 1:100 goat-antimouse-Alexa488 
(Invitrogen) to assess colocalization. Images obtained by a Leica DM5500B microscope were 
merged using Adobe Photoshop CS3.
 
Results
Murine specificity of the selected VHH
Immunostained brain sections of aged APP/PS1 and wildtype littermates using tagged VHH ni3A 
and pa2H were made to assess their capacity to selectively recognize different types of deposits. 
(Figure 9.1) Pa2H stained positive for all forms of Aβ depositions. In this transgenic mouse 
model, ni3A did not show selective affinity for vascular Aβ; both vascular and parenchymal Aβ 
depositions were clearly labeled. Compared to ni3A, equivalent staining protocols with pa2H 
resulted in higher specificity for Aβ combined with a low unspecific background binding. For 
neither VHH specific affinity was detected within the brain sections of wildtype animals.
Biodistribution and clearance
Biodistribution and brain uptake
The distribution of a bolus injection of radiolabeled tagged ni3A and pa2H over time is shown 
in Table 9.1 and 9.2. No significant differences in organ uptake between wildtype and transgenic 
animals were found, except for the brain uptake of 99mTc-pa2H after 24 hours. Although the 
amount was low (0.038 %I.D./g), cerebral uptake was 40% higher in the transgenic animals. The 
cerebrum/blood ratio did not differ, indicating that this difference was not caused by different 
VHH concentrations within the blood pool. For the cerebellum similar results were found. 
Repeated experiments for this particular endpoint resulted in similar findings.
To investigate whether these findings were not confounded by either the non-specific 
radiolabeling procedure or the presence of additional peptide tags, the biodistribution 
experiment was repeated with untagged DTPA(111In)-pa2H. (Table 9.2) With this labeling 
protocol, we no longer observed a significantly higher cerebral uptake in amyloid-bearing mice. 
Regardless of the tag, the majority of radiolabeled VHH was excreted via the kidneys. Cellular 
involvement as shown by distinctive hepatic clearance or splenal activity was low. In comparison 
to 99mTc-ni3A, 99mTc-pa2H showed about 3 times higher clearance via liver and spleen. Also, the 
clearance rate for 99mTc-pa2H was lower, independent of genotype. However, within the first 3 
hours 99mTc-ni3A resulted in a higher general organ uptake, with exception of the aforementioned 
liver and spleen.
Blood clearance and analysis
Blood clearance of the tagged 99mTc-VHH consisted of a fast and a slow component. (Figure 
9.2A) In general, the majority of the radiolabeled VHH was cleared from the blood with a half-life 
of 10–20 minutes (Table 9.3). The actual half-life of the slow component of 99mTc- VHH could 
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Table 9.1. Biodistribution of 99mTc-ni3A in mice
t = 3 hr t = 6 hr t = 24 hr
Tissue / 
organ
Wildtypes APP/PS1 Wildtypes APP/PS1 Wildtypes APP/PS1
blood 1.202 ± 0.379 1.146 ± 0.131 0.778 ± 0.048 0.808 ± 0.115 0.451 ± 0.073 0.363 ± 0.051
heart 0.525 ± 0.129 0.508 ± 0.109 0.347 ± 0.049 0.337 ± 0.127 0.252 ± 0.041 0.216 ± 0.014
lungs 0.850 ± 0.184 0.819 ± 0.208 0.659 ± 0.184 0.743 ± 0.301 0.375 ± 0.113 0.291 ± 0.055
liver 1.078 ± 0.235 1.000 ± 0.293 1.078 ± 0.188 1.223 ± 0.424 0.568 ± 0.149 0.488 ± 0.164
kidneys 15.531 ± 2.986 15.192 ± 3.075 10.266 ± 1.657 14.294 ± 4.337 9.089 ± 6.152 9.901 ± 1.158
spleen 0.590 ± 0.257 0.531 ± 0.084 0.792 ± 0.144 0.753 ± 0.291 0.397 ± 0.056 0.465 ± 0.234
muscle 0.171 ± 0.075 0.120 ± 0.069 0.111 ± 0.088 0.086 ± 0.022 0.043 ± 0.007 0.048 ± 0.008
cerebrum 0.035 ± 0.009 0.035 ± 0.007 0.031 ± 0.007 0.035 ± 0.008 0.018 ± 0.003 0.019 ± 0.001
cerebellum 0.073 ± 0.031 0.063 ± 0.009 0.098 ± 0.009 0.096 ± 0.014 0.029 ± 0.005 0.026 ± 0.002
cerebrum/
blood ratio
0.030 ± 0.003 0.030 ± 0.004 0.040 ± 0.010 0.043 ± 0.004 0.040 ± 0.001 0.053 ± 0.008 *
cerebrum/
muscle ratio
0.242 ± 0.142 0.335 ± 0.116 0.407 ± 0.270 0.428 ± 0.171 0.422 ± 0.029 0.403 ± 0.100
A bolus injection of 2 µg 99mTc-ni3A was administered intravenously into 12 – 14 month old APP/PS1 mice or their wild 
type littermates. At three time points after injection the animals were sacrificed and various tissues and entire organs 
were removed, weighed and counted for radioactivity. Values are expressed as a percentage of the injected dose per 
gram tissue (mean ± SD). * = P<0.05 wildtype mice compared to APP/PS1 mice.
























Figure 9.2 Blood clearance 
These graphs represent the blood half lives of tagged 99mTc-ni3A and -pa2H (A), and untagged DTPA(111In)-pa2H (B) in APP/
PS1 mice and wildtype littermates. Data is shown as percentage of injected dose per gram of blood (%ID/g) over time. Based 
upon this plot the clearance is suggested to respectively consist of a fast and a slow phase, or only a single phase.
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only be calculated with limited accuracy, since the half-life was longer than the blood sampling 
period. In line with the above biodistribution, six hours post-injection, the blood levels of 99mTc-
pa2H were remarkably higher compared to earlier time points, which is characteristic for a 
second passage. Within the first 90 minutes about 80% of the 99mTc-VHH remained within the 
blood plasma, indicating that no significant cellular uptake occurred. (Table 9.4)
In contrast to tagged 99mTc- VHH, the blood clearance of untagged DTPA(111In)-pa2H was mono-
exponential, with a similar rapid clearance within 20 minutes, but without a slow component. 
(Figure 9.2B)
Specificity of 99mTc-pa2H
After radiolabeling of the tagged pa2H it’s specificity for Aβ was unaffected, as shown by 
scintigraphic analysis; binding of 99mTc-pa2H was higher in those sections including Aβ. (Table 
9.5) Furthermore, binding was significantly (p<0.001) reduced when the tracer was pre-incubated 
with either monomeric or fibrillar Aβ. 
Day 0 Day 0 Day 0
Day 1 Day 2 Day 2
 ni3A-Alexa594 + Methoxy-X04 ni3A-Alexa594  pa2H-Alexa594
Figure 9.3 In vivo Aβ imaging after direct brain application
Topical application of ni3A- or pa2H-Alexa594 (red) as visualized over time by intravital multiphoton microscopy in APP/PS1 
mice clearly shows the specific in vivo labeling of different Aβ deposits. In the left, vascular and parenchymal Aβ deposits, 
detected by prior labeling with Methoxy-X04 (blue), colocalize with ni3A-Alexa594 (red) directly following topical application. 
One day later, labeling of the plaques has diminished to almost none with some residual left bound to CAA. With interpretation 
hampered by Methoxy-X04, middle images show a similar experiment. Colocalization with Aβ deposits based upon 
autofluorescence (green) gave comparable results and almost complete wash out after two days. Pa2H-Alexa594 (red), as 
shown in the right images, remains bound to vascular Aβ even two days after application, when the plaques remained 
undetected. All images are maximum intensity projections of a 3D cortical volume with a field of view 615 x 615 µm.
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In vivo Aβ targeting by VHH
In vivo Aβ imaging by topical application
After direct application onto the exposed mouse brain, fluorescent VHH were followed up for 
at least 48 hours by in vivo multiphoton microscopy. (Figure 9.3) Specific in vivo labeling of Aβ 
plaques by ni3A-Alexa594 was initially confirmed by colocalization with Methoxy-X04, a known 
in vivo amyloid targeting fluorophore. Beside possible binding competition with the VHH, 
Methoxy-X04 hampered good validation due to signal cross-over into the red channel. However, 
colocalization based on the typical autofluorescence patterns of the different Aβ deposits 
resulted in similar findings. Selectivity was confirmed by lack of nonspecific background signal. 
Although both VHH were capable of targeting Aβ in vivo, only pa2H-Alexa594 was detectable 
after two days, mainly bound to vascular amyloid. 
Specific in vivo Aβ binding after BBB disruption 
Based on the above findings, co-injections of  pa2H-Alexa594 with mannitol were done in the 
right carotid artery to selectively open the BBB in the ipsilateral hemisphere to study the in vivo 
characteristics throughout the brain. Two hours post-injection, fluorescence was detected in 
the right hemisphere, co-localizing with Aβ. (Figure 9.4) Even within the deeper brain structures, 
no nonspecific binding was observed. Aβ related fluorescent signal remained detectable for at 
least 24 hours post-injection. Without BBB disruption or within wildtype littermates, no apparent 
Aβ labeling could be detected.
Immunofluorescence using VHH-Alexa594
Selectivity for specific Aβ deposits was not altered after fluorescent labeling of the VHH, since 
on human sections, ni3A-Alexa594 selectively stained vascular Aβ and  pa2H-Alexa594 stained 
both parenchymal and vascular Aβ. (Figure 9.5) On murine material all Aβ deposits were stained 
by both fluorescent VHH.
 
Table 9.3 Blood half lives of radiolabeled VHH
Fast t½ Slow t½
 VHH  genotype (min) (95% C.I.) % (min) % (95% C.I.)
99mTc-ni3A APP/PS1 14.71 (8.65 - 49.13) 89.7 580 10.3 (101.8 - ∞)
Wildtype ND ND ND ND
99mTc-pa2H APP/PS1 21.89 (14.24 - 39.38) 79.8 2562 20.2 (975.0 - ∞)
Wildtype 10.78 (7.27 - 20.76) 87.1 5861 12.9 (969.3 - ∞)
        
DTPA(111In)-pa2H APP/PS1 19.69 12.63 - 44.60 100 - -
Wildtype 15.83 9.30 - 53.37 100 - -
Half lives were determined by fitting a one or a two phase exponential decay model based on blood obtained from both 
tail vein and cardiac puncture at several time points after intravenous bolus injection of 2 µg radiolabeled VHH in 12 – 14 
month old APP/PS1 mice and wildtype littermates, as depicted in Figure 9.2. Please note that DTPA(111In)-pa2H was 
produced without any additional peptide tags.
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Figure 9.4 Specific in vivo Aβ binding after BBB disruption 
After disruption of the BBB using a co-injection of 15% mannitol with pa2H-Alexa594 into the right carotid artery of an aged 
APP/PS1 mouse sacrificed 2hrs post injection, amyloid plaques are clearly depicted in both hemispheres using a Thioflavin 
T (ThT) staining (A), while the pa2H-Alexa594 signal is only detected in the right hemisphere (B). More careful examination 
shows all Alexa594 signal colocalizes with ThT in the right hemisphere, while in the left only some autofluorescense can be 
detected. Furthermore, immunofluorescense anti-Aβ staining of the plaques using Alexa488 within the left hemisphere (C) 
results only in green signal, while within the right hemisphere (D) the red signal from pa2H-Alexa594 nicely colocalizes within 
the plaques. Experiments performed in a similar setting but sacrificed 24hrs post-injection, showed similar results with 
pa2H-Alexa594 still nicely corresponding to the green labeling of the anti-Aβ staining within the right hemisphere (E).
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Discussion
In this study, we assessed two previously described VHH for their potential to cross the blood-
brain barrier and distinctively detect vascular and parenchymal Aβ deposits in vivo. 
Specific detection of parenchymal and vascular amyloid in APP/PS1 mice
Both VHH stained positive for Aβ upon APP/PS1 brain sections confirming appropriate use of 
this transgenic model. In vivo binding to parenchymal and vascular Aβ was confirmed when the 
BBB was circumvented. Signal remained detectable for at least 24 hours while in vivo pa2H 
showed a high affinity combined with a low off-rate. However, previously shown selectivity for 
solely vascular Aβ in human post-mortem brain sections by ni3A was not observed within this 
mouse model. (Figure 9.1, 9.3 and 9.5) Fluorescent or radiolabeling prior in vivo application did 
not affect their specificity. The unique specific reactivity of ni3A for vascular amyloid deposition 
on human brain material is not yet completely understood.9 Known differences in morphology 
and composition of human and murine Aβ deposits might help to understand ni3A’s specific 
reactivity.21,22 Human plaques consist of discontinuous patches with decreased density and 
random fibrillar orientation within the amyloid core; murine plaques are generally built up by 
long organized fibrils, resulting in densely packed amyloid plaques with a relatively large core.23 
Table 9.4. Blood distribution of 99mTc-pa2H
Sample Time p.i. Fraction APP/PS1 Wildtype
(min) (%) sd (%) sd
99mTc-pa2H 10 Plasma 88,9 6,2 80,3 5,2
Cell Pellet 11,1 19,7
90 Plasma 83,6 8,7 72,0 8,2
Cell Pellet 16,4 28,0
At different time point after bolus injection of 99mTc-pa2H blood collected from the tail vein of 12-14 month old APP/PS1 
mice or wildtype littermates. Separated into the cell pellet and plasma, samples were counted for radioactivity. Fractions 
are expressed in percentage of total activity at that time point. No significant differences were calculated using a student 
t-test (p < 0.05).
Table 9.5. Quantitative autoradiography
Brain tissue Binding of 99mTc-VHH Competion binding
Monomeric Aβ Fibrillar Aβ
ng (± sd) ng (± sd) ng (± sd)
APP/PS1 98.8 (± 20,7)* 60.1 (± 22.2) 31.4 (± 14.3)
Wildtype 86.4 (± 14.8) 56.4 (± 19.5) 27.1 (± 12.5)
AD human 190.1 (± 73.5)* 81.4 (± N.D.) 42.3 (± 29.2)
Control human 102.3 (± 30.2) 27.2 (± N.D.) 49.9 (± 17.4)
Differences in radioactivity were measured after application of 1 µg 99mTc-pa2H to human and murine APP/PS1 brain 
sections. *Statistical difference (p < 0.05) between either murine or human control versus Aβ bearing sections.
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Besides morphological differences, posttranslational modifications of Aβ differ from mouse to 
man leading to alterations of the Aβ molecule itself.21,24,25 Differences in metal ion content are 
known to influence the tertiary structure.26,27 Previous epitope mapping revealed that ni3A has 
no other cross reaction but to Aβ1-42,9 which is highly abundant in parenchymal and vascular 
deposits in both humans and APP/PS1 mice. Altogether, this leads to the conclusion that the 
selective reactivity of ni3A must depend on the structural presentation of Aβ1-42, in which case 
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Figure 9.5 Immunofluorescence with VHH-Alexa594
Shown are the results of immunofluorescence staining with ni3A- and pa2H-Alexa594 on cryosections of APP/PS1 murine 
and human AD/CAA brain tissue, including wildtype or healthy controls. Both VHH stain positive for CAA in all sections (A,D,G,J). 
Only ni3A-Alexa594 stained negative for human parenchymal Aβ (B), while pa2H stained positive for several types of 
parenchymal Aβ deposits (G,H,J,K) in both humans and mice. In either human of murine control tissue no such staining 
patterns were observed (C,F,I,L).
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In vivo blood-brain barrier passage
Previous in vitro data suggested that our VHH actively migrated across the BBB in a more efficient 
way than FC5, a VHH specifically selected to pass the BBB.12 However, the in vivo experiments 
resulted only in a small cerebral uptake of the tagged 99mTc-pa2H at 24 hours after intravenous 
administration, and the current brain uptake levels were insufficient to assess the uptake kinetics 
in vivo with for example SPECT imaging. (data not shown) Additional experiments with untagged 
DTPA(111In)-pa2H further confirmed the current limitations as hardly any cerebral uptake was 
observed with this labeling protocol. The increased brain uptake for 99mTc-pa2H compared to 
DTPA(111In)-pa2H may be due to the slower blood clearance for 99mTc-pa2H. The observed fast 
blood clearance and relatively high renal retention for the VHH in this study is in line with 
previous reports 28,29, and typical for peptides and proteins smaller than the filtering threshold 
of the glomerular membrane (<60kDa).30 However, in general, a short blood residential time 
effectively reduces the blood-to-brain transfer. 
In vivo studies with the BBB crossing VHH FC5 demonstrated 4 %ID/g brain uptake, which is 
much higher than our findings.31 This discrepancy may be due to the lower dose that we used, 
but several other factors may also play a part. For FC5 it is known it uses receptor-mediated 
endocytosis via the α(2,3)-sialoglycoprotein.32 For our VHH, in vitro active transport mechanisms 
are involved, but the specific receptors are as yet unknown.12 Possibly, the in vivo BBB passage 
may be limited by the availability of these receptors in our mouse model. 
To improve BBB penetration for the amyloid-targeting VHH, one could increase the blood 
circulation time by multimerization or by conjugating the VHH to an albumin-targeting moiety 
or VHH.33,34 An alternative approach would be to incorporate the VHH into a BBB-targeting 
nanoparticle. Recently, several nanoparticle carrier systems have been developed for brain 
delivery of therapeutics that would also be suitable for loading with VHH. 35
Diagnostic and therapeutic value of VHH
In general, VHH constitute many unique characteristics that make them interesting tools for 
either diagnostics or therapeutics. Compared to conventional monoclonal antibodies or Fab’, 
VHH express a similar unique level of specificity and affinity, but because of their single domain, 
production and modification is relatively easy and cost-efficient.29  
Currently used amyloid-targeting ligands, like 11C-PiB recognize amyloid plaques rather than 
Aβ. In contrast, we already showed that VHH may be more specific to a certain sub-types of Aβ 
accumulation.9 Further selection may allow the in vivo detection of the full range of Aβ aggregates 
from oligomers to dense core plaques to CAA. 
Besides diagnostics, several VHH have shown their potential therapeutic value in vitro, preventing 
aggregation of amyloid fibrils, oligomeric forms of Aβ and polyA-binding protein nuclear 1.36-39 
In the latter case, even complete clearance of existing aggregates was reported. Whether VHH 
evaluated in this study possess similar abilities is currently under investigation. However, within 
the data presented here, we observed that several Aβ plaques, as detected by their 
autofluorescence, could no longer be seen two days after VHH application. (Figure 9.3) 
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Whereas current passive immunotherapies targeting Aβ are hampered by unwanted 
immunogenic side effects, repetitive administration of VHH has shown to be non-immunogenic.4,40 
Furthermore, their selective binding to different Aβ species, like ni3A’s specific binding for CAA, 
could shift Aβ brain efflux in the favored direction, which could be used to tailor anti-Aβ therapy 
to further reduce therapy-induced complications, e.g. CAA related microbleeds.4,5,41
These initial in vivo studies to investigate whether Aβ specific VHH can be exploited as diagnostic 
tools show promising results for further development. Although capable of strong specific 
binding in vivo with low unspecific background binding and favorable wash-out, issues regarding 
higher brain uptake and clearance need to be addressed in the future. 
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Abstract
Detection of cerebral β-amyloid (Aβ) by targeted contrast agents remains of great interest to 
aid the in vivo diagnosis of Alzheimer’s disease (AD). Bis-styrylbenzenes have been previously 
reported as potential Aβ imaging agents. To further explore their potency as 19F MRI contrast 
agents we synthetized several novel fluorinated bis-styrylbenzenes and studied their fluorescent 
properties and amyloid-β binding characteristics. The compounds showed a high affinity for 
Aβ plaques on murine and human brain sections. Interestingly, competitive binding experiments 
demonstrated that they bound to a different binding site than chrysamine G. Despite their high 
logP values, many bis-styrylbenzenes were able to enter the brain and label murine amyloid in 
vivo. Unfortunately initial post-mortem 19F NMR studies showed that these compounds as yet 





Alzheimer’s disease (AD) is the predominant form of dementia in the aging population. 
The disease is marked by neuronal degeneration associated with deposits of tau proteins in 
intraneuronal neurofibrillary tangles (NFTs) and of amyloid-β (Aβ) peptides in extracellular 
amyloid plaques.1 Although the precise role of amyloid in AD pathology is still not completely 
understood, accumulation of amyloid plaques is thought to precede the onset of the first clinical 
symptoms by up to two decades.2,3 A clinical imaging technique capable of visualizing and 
quantifying these early changes thus may enable early diagnosis and better understanding of 
the pathophysiology. 
Over the past years progress has been made in the development of Aβ-targeting imaging ligands 
suitable for visualization by positron emission tomography (PET), single positron emission 
tomography (SPECT), fluorescence microscopy or magnetic resonance imaging (MRI). 
For clinical use, the [11C]-benzothiazole derivative Pittsburgh compound B (PiB, 1, Figure 10.1) 
is the best characterized in vivo PET radiotracer. However, as the short half-life of 11C limits its 
use to medical centers with an on-site cyclotron, alternatives are desired. Therefore, several 
longer-lived 18F radiofluorinated derivatives have been designed, like flutemetamol (2)4, 
florbetapir (3) and florbetaben(4)5, of which the first two recently have been the first to be 
admitted for commercial use with the last one expected to follow soon thereafter.6,7 Despite 
the inherent high sensitivity of PET, the development of Aβ-targeted imaging probes suitable 
for clinical MRI remains attractive as this would lower the threshold for performing amyloid 
scans given the wider availability of MRI systems as compared to PET systems, the lack of ionizing 
irradiation and the lower costs involved in performing clinical MRI as compared to PET. 
Furthermore, such agents could be used in one scan session comprising a comprehensive 
structural and functional scan protocol as well as a scan to detect the molecular imaging tracers, 
whereas one PET examination only provides one biomarker.
Based on congo red (5), several bis-styrylbenzenes have been reported to show strong Aβ 
binding affinities and serve as potential backbones for in vivo PET or SPECT imaging probes, like 
6 (chrysamine G), 7 (X-34)8, 8 (ISB)9 and 10 (Methoxy-X04)10 (Figure 10.1 and Scheme 10.1). 
The styrylbenzene backbone has also been explored for the development as an MRI contrast 
agent. The initial breakthrough came with the design of compound 9 (FSB), which was specifically 
designed for in vivo detection of Aβ using 19F MRI.11 Since normal biological tissue completely 
lacks fluorine, 19F MRI would allow direct imaging of the amyloid binding compound, without 
any endogenous background signal (‘hot spot imaging’). Initial in vivo animal studies with 
compound 9 showed promising results. Unfortunately, 19F MRI in vivo experiments suffer from 
the inherently low sensitivity of MRI with a detection limit in the micromolar to millimolar range 
depending merely on the voxel size and magnetic field strength. As initial 19F  compound  only 
carried a single fluorine atom this makes 19F MRI  a technical challenge requiring long acquisition 
times. The incorporation of multiple magnetically equivalent 19F atoms could aid with respect 
to this aspect, as the spin of each individual 19F nucleus directly adds to the MR signal. The study 
therefore aimed to further exploit the bis-styrylbenzene backbone as a specific amyloid-β 
targeting MR contrast agent by increasing the number of fluorine atoms positioned to maintain 
favorable NMR characteristics as well as solubility. 
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Synthetized compounds were evaluated with respect to their Aβ binding and specificity, and 
their fluorescent properties. Partition coefficients (logP) were determined to assess 
hydrophobicity. Compounds were injected systemically in  transgenic AD mice  to determine 
BBB passage and affinity for amyloid plaques in vivo. For the most promising compound, in vitro 
and post-mortem 19F NMR studies were performed.
Design
Previously Flaherty et al. have designed a similar series of polyfluorinated compounds, based 
on a bis-styrylbenzene structure with either a non-substituted core with fluorine substitutions 
on the outer rings, or four 19F atoms on the inner ring with a polar substitutent on the outer 
ring.12 These compounds were found to target Aβ in vivo. As was already proven for Methoxy-X04 
Figure 10.1 Previously reported amyloid-β binding ligands
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(10), acidic functional groups are not required for high affinity Aβ binding, with the apparent 
Kd’s of these fluorinated compounds being ~300 fold lower compared to 9. Despite their ability 
to label amyloid in vivo, however, the Flaherty compounds are very hydrophobic, and therefore 
their solubility and blood-brain barrier (BBB) passage are likely to limit their full potential as a 
19F MRI agent. Furthermore, positioning of the 19F group directly on the planar backbone may 
have a detrimental effect on its relaxometry following binding, while it has been suggested that 
in addition to the inherent sensitivity of MRI also 19F relaxivity plays an important role in the 
Scheme 10.1 General synthesis route of envisioned fluorinated bis-styrylbenzenes
R1 R2 R3 R4
10 (Methoxy-X04) OMe H OH H
11 OMe OMe OH H
12 OMe H CH2OH H
13 OMe H CF3 H
14 OMe H OCF3 H
15 OMe H CF2CF2H H
16 OH H CF3 H
17 OH H OCF3 H
18 OH H CF2CF2H H
19 CF3 H OH H
20 OCH2CF3 H OH H
21 O(CH2)3CF3 H OH H
22 OC(CF3)3 H OH H
23 OH H OMe CF3
24 OMe H OMe CF3
Reagents and conditions: a) N-bromosuccinimide, benzoyl peroxide, CCl4, reflux, 16 h. b) Triethyl phosphite, 150 ºC, 16 
h. c) 1. KOtBu or NaH, THF, -10 or 0 °C, 20 min. then D, rt, 16 h. d) tetra-n-butylammonium fluoride, THF, 0 °C, rt, 16 h.
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detection, due to a reduction of the transverse relaxation time (T2) caused by binding to amyloid, 
or by a hydrophobic environment like brain tissue.13 Therefore, we set out to extend the existing 
bis-styrylbenzene library by adding one or more polar moieties to improve solubility and 
increase the number of (magnetically equivalent) fluorine atoms positioned such to maintain 
favorable NMR characteristics. 
As a starting point, Methoxy-X04 (10) was chosen.10 With an affinity for Aβ in the nanomolar 
range (Ki = 26.8 nM), this fluorescent small molecule is frequently used for intravital microscopy 
studies as it has high affinity for Aβ plaques in vivo following intravenous or intraperitoneal 
injection.14 We designed a series of bis-styrylbenzenes with incorporating multiple preferably 
magnetically equivalent fluorine atoms (11 – 24) or additional minor modifications. (Scheme 
10.1) 
Compounds 11 – 24  are accessible from the general synthesis route given in Scheme 10.1, 
with the key building blocks being a diphosphonate (C) and an aromatic aldehyde (D). Substituted 
p-xylene (A) is subjected to radical bromination to yield dibromide (B). This dibromide is then 
treated with triethyl phosphite in an Arbuzov reaction to give diphosphonate (C). A Horner-
Wadsworth-Emmons (HWE) reaction between diphosphonate (C) and an aldehyde (D) yields 
the (E, E)-bis-styrylbenzene (E). If necessary, an additional deprotection step with TBAF is carried 
out to remove the silyl protecting groups (only in the cases where the final compounds have 
hydroxyl substituents). Independently, a similar synthesis route for the design of NFT and 
amyloid probes based on styrylbenzenes was recently published by Boländer et al.15 
The building blocks needed for the synthesis of compounds 10 – 24 are depicted in Figure 




All synthesized compounds are expected to have fluorescent properties based on their 
conjugated ring structures. We therefore determined excitation and emission wavelengths of 
300 nM solutions and the corrected emission intensities were compared to that of Methoxy-X04. 
(Table 10.1) 
It has been reported that binding to amyloid may have a significant effect on fluorescence 
properties16, and therefore the fluorescence was also measured in the presence of synthetic 
Aβ fibrils. The parent compound 10 showed the highest intrinsic fluorescence with a 10-fold 
increase in the presence of amyloid fibrils. A similar increase was typically only observed for 
those compounds that only had minor modifications on the outer rings. Several previously 
reported Aβ-targeting fluorophores have shown a clear red-shifted emission spectrum following 
binding.17,18 Some of our compounds showed a similar red-shift; though resulting in multiple 
emission peaks in the spectrum. (Figure 10.3) This observation suggests the presence of 
multiple binding sites, similar to what has previously been reported, for example for Thioflavin.19
POLYFLUORINATED BIS-STYRYLBENZENES
|  157
Qualitative assessment of human and murine amyloid plaques binding
Fluorescence microscopy was used for a qualitative assessment of the amyloid-binding 
properties. A concentration series of each compound (1 – 10 – 100 μM) was applied to brain 
slices of APP/PS1 mice and human AD patients. At 100 μM all compounds, except 11 and 21, 
showed characteristic staining of amyloid plaques on both human and murine sections. At 
the lower concentrations, however, clear differences in affinity were found. (Table 10.1 and 
Figure 10.4) Amyloid plaques in humans and mice differ in composition and compactness.20 
This is likely the reason that all compounds showed higher affinity for murine plaques as they 
were visible even after staining with 1 μM concentration, whereas compounds 19 – 21 and 
23 – 24 showed no detectable amyloid plaques in the human sections at this concentration. 
To illustrate these differences, Table 10.1 and Figure 10.4 highlight the results of the 10 μM 
staining on human sections and the 1 μM concentration used to stain the murine sections. 
In general, planarity is considered one of the criteria for binding to Aβ plaques.21 The introduction 
of an additional substitution on the middle ring, which disturbs the planar conformation, has 
a detrimental effect on the binding affinity, as virtually no binding was seen using 11.
Although previous studies have reported possible interaction of styrylbenzenes with NFTs15, for 
none of our compounds NFTs staining was observed in the human AD cortex at these 
concentrations. Furthermore, with no background staining in either human or murine control 
brain sections this suggested their specificity to amyloid. As stated in the previous paragraph, 
the fluorescence intensity with and without amyloid fibrils differed significantly for the various 
compounds. Therefore, the fluorescence intensity in the presence of fibrils was calculated and 
expressed relative to the intensity of Methoxy-X04 (10). (Table 10.1) 
Figure 10.2 Structures of the building blocks 25-38






























































































































































































































































































































































































































































































































































































































Assuming that the fluorescence yield in the presence of synthetic Aβ is representative for that 
in the presence of amyloid plaques, the data in Figure 10.4 can be interpreted as follows. 
Despite having a lower fluorescent intensity for the bound compound, compounds 16 – 18 and 
22 labeled more human amyloid, thus suggesting an improved binding compared to 
Methoxy-X04. Similar analysis of the stained APP/PS1 sections revealed the affinity of all 
compounds, except 11 and 21, to be significantly higher than that of our lead compound 
Methoxy-X04 (Kd 26.8 nM). Compounds 13 and 15 were found to have the most efficient binding 
properties for murine amyloid plaques. With the lowest fluorescent intensity after binding to 
amyloid, being 100 x less than Methoxy-X04, the murine amyloid plaques nonetheless appeared 
very bright.   
Affinity for synthetic amyloid-β fibrils
A competition assay with [3H]chrysamine G (6) was used to determine the binding inhibition 
coefficient (Ki) for the compounds. Based on this assay reproducible results could only be 
obtained for those compounds with a hydroxyl substituent on the outer rings. (Figure 10.5) 
The ex vivo stainings clearly showed that many of the other compounds show affinity for amyloid, 
implying that these compounds probably use different binding sites than chrysamine G. Even 
the provided Ki values for compounds 19 – 23  only reflect competition against the [3H]
chrysamine G binding sites, and therefore most likely underestimate the overall affinity of these 
compounds for synthetic Aβ fibrils.
LogP values
The blood-brain barrier (BBB) is a tight layer of endothelial cells in the wall of cerebral blood 
vessels that limits the passage of blood compounds into the brain. It is traditionally stated that 
for optimal passive BBB passage, compounds should preferably have moderately hydrophobicity 
(logD or logP 2.0 - 3.5) however a number of successful radiopharmaceuticals do not meet this 








































































300 nM of 20 300 nM of 20 with brillar Ab
Figure 10.3 Excitation and emission spectra of compound 22
Shown are the excitation/emission spectra of compound 22 to illustrate possible effects on the fluorescent properties 
following binding of amyloid.

















 Human AD APP/PS1 In vivo APP/PS1  Human AD APP/PS1 In vivo APP/PS1
100 µm100 µm 200 µm 100 µm100 µm 200 µm
Figure 10.4 Staining for murine and human amyloid plaques
Shown paraffin embedded 8 µm thick human AD sections are stained using 10 µM, whereas APP/PS1 murine sections are 
stained using 1 µM to best depict the differences in amyloid staining between the different compounds. Thirty micrometer 
thick murine APP/PS1 sections following in vivo administration are shown with two times less magnification to allow 
visualization of a larger cortical region. All images were digitized using the same settings. 
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but it is a valid parameter for selection nonetheless when applied within one series of 
compounds. For each of our compounds 10 – 24, logP values were determined with an HPLC-
based method according to Benhaim et al.23-25 The found logP values are shown in Table 10.2. 
The limitation of this method is that logP values > 7 cannot be measured reliably. Not surprisingly, 
many of the compounds actually do show logP values > 7, which is a logical consequence of 
the fact that Methoxy-X04 (10) itself already has a logP value of 5.05 and that the introduction 
of fluorine makes the molecules more hydrophobic.
In vivo amyloid plaque labeling in transgenic AD mice
To assess the ability of the compounds to pass the BBB in vivo and subsequently bind to amyloid, 
solutions of each compound were injected intravenously in living transgenic APP/PS1 mice that 
had extensive cerebral amyloid plaques. The mice were sacrificed, their brains were removed 
and post-mortem sections were studied using the same fluorescence microscopy set-up as for 
the stained brain sections. In vivo labeling of amyloid plaque was observed for almost all 
compounds, except 11, 23 and 24, showing their ability to pass the BBB. (Figure 10.4 and Table 
10.2) Apparently, a high logP value does not necessarily prohibit BBB passage.  Some 
compounds, particularly 13, showed a comparable signal intensity after intravenous injection 
compared to Methoxy-X04, despite having a 100-fold lower fluorescence yield. This suggests 
that these compounds have a high affinity and/or cross the BBB more efficiently than 
Methoxy-X04. 





In vivo amyloid 
labeling
10 5.55 4.84 +
11 5.46 5.00 -
12 5.53 4.99 +
13 9.06 >7 +
14 8.44 >7 +
15 10.04 >7 +
16 8.74 6.18 +
17 8.12 >7 +
18 9.72 >7 +
19 6.74 5.64 +
20 6.82 5.25 +
21 7.37 5.79 +
22 10.22 >7 +
23 8.57 7.17 -
24 8.89 >7 -
aLogP values were calculated used web-based methods: www.molinspiration.
com and http://intro.bio.umb.edu/111-112/OLLM/111F98/jlogp/test.html. 
The ability to label amyloid plaques in the brains of APP-PS1 mice following 
intravenous injection were scored absent (-) or present (+).
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In vitro and post-mortem fluorine NMR
Based on the above experiments, compounds 13 and 22 were identified as the most promising 
leads, based on favorable binding, and positive staining after intravenous injection in vivo 
indicating good BBB passage. Initial 19F NMR studies were only conducted with compound 22, 
which had the highest number of magnetically equivalent 19F atoms. NMR spectra were acquired 
for 1.92 mM of 22 with or without an excessive amount of fibrillar Aβ. Binding to fibrillar amyloid 
did not result in significant line broadening of the NMR spectrum. (Figure 10.6A) The NMR 
spectrum corresponding to compound 22 mixed with homogenized APP/PS1 brain, however, 
revealed a small chemical shift of 0.03 ppm and a severe reduction in T2 as observed by the 
line broadening of the peak. As suggested previously, most likely the lipophilic environment of 
the brain tissue itself results in a reduced relaxation time and thereby signal loss.13 
Finally, 30 µmol/kg of 22 was injected intravenously in APP/PS1 mice. The brains were removed 
after 24 hours and a 19F NMR spectrum was obtained of the brain homogenate. No 19F signal 
was observed, although antemortem intravital microscopy showed clear labeling of cerebral 
amyloid. (Figure 10.6B-C)
The severe attenuation of the 19F NMR signal due the hydrophobic nature of both the fluorinated 
compounds as well as the brain itself seemed to hampered the detection of the 19F signal in 
the mouse brain. This is contrary to the initial publication of a 19F amyloid ligand by Higuchi et 
al.11, but in agreement with the findings of Amatsubo et al.13 Our design balanced between the 
planarity needed for amyloid binding and free rotation for the fluorine groups to maintain 
favourable NMR characteristics, however, this data still suggests that  the hydrophobic 
interaction between the brain and the 19F groups are responsible for line broadening. As recently 
pointed out in vivo by Yanagisawa et al. this problem might be overcome by the use of a 




















Figure 10.5  Binding competition 
with chrysamine G
Non-linear fitting to assess affinity for 
synthetic amyloid-β fibrils by a com-




In this work, a series of 15 analogs of Methoxy-X04 (10) with various number of fluorine atoms 
has been synthesized and evaluated for their Aβ binding properties and ability to pass the BBB. 
The incorporation of suitably placed fluoro substitutions could improve the current (MRI) 
contrast agents for the diagnosis of Alzheimer’s disease. It was concluded that the introduction 
of a second substitution on the inner ring was not well tolerated, whereas single bulky 
modifications on both the outer and inner rings were well tolerated. Despite the observed high 
logP values brain entry did not seem to be inhibited for most compounds. Based on all findings, 
compounds 13 and 22 were considered most promising for the development of Aβ imaging 
agents. However, the post-mortem NMR results leave us to conclude that there seems to be 
no role for these compounds as MR imaging agents for the diagnosis of AD. To our opinion it 
remains doubtful whether the incorporation of other fluorine moieties or higher field magnetic 
field strength will help to overcome these hurdles next to those set by the inherent relatively 
low sensitivity of 19F MRI in combination with known cerebral Aβ concentrations.  
Nevertheless, this study expands the existing knowledge on bis-styrylbenzenes as amyloid 
targeting agents in general and creates opportunities for their application as fluorescent amyloid 
ligands for preclinical optical imaging. Recent advances in fluorine chemistry create further 
opportunities to radiolabel compounds of our series with 18F.27,28 These compounds might 
provide additional information regarding accumulation of cerebral amyloid, especially since we 
have found that our series of compounds bind to a distinct binding site.
35 30 25 20 15 10 5 0 -5
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1.92 mM of 22  (A )
(A ) with brillar Aß
(A ) with APP-PS1 brain homogenate
A C
B
Figure 10.6  In vitro and post-mortem 19F NMR analyses of compound 22 
(A) shows the NMR spectra corresponding to 1.92 mM of compound 22 in solution without (-) or with the presence of 22 
µM fibrillar Aβ (- -) or mixed with a homogenized aged APP/PS1 mouse brain. All spectra are relative to trifluoroacetic acid 
set at 0 ppm. In (B) shows a NMR spectra of a homogenized APP/PS1 mouse brain made 24 hours post-injection of 30 µmol/
kg of dissolved 22. The corresponding intravital microscopic image presented in (C) clearly shows the antemortem labeling 
of cerebral amyloid (blue) in both vasculature as well as parenchymal amyloid plaques. Image dimensions are 615 x 615  µm.
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Materials and Methods
Preparation of Aβ1-40 fibrils
Aβ fibrils were prepared by stirring a 0.5 mg/ml solution of Aβ peptide (1-40) (RPeptide, Bogart, 
GA) at 37 ºC for 3 days, which resulted in a cloudy solution. The presence of fibrils was confirmed 
by the appearance of an emission peak at 482 nm (excitation 440 nm) upon addition of a 5 μM 
solution in PBS of Thioflavin T (Sigma, Germany) to a small amount of fibrils. Aliquots of 10 μl 
were transferred to Eppendorf vials and stored at -80 ºC until the assay was to be performed. 
Fluorescence spectra
All compounds were dissolved in DMSO at 0.3 mM and diluted to 300nM with 9:1 PBS:ethanol. 
Fluorescence spectra were measured on a Varian Cary Eclipse fluorescence spectrophotometer 
to obtain peak excitation and emission wavelengths, which were used to select the correct 
fluorescence filter settings for further microscopic evaluation. All measurements were carried 
out at 20 ºC and in triplicate. 3D fluorescence spectra were obtained by adding 500 μL of the 
dissolved compounds to previously prepared Aβ aliquots. After manual shaking for 30 sec, 300 
μL samples were measured (Infinity M1000, Tecan, Switzerland). 
Staining of human and transgenic AD brain sections
Stock solutions of 3 mM in DMSO were diluted to 1 – 10 – 100 µM in 2:3 PBS:ethanol and 
sonicated for 15 minutes. Paraffin sections (8 µm) of the medial temporal lobe cortex of human 
AD subject that was assigned as Braak IV, 14 months old transgenic murine APP/PS1 brain and 
age-matched control cortices were deparaffinized prior to staining for 10 minutes in absolute 
darkness. After gently rinsing with tap water, sections were placed in 0.1 % NaOH in 80% ethanol 
for 2 minutes, air dried and coverslipped using Aqua / Polymount. Fluorescence of the stained 
sections was analyzed using a whole microscopic slide scanner (Pannoramic MIDI, 3DHistech, 
Hungary) with a DAPI filter cube (Ex 365 nm; Em 445/50 nm) using the same intensity setting 
throughout all experiments.
In vivo Aβ plaque labeling in transgenic AD mice
Twelve-to-fourteen-month-old APP/PS1 mice or age-matched wildtype animals (n=2 per 
compound) were injected intravenously with 0.05 M dissolved in 1:1 DMSO:Cremophor diluted 
with PBS to a total volume of 200 µl, resulting in a total dose of 30µmol/kg. One day after 
injection, animals were sacrificed using 200 µl Euthanasol (AST Pharma) prior to transcardial 
perfusion with 4% paraformaldehyde in PBS. Brains were removed and cryoprotected in 4% 
PFA with 10% sucrose for 4 hours followed by immersion in 4% PFA with 30% sucrose overnight. 
Snap-frozen brains were cryosectioned (30 µm) and fluorescence images were analyzed as 
described above.
Competition binding assay
Competition binding experiments were conducted at room temperature, in a final volume of 1 
ml assay buffer (150 mM Tris-HCl, 20% ethanol, pH 7.0). Compounds were dissolved as 3 mM 
stock solutions in DMSO, sonicated for 15 min, and used in a final concentration range of 30 
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μM to 30 pM. 10 μl of unlabeled test compounds was combined with 890 μl of assay buffer and 
50 μl of 100 nM [3H]-chrysamine G stock (specific activity 33.8 Ci/mmole).  The mixture was 
sonicated for 10 min, and the assay was subsequently started by the addition of 50 μl synthetic 
Aβ1-40 fibrils, to achieve final concentrations of 5 nM [3H]chrysamine G and 50 nM fibrils. 
Nonspecific binding was determined in the presence of 1 μM Methoxy-X04.  Incubations were 
terminated after 1 h via filtration through Whatman GF/B filters (pre-soaked in binding buffer), 
using a 48-well Brandel harvester.  The filters were washed two times with 3 ml of ice-cold 
binding buffer (pH 7.0), and radioactivity was determined by liquid scintillation spectrometry in 
5 ml of Optiphase-HiSafe 3, at an efficiency of 40 %.
Ki values were determined by nonlinear regression analysis using the equation: logEC50 = 
log[10^logKi*(1+RadioligandNM/HotKdNM)] where Kd = 200 nM, and radioligand = 5nM. 
(GraphPad Software Inc., San Diego, CA)
Procedure for logP determinations
LogP determinations were performed using literature procedures.23 The measurements were 
performed on a Jasco HPLC-system (detection simultaneously at 214 and 254 nm) coupled to 
a Perkin Elmer Sciex API 165 mass instrument with a custom-made Electrospray Interface (ESI). 
An analytical Gemini C18 column (Phenomenex, 50 x 4.60 mm, 3 micron) was used in combination 
with buffers A) phosphate buffer of pH = 7.0 (0.02 M Na2HPO4 adjusted to pH = 7.0 with 
phosphoric acid) and  B) 0.25% octanol in methanol. 
Of all compounds to be evaluated, stock solutions of 0.5 mg/ml were prepared in methanol. 
These stock solutions were then diluted with water, making sure that the volume percentage 
of water was such that the compounds did not precipitate (max 40% water). A 0.25 mg/ml 
solution of NaNO3 in water was used as a non-retaining compound to determine the dead time 
of the system. For calibration purposes known compounds were taken from the literature. Of 
these compounds, 0.25 mg/ml solutions in either 75% H2O/MeOH or 50% H2O/MeOH were 
made. 
For each sample, a series of four isocratic runs was performed, (for instance 55, 60, 65, 70% 
B), and the retention times (from UV-detection at 214 nm) thus obtained were converted to the 
retention factor k’ according to the formula k’ = (tR-t0)/t0, with tR being the retention time of the 
compound and t0 being the retention time of NaNO3. The retention factors were extrapolated 
to 0% B, yielding k’w. As there is a linear relationship between logP and log k’w plotting logP values 
of known compounds (Table 10.3) against obtained log k’w values in this system yields a 
calibration curve. From this curve, logP values of unknown compounds can be calculated from 
their k’w values.
In vitro 19F NMR analyses
To investigate the possible effect on its NMR properties caused by either binding to amyloid or 
the lipophilic environment of the brain several samples were prepared similar to the protocol 
described previously.13 The in vitro 19F NMR analyses were performed using a Bruker DMX400 
NMR spectrometer (Bruker, Germany). All samples were diluted with 10% D2O in 0.1 M PBS with 
one EDTA-free protease inhibitor tablet (Complete Mini, Roche Diagnostics) added to every 10 
ml. Aliquots (500 µl) of only the solvent, the solvent containing 22 µM of aggregated Aβ or the 
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brain homogenate were added to 20 µl of 0.05 M of 22 in 1:1 DMSO:Cremophor to achieve a 
final concentration of 1.92 mM of compound 22. The mixtures were transferred to a standard 
5 mm NMR tube. NMR spectra were obtained using a single pulse sequence with a 22,573 Hz 
spectral width (SW) and 100 scans. The chemical shifts of the 19F NMR signals were identified 
by setting the reference trifluoroacetic acid (TFA) at 0 ppm.
Post-mortem 19F NMR in APP/PS1 mice
Twelve-to-fourteen-month-old APP/PS1 mice (n=2) received an intravenous injection with 0.05 
M of compound 22 dissolved in 1:1 DMSO:Cremophor diluted with PBS to a total volume of 
200 µl to achieve a  total dose of 30 µmol/kg. Prior injection the animals underwent cranial 
window surgery.14 Twenty four hours post injection the animals underwent in vivo multiphoton 
microcopy (LSM 710 MP, Carl Zeiss, Germany) operating at 750 nm to validate the presence 
and labeling of cerebral amyloid. After perfusion the resected brain was snap frozen and 
prepared for NMR similar to the above brain homogenates. A similar fluorine NMR spectrum 
was obtained using a single pulse sequence with a 94340 Hz SW and 1200 scans.
Synthetic Procedures
General 
Reagents and solvents were used as provided, unless stated otherwise. 4-trifluoromethyl-
benzaldehyde (35), 4-trifluoromethoxybenzaldehyde (36), 4-(1,1,2,2-tetrafluoroethyl)
benzaldehyde (37), 3-trifluoromethyl-4-methoxybenzaldehyde (38) (Figure 10.2) were 
purchased at standard suppliers. The other building blocks were prepared following literature 
procedures (see Appendix I). THF was distilled over LiAlH4 prior to use. Reactions were carried 
out under inert conditions and ambient temperature, unless stated otherwise. Prior to 
performing a reaction, traces of water were removed from the starting materials by repeated 
coevaporation with anhydrous 1,4-dioxane or anhydrous toluene. These solvents were stored 
over 4 Å molsieves. Reactions were monitored by thin layer chromatography on aluminum 
coated silica sheets (Merck, silica 60 F254), using visualization either with iodine, or spraying 
with a solution of 25 g (NH4)2MoO4, 10 g (NH4)4Ce(SO4)4 in 100 ml H2SO4 and 900 ml H2O, or a 








Based on known literature values, the logP of several reference compounds 




solution of 20% H2SO4 in ethanol, followed by charring at ~150 °C. Column chromatography 
was carried out with silica gel (Screening Devices bv, 40-63 μm particle size, 60 Å), using 
technical grade solvents. NMR spectra were recorded at 298K on a Bruker AV400 using 
deuterated solvents. All carbon spectra are proton-decoupled. Chemical shifts (δ) are given in 
ppm, in 13C spectra relative to the solvent peaks of CDCl3 (77.0 ppm), CD3OD (49.0 ppm), DMF-d7 
(29.76 ppm), acetone-d6 (29.9 ppm) or DMSO-d6 (39.51 ppm), in 1H spectra relative to the 
solvent peak of tetramethylsilane (0.0 ppm), CD3OD (3.31 ppm), DMF-d7 (2.75 ppm), acetone-d6 
(2.05 ppm) or DMSO-d6 (2.50 ppm), in 19F spectra relative to the solvent peak of TFA (0 ppm). 
Coupling constants are given in Hz. IR spectra were recorded on a Perkin Elmer Paragon 1000 
FT-IR Spectrometer. High resolution mass spectra were recorded by direct injection (2 µL of a 
2 µM solution in H2O/MeCN; 50/50; v/v and 0.1% formic acid) on a mass spectrometer (Thermo 
Finnigan LTQ Orbitrap) equipped with an electrospray ion source in positive mode (source 
voltage 3.5 kV, sheath gas flow 10, capillary temperature 250 °C) with resolution R = 60000 at 
m/z 400 (mass range m/z = 150-2000) and dioctylpthalate (m/z = 391.28428) as a “lock mass”. 
The high resolution mass spectrometer was calibrated prior to measurements with a calibration 
mixture (Thermo Finnigan). It should be noted that, with the exception of compound 9 (data 
not shown) and only certain intermediates ionized correctly, none of the target compounds 
provided useful (HR)MS data.
LC-MS analysis was performed on a Finnigan Surveyor HPLC system with a Gemini C18 50 × 4.6 
mm column (3 micron, Phenomenex, Torrance, CA, USA) (detection at 200-600 nm), coupled 
to a Thermo Finnigan LCQ Advantage Max mass spectrometer (Breda, The Netherlands) with 
electrospray ionization (ESI; system 1), with as eluents (A): H2O; (B): MeCN and (C): 1% aq. TFA. 
General procedure A: Horner-Wadsworth-Emmons reaction with NaH 
The diphosphonate (0.83 mmol) was dissolved in THF (2.6 ml) and cooled to 0 ºC. NaH (60% wt. 
dispersion in mineral oil, 0.17 g, 4.17 mmol) was added and the mixture stirred for 30 min at 
0ºC. The aldehyde (2.08 mmol) was dissolved in THF and added to the reaction mixture, which 
was subsequently stirred for 16 h at rt. After cooling and quenching with water, the mixture 
was extracted three times with EtOAc and the combined organic layers were washed with sat. 
aq. NaHCO3, dried (Na2SO4), filtered and concentrated. The crude product was subjected to 
column chromatography to yield the pure product. 
General procedure B: Horner-Wadsworth-Emmons reaction  with KOtBu  
The diphosphonate (0.95 mmol) was dissolved in THF (20 ml) and cooled to -10 ºC. KOtBu (0.30 
g, 2.45 mmol) was added and the black mixture stirred for 20 min. A solution of the aldehyde 
(2.37 mmol) in THF (6 ml) was added and the reaction stirred at room temperature for 16 h. 
The reaction was cooled to 0 ºC, quenched with water and extracted five times with EtOAc. The 
combined organic layers were dried (Na2SO4), filtered and concentrated. The crude product 
was subjected to column chromatography to yield the pure product. 
General procedure C: silyl deprotection 
A solution of protected bis-styrylbenzene (0.63 mmol) in THF (2 ml) was cooled to 0 ºC and TBAF 
(1 M in THF, 3.14 ml, 3.14 mmol) was added. The blood-red solution was stirred for 16 h after 
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which water was added and the reaction mixture was extracted with EtOAc. To the aqueous 
layer 1 M HCl was added, followed by two times extracting with EtOAc. The combined organic 
layers were dried (Na2SO4), filtered and concentrated. The pure product was obtained by column 
chromatography (0  25% EtOAc/light petroleum).
(E, E)-1-methoxy-2,5-bis(4-hydroxy)styrylbenzene; Methoxy-X04 (10) 
Methoxy-X04 was prepared according to general procedures A and C, using diphosphonate 25 
and aldehyde 33. Physical data corresponded to those reported by Klunk et al.10 
(E, E)-1,4-dimethoxy-2,5-bis(4-hydroxy)styrylbenzene (11)
Following general procedure A, diphosphonate 26 (0.34 g, 0.78 mmol) was reacted with aldehyde 
33(0.46 g, 1.9 mmol). A bright yellow solid was isolated (221 mg) by column chromatography 
(10  30% EtOAc/light petroleum) of which 100 mg was purified by preparative HPLC (40:60  
20:80 of 20 mM NH4OAc/MeOH), to yield 22 mg (0.059 mmol, 8%) of compound 11. 
1H NMR (CD3OD, 400 MHz): δ 7.43 (d, J = 8.6 Hz, 4H); 7.33 (d, J = 16.5 Hz, 2H); 7.27 (s, 2H); 7.19 
(d, J = 16.5 Hz, 2H); 6.82 (d, J = 8.6 Hz, 4H); 3.93 (s, 6H). 13C NMR (CD3OD, 100 MHz): δ 158.5; 
152.6; 130.9; 129.7; 128.9; 127.6; 121.1; 116.6; 109.9; 56.8. IR (neat): 3359.6; 1605.3; 1515.7; 
1495.6; 1463.6; 1435.4; 1408.7; 1260.0; 1196.0; 1171.8; 1022.4; 958.3; 849.6; 819.7; 790.1; 
685.9; 551.0; 521.6. LC-MS retention time: 8.99 min (10 g 90% MeCN, 15 min run). 
(E, E)-1-methoxy-2,5-bis(4-hydroxymethyl)styrylbenzene (12)
Following general procedure A, diphosphonate 25 (0.2 g, 0.5 mmol) was reacted with aldehyde 
34 (0.31 g, 1.25 mmol). The crude product was subjected to column chromatography (0  2% 
EtOAc/light petroleum) to yield the intermediary bis-TBDMS protected styrylbenzene (0.28 g, 
0.48 mmol, 96%) as a bright yellow solid. 1H NMR (CDCl3, 400 MHz): δ 7.58 (d, J = 8.1 Hz, 1H); 
7.51 (d, J = 6.1 Hz, 2H); 7.49 (d, J = 6.3 Hz, 2H); 7.44 (s, 1H); 7.34-7.28 (m, 4H); 7.16-7.13 (m, 2H); 
7.13-7.09 (m, 2H); 7.03 (d, J = 1.4 Hz, 1H); 4.75 (d, J = 2.4 Hz, 4H); 3.95 (s, 3H); 0.95 (s, 9H); 0.95 
(s, 9H); 0.11 (s, 6H); 0.11 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 157.0; 141.0; 140.7; 137.9; 136.7; 
136.0; 128.7; 128.4; 128.1; 126.4; 126.4; 126.4; 126.0; 122.7; 119.3; 108.6; 64.9; 64.8; 55.6; 26.0; 
18.4; -5.2. IR (neat): 2953.7; 2927.5; 2855.3; 1593.8; 1553.7; 1515.3; 1458.3; 1421.9; 1377.6; 
1248.7; 1206.0; 1084.2; 1037.1; 1005.7; 967.3; 837.4; 773.9; 668.1; 504.2. The bis-TBDMS 
protected (E, E)-styrylbenzene (0.27 g, 0.46 mmol) was treated with TBAF according to general 
procedure C. Compound 12 was obtained by column chromatography (50% EtOAc/light 
petroleum  10% MeOH/EtOAc) as a bright yellow solid (0.14 g, 0.37 mmol, 79%). 
1H NMR (DMF-d7, 400 MHz): δ 7.68 (d, J = 8.0 Hz, 1H); 7.59 (d, J = 8.1 Hz, 2H); 7.55 (d, J = 8.1 Hz, 
2H); 7.49 (d, J = 16.6 Hz, 1H); 7.39-7.34 (m, 4H); 7.31 (d, J = 5.0 Hz, 2H); 7.28 (d, J = 4.9 Hz, 1H); 
7.25-7.21 (m, 2H). 13C NMR (DMF-d7, 100 MHz): δ 157.7; 142.6; 142.3; 138.8; 137.2; 136.6; 129.0; 
128.9; 128.4; 127.4; 126.8; 126.8; 126.6; 126.0; 122.9; 119.7; 109.3; 63.8; 55.6. IR (neat): 1592.0; 
1557.6; 1515.8; 1455.9; 1418.0; 1340.0; 1269.9; 1243.7; 1211.9; 1158.1; 1112.4; 1034.2; 1011.7; 
956.3; 825.7; 624.2.  
(E, E)-1-methoxy-2,5-bis(4-trifluoromethyl)styrylbenzene (13) 
Following general procedure A, diphosphonate 26 (0.20 g, 0.5 mmol) was reacted with aldehyde 
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35 (0.22 g, 1.25 mmol). After work-up, the crude product was purified by column chromatography 
(0  1% EtOAc/light petroleum) and the compound 13 was obtained as a bright yellow solid 
(80 mg, 0.18 mmol, 36%). 
1H NMR (acetone-d6, 400 MHz): δ 7.82 (d, J = 8.2 Hz, 2H); 7.79 (d, J = 8.5 Hz, 2H); 7.76-7.69 (m, 
5H); 7.66 (d, J = 16.7 Hz, 2H); 7.43 (s, 2H); 7.38 (d, J = 16.4 Hz, 2H); 7.29 (dd, J = 8.1 Hz, J = 1.3 Hz, 
1H); 4.00 (s, 3H). 13C NMR (acetone-d6, 100 MHz): δ 158.5; 143.0; 142.4; 139.3; 132.1; 128.3; 
128.3; 127.9; 127.9; 127.8; 126.7; 126.5; 126.5; 126.5; 120.7; 110.3; 56.1. 19F NMR (acetone-d6, 
375 MHz): δ 12.70 (s, 3F); 12.65 (s, 3F). IR (neat): 1608.4; 1464.0; 1420.1; 1323.6; 1246.5; 1158.5; 
1116.6; 1105.9; 1065.5; 1036.4; 1014.1; 967.0; 954.2; 866.5; 848.8; 829.9; 759.2; 744.8; 622.2; 
593.3; 508.4. 
(E, E)-1-methoxy-2,5-bis(4-trifluoromethoxy)styrylbenzene (14) 
Following general procedure A, diphosphonate 25 (0.20 g, 0.5 mmol) was reacted with aldehyde 
36 (0.24 g, 1.25 mmol). After work-up, the product 14 was obtained by column chromatography 
(0  1.5% EtOAc/light petroleum) as a bright yellow solid (83 mg, 0.17 mmol, 35%). 
1H NMR (CDCl3, 400 MHz): δ 7.56 (d, J = 8.0 Hz, 1H); 7.54-7.50 (m, 4H); 7.44 (d, J = 16.5 Hz, 1H); 
7.19 (t, J = 7.8 Hz, 4H); 7.14-7.10 (m, 2H); 7.09-7.05 (m, 2H); 7.01 (d, J = 1.3 Hz, 1H); 3.94 (s, 3H). 
13C NMR (CDCl3, 100 MHz): δ 157.2; 137.7; 136.7; 135.9; 127.7; 127.5; 127.2; 126.6; 125.9; 124.1; 
121.2; 121.1; 119.4; 108.5; 55.5. 19F NMR (CDCl3, 375 MHz): δ 19.80 (s, 3F); 19.79 (s, 3F). IR (neat): 
1593.1; 1557.6; 1510.2; 1421.9; 1254.6; 1199.8; 1159.4; 1104.9; 1034.0; 1015.7; 962.2; 921.6; 
838.6; 673.8; 620.1; 530.0; 505.9. 
(E, E)-1-methoxy-2,5-bis(4-{1,1,2,2-tetrafluoroethyl})styrylbenzene (15) 
Following general procedure A, diphosphonate 25 (0.20 g, 0.5 mmol) was reacted with aldehyde 
37 (0.28 g, 1.25 mmol). After work-up, compound 15 was isolated by column chromatography 
(0  7.5% EtOAc/light petroleum) as a yellow solid (0.14 g, 0.25 mmol, 50%). 
1H NMR (CDCl3, 400 MHz): δ 7.56 (d, J = 7.3 Hz, 1H); 7.55-7.49 (m, 4H); 7.33 (d, J = 16.5 Hz, 1H); 
7.24-7.16 (m, 4H); 7.13-7.04 (m, 4H); 7.01 (d, J = 2.3 Hz, 1H); 6.07-5.76 (m, 2H); 3.94 (s, 3H). 13C 
NMR (CDCl3, 100 MHz): δ 157.1; 148.5; 148.2; 137.7; 136.4; 135.6; 129.2; 128.7; 127.9; 127.8; 
127.6; 127.5; 127.2; 126.6; 125.8; 122.4; 121.9; 121.8; 121.8; 121.7; 119.4; 119.1; 116.7; 116.4; 
116.2; 115.5; 110.2; 108.7; 108.1; 107.7; 107.3; 55.5. 19F NMR (CDCl3, 375 MHz): δ -10.5 (s, 4F); 
-59.06 (t, J = 5.5 Hz, 2F); -59.20 (t, J = 5.5 Hz, 2F). IR (neat): 1510.5; 1463.9; 1421.9; 1392.9; 1302.4; 
1274.0; 1195.2; 1115.4; 1035.7; 1015.7; 961.8; 837.0; 784.1; 766.2; 709.4; 623.3; 600.0; 544.1. 
(E, E)-1-hydroxy-2,5-bis(4-trifluoromethyl)styrylbenzene (16) 
Following general procedure B, diphosphonate 27 (0.85 g, 1.34 mmol) was reacted with aldehyde 
35 (0.59 g, 3.36 mmol). After work-up, the crude product was purified by column chromatography 
(0  6% EtOAc/light petroleum) and product 16 was obtained as a bright yellow solid (0.2 g, 
0.48 mmol, 36%). 
1H NMR (CD3OD, 400 MHz): δ 7.67-7.52 (m, 10H); 7.21 (d, J = 16.5 Hz, 1H); 7.14 (d, J = 2.2Hz, 2H); 
7.07 (dd, J = 8.1 Hz, J = 1.5 Hz, 1H); 7.02 (d, J = 1.6 Hz, 1H). 13C NMR (CD3OD, 100 MHz): δ 156.2; 
142.7; 141.9; 138.6; 131.7; 129.2; 127.8; 127.8; 127.5; 127.4; 127.2; 126.9; 126.2; 126.2; 126.1; 
126.1; 125.0; 119.5; 114.3. 19F NMR (CD3OD, 375 MHz): δ 14.98 (s, 3F); 14.91 (s, 3F). IR (neat): 
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1611.5; 1428.3; 1319.9; 1163.2; 1107.4; 1066.6; 1014.2; 967.4; 956.5; 872.2; 831.8; 757.9; 750.6; 
624.8; 592.8; 507.7. 
(E, E)-1-hydroxy-2,5-bis(4-trifluoromethoxy)styrylbenzene (17) 
Following general procedure B, diphosphonate 27 (0.99 g, 1.56 mmol) was reacted with aldehyde 
36 (0.74 g, 3.91 mmol). The crude product was purified by column chromatography (0  8% 
EtOAc/light petroleum) and product 17 was obtained as a bright yellow solid (0.47 g, 1.01 mmol, 
65%). 
1H NMR (CD3OD, 400 MHz): δ 7.63 (d, J = 5.8 Hz, 2H); 7.61 (d, J = 5.6 Hz, 2H); 7.48 (d, J = 16.5 Hz, 
1H); 7.40-7.34 (m, 1H); 7.27-7.18 (m, 5H); 7.12 (d, J = 3.2 Hz, 2H); 7.07 (dd, J = 8.1 Hz, J = 1.5 Hz, 
1H); 7.02 (d, J = 1.6 Hz, 1H). 13C NMR (CD3OD, 100 MHz): δ 156.7; 149.7; 149.4; 149.4; 139.2; 139.0; 
138.1; 133.0; 130.8; 129.0; 128.8; 128.1; 127.9; 127.7; 126.0; 125.4; 122.3; 122.2; 121.6; 119.7; 
114.4. 19F NMR (CD3OD, 375 MHz): δ 18.85 (s, 6F). IR (neat): 1604.3; 1557.6; 1515.8; 1505.7; 
1269.9; 1158.4; 1099.9; 1015.6; 967.6; 928.0; 839.2; 676.6; 624.0; 525.1. 
(E, E)-1-hydroxy-2,5-bis(4-{1,1,2,2-tetrafluoroethyl})styrylbenzene (18) 
Following general procedure B, diphosphonate 27 (0.74 g, 1.17 mmol) was reacted with aldehyde 
37 (0.65 g, 2.92 mmol). After work-up, the crude product was subjected to column 
chromatography (0  10% EtOAc/light petroleum) to yield product 18 as a bright yellow solid 
(0.27 g, 0.5 mmol, 43%). 
1H NMR (CD3OD, 400 MHz): δ 7.61 (d, J = 5.3 Hz, 2H); 7.59 (d, J = 5.2 Hz, 2H); 7.56 (d, J = 8.1 Hz, 
1H); 7.48 (d, J = 16.6 Hz, 1H); 7.25-7.19 (m, 5H); 7.12 (d, J = 5.5 Hz, 2H); 7.08 (dd, J = 7.9 Hz, J = 1.7 
Hz, 1H); 7.02 (d, J = 1.5 Hz, 1H); 6.46-6.14 (m, 2H). 13C NMR (CD3OD, 100 MHz): δ 156.6; 149.2; 
139.2; 138.4; 137.6; 130.4; 128.8; 128.6; 128.1; 128.0; 127.9; 125.6; 125.4; 123.0; 123.0; 119.7; 
114.3. 
(E, E)-1-trifluoromethyl-2,5-bis(4-hydroxy)styrylbenzene (19) 
Following general procedure A, diphosphonate 28 (0.37 g, 0.83 mmol) was reacted with aldehyde 
33 (0.49 g, 2.1 mmol). After work-up, the crude product was purified by column chromatography 
(0  4% EtOAc/light petroleum) and the intermediary bis-TBDMS protected styrylbenzene was 
obtained as a bright yellow solid (0.36 g, 0.59 mmol, 71%). 1H NMR (CDCl3, 400 MHz): δ 7.77-7.72 
(m, 2H); 7.61 (d, J = 8.1 Hz, 1H); 7.44-7.37 (m, 4H); 7.31 (dd, J = 16.1 Hz, J = 1.8 Hz, 1H); 7.11 (d, J 
= 16.3 Hz, 1H); 7.05 (d, J = 16.0 Hz, 1H); 7.00-6.92 (m, 1H); 6.88-6.81 (m, 4H). 13C NMR (CDCl3, 100 
MHz): δ 156.0, 155.9, 136.5, 135.0; 131.7, 130.3, 130.2, 129.6, 129.0, 128.1, 127.9, 126.9, 125.0, 
123.8, 122.0, 120.4, 29.7, 25.7, -4.4. 19F NMR (CDCl3, 375 MHz): δ 18.17 (s, 3F). IR (neat): 1598.9; 
1508.0; 1471.8; 1327.9; 1314.0; 1251.5; 1170.0; 1154.7; 1131.4; 1115.5; 1102.1; 1051.1; 962.1; 
938.5; 906.8; 834.5; 778.2; 700.2; 667.7; 660.3; 638.4; 554.5; 534.7. 
The bis-TBDMS protected styrylbenzene (0.34 g, 0.54 mmol) was treated with TBAF according 
to general procedure C, and following column chromatography (0  30% EtOAc/light petroleum), 
the impure product was purified by HPLC (CN column, 35:65  10:90 of 0.2% aq. TFA/MeOH) 
and product 19 was obtained as a yellow solid (83 mg, 0.22 mmol, 40%).
1H NMR (CD3OD, 400 MHz): δ 7.81 (d, J = 8.2 Hz, 1H); 7.73 (s, 1H); 7.70 (d, J = 8.5 Hz, 1H); 7.42 (d, 
J = 8.0 Hz, 2H); 7.38 (d, J = 8.0 Hz, 2H); 7.23 (d, J = 16.0 Hz, 1H); 7.14 (t, J = 16.9, 2H); 6.99 (d, J = 
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16.3 Hz, 1H); 6.80 (dd, J = 7.8 Hz, J = 3.5 Hz, 4H). 
13C NMR (CD3OD, 100 MHz): δ 159.1; 158.9; 138.3; 136.2; 133.3; 131.1; 130.2; 130.0; 129.3; 
129.2; 128.4; 128.0; 127.5; 125.0; 124.9; 124.7; 124.7; 124.6; 124.6; 121.7; 116.7; 116.6. 19F NMR 
(CD3OD, 375 MHz): δ 17.64 (s, 3F). IR (neat): 1605.0; 1512.1; 1441.0; 1313.9; 1257.1; 1239.9; 
1199.4; 1171.9; 1153.6; 1108.8; 1079.5; 1049.9; 959.8; 869.9; 837.2; 812.7; 671.7; 552.7; 522.1. 
(E, E)-1-(2,2,2-trifluoroethoxy)-2,5-bis(4-hydroxy)styrylbenzene (20)
Following general procedure B, dipshosphonate 29 (0.45 g, 0.95 mmol) was reacted with 
aldehyde 33 (0.56 g, 2.37 mmol). After work-up, the crude product was subjected to column 
chromatography (0  5% EtOAc/light petroleum) and the bis-TBDMS protected styrylbenzene 
was obtained as a bright yellow solid (0.4 g, 0.63 mmol, 66%). 1H NMR (CDCl3, 400 MHz): δ 7.59-
7.51 (m, 4H); 7.43 (d, J = 16.5 Hz, 1H); 7.31 (d, J = 7.7 Hz, 1H); 7.69 (d, J = 8.0 Hz, 1H);  7.24 (d, J = 
16.4 Hz, 1H); 7.18 (d, J = 16.3 Hz, 1H); 7.10-7.06 (m, 2H); 7.00 (dd, J = 8.6 Hz, J = 2.0 Hz, 4H); 4.56 
(q, J = 8.2 Hz, J = 8.1 Hz, 2H); 1.16 (s, 18H); 0.38 (s, 6H); 0.38 (s, 6H). 13C NMR (CDCl3, 100 MHz): 
δ 155.6; 155.5; 154.7; 137.9; 131.8; 131.0; 130.3; 129.3; 128.6; 127.7; 126.7; 126.7; 125.8; 121.0; 
120.4; 120.3; 120.1; 110.7; 67.2; 66.8; 66.5; 66.1; 29.7; 25.6; -4.4. 19F NMR (CDCl3, 375 MHz): δ 
3.80 (t, J = 8.1 Hz, 3F). 
The bis-TBDMS protected styrylbenzene (0.4 g, 0.63 mmol) was treated with TBAF according to 
general procedure C. After work-up, the crude product was purified by column chromatography 
(0  25% EtOac/light petroleum) and product 20 was obtained as a bright yellow solid (0.127 
g, 0.31 mmol, 49%). 
1H NMR (CD3OD, 400 MHz): δ 7.51 (d, J = 8.1 Hz, 1H); 7.40-7.29 (m, 4H); 7.20 (d, J = 16.5 Hz, 1H); 
7.13 (dd, J = 8.1 Hz, J = 1.0 Hz, 1H); 7.05 (d, J = 16.5 Hz, 1H); 7.03 (d, J = 16.3 Hz, 1H); 7.00 (d, J = 
1.1 Hz, 1H); 6.87 (d, J = 16.3 Hz, 1H); 6.81-6.75 (m, 4H); 4.48 (q, J = 8.3 Hz, J = 8.3 Hz, 2H). 13C NMR 
(CD3OD, 100 MHz): δ 157.8; 157.6; 155.5; 138.9; 130.4; 130.0; 129.7; 129.5; 128.6; 128.5; 127.2; 
125.7; 121.5; 120.0; 116.2; 116.2; 111.4; 67.4; 67.0; 66.7. 19F NMR (CD3OD, 375 MHz): δ 6.89 (t, 
J = 7.5 Hz, 3F). IR (neat): 3331.9; 1606.2; 1515.7; 1505.9; 1455.8; 1427.9; 1238.9; 1169.7; 1118.3; 
964.1; 828.9; 667.9; 617.9; 518.9. 
(E, E)-1-(4,4,4-trifluorobutoxy)-2,5-bis(4-hydroxy)styrylbenzene (21) 
Following general procedure B, diphosphonate 30 (0.50 g, 1 mmol) was reacted with aldehyde 
33 (0.59 g, 2.5 mmol). After work-up, the crude product was purified by column chromatography 
(0  2% EtOAc/light petroleum) and the bis-TBDMS protected styrylbenzene was obtained as 
a bright yellow solid (0.3 g, 0.46 mmol, 46%). 1H NMR (CDCl3, 400 MHz): δ 7.53 (d, J = 8.1 Hz, 1H); 
7.38 (d, J = 8.4 Hz, 4H); 7.28 (d, J = 16.5 Hz, 1H); 7.12-7.05 (m, 2H); 7.03 (d, J = 16.2 Hz, 1H); 6.95 
(d, J = 1.1 Hz, 1H); 6.92 (d, J = 16.3 Hz, 1H); 6.86-6.80 (m, 4H); 4.13 (t, J = 6.0 Hz, 2H); 2.46-2.31 (m, 
2H); 2.20-2.10 (m, 2H); 0.99 (s, 18H); 0.21 (s, 12H). 13C NMR (CDCl3, 100 MHz): δ 155.9; 155.6; 
155.4; 137.9; 131.3; 130.6; 128.7; 128.3; 127.7; 127.6; 126.5; 126.5; 126.1; 120.9; 120.4; 120.3; 
119.6; 109.6; 66.6; 31.1; 30.8; 29.4; 25.7; 22.4; 22.3; 18.2; -4.4. 19F NMR (CDCl3, 375 MHz): δ 
11.39 (t, J = 10.9 Hz, 3F). IR (neat): 1599.9; 1508.7; 1471.7; 1250.8; 1166.6; 1153.9; 1027.7; 908.7; 
833.2; 798.6; 779.1; 700.5; 661.8; 623.5; 531.4; 504.4. 
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The silylated bis-styrylbenzene (0.3 g, 0.46 mmol) was deprotected according to general 
procedure C. After work-up, the crude product was purified using column chromatography (10 
 22.5% EtOAc/light petroleum) and product 21 was obtained as a bright yellow solid (0.12 g, 
0.27 mmol, 58%). 
1H NMR (CD3OD, 400 MHz): δ 7.50 (d, J = 8.1 Hz, 1H); 7.38 (d, J = 8.6 Hz, 2H); 7.34 (d, J = 8.6 Hz, 
2H); 7.24 (d, J = 16.5 Hz, 1H); 7.11-7.02 (m, 4H); 6.92 (d, J = 16.3 Hz, 1H); 6.80-6.75 (m, 4H); 4.13 
(t, J = 6.0 Hz, 2H); 2.50-2.35 (m, 2H); 2.16-2.06 (m, 2H). 13C NMR (CD3OD, 100 MHz): δ 158.4; 
158.2; 157.3; 139.4; 131.1; 130.4; 129.7; 129.5; 128.9; 128.6; 127.3; 127.1; 126.6; 121.1; 120.4; 
116.5; 110.8; 67.8; 32.1; 31.8; 31.5; 31.2; 23.5; 23.4; 23.4. 19F NMR (CD3OD, 375 MHz): δ 3.48 (t, 
J = 11.3 Hz, 3F). IR (neat): 3325.9; 1605.69; 1593.7; 1515.5; 1505.9; 1447.9; 1385.8; 1338.1; 
1241.0; 1171.3; 1026.0; 961.8; 826.7; 621.1; 519.8. 
(E, E)-1-(nonafluoro-tert-butoxy)-2,5-bis(4-hydroxy)styrylbenzene (22)
Following general procedure B, diphosphonate 32 (0.55 g, 0.89 mmol) was reacted with aldehyde 
33 (0.53 g, 2.2 mmol). After work-up, the crude product was purified by column chromatography 
(0  2% EtOAc/light petroleum) and the bis-TBDMS protected styrylbenzene was obtained as 
a bright yellow solid (0.22 g, 0.28 mmol, 32%). 1H NMR (CDCl3, 400 MHz): δ 7.27-7.20 (m, 4H); 
7.20-7.12 (m, 2H); 6.90-6.81 (m, 2H); 6.79-6.73 (m, 2H); 6.72-6.64 (m, 4H); 7.48 (d, J = 8.2 Hz, 1H); 
0.84 (s, 1H); 0.06 (s, 6H); 0.06 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 155.8; 155.8 150.5; 137.9; 
130.5; 130.5; 130.2; 130.0; 129.3; 127.9; 127.8; 126.1; 125.3; 124.2; 120.5; 119.0; 31.9; 29.4; 
25.7; -4.4. 19F NMR (CDCl3, 375 MHz): δ 8.81 (s, 9F). IR (neat): 1600.0; 1508.4; 1472.0; 1249.8; 
1169.5; 1155.1; 1124.8; 998.7; 965.7; 904.5; 833.8; 779.5; 726.0; 700.6; 537.4; 504.5. The bis-
TBDMS protected styrylbenzene was treated with TBAF according to general procedure C. The 
crude product was subjected to column chromatography (10  25% EtOAc/light petroleum) 
and product 22 was obtained as a bright yellow solid (72 mg, 0.13 mmol, 47%). 
1H NMR (CD3OD, 400 MHz): δ 7.72 (d, J = 8.3 Hz, 1H); 7.46-7.34 (m, 5H); 7.31 (s, 1H); 7.22 (d, J = 
16.5 Hz, 1H); 7.05 (d, J = 16.4 Hz, 1H); 7.10 (d, J = 12.4 Hz, 1H); 6.96-6.90 (m, 1H); 6.82-6.77 (m, 4H). 
13C NMR (CD3OD, 100 MHz): δ 159.0; 158.9; 151.6; 139.6; 131.8; 131.7; 130.9; 130.1; 129.9; 
129.3; 129.1; 127.4; 125.5; 125.1; 123.0; 120.1; 119.8; 118.7; 116.7; 116.6. 19F NMR (CD3OD, 375 
MHz): δ 10.93 (s, 9F). IR (neat): 3332.1; 1606.3; 1515.6; 1250.3; 1171.8; 1123.0; 1000.3; 965.1; 
829.3; 727.4; 668.0; 529.1. 
(E, E)-1-hydroxy-2,5-bis(3-trifluoromethyl-4-methoxy)styrylbenzene (23)
Following general procedure B, diphosphonate 27 (0.52 g, 1 mmol) was reacted with aldehyde 
38 (0.51 g, 2.5 mmol). After work-up, the crude product was purified by column chromatography 
(0  17% EtOAc/light petroleum), followed by preparative TLC (eluent: 50% EtOAc.light 
petroleum) and product 23 was obtained as a bright yellow solid (58 mg, 0.12 mmol, 12%). 
1H NMR (acetone-d6, 400 MHz): δ 7.80-7.71 (m, 4H); 7.54 (d, J = 8.0 Hz, 1H); 7.39 (d, J = 16.6 Hz, 
1H); 7.26-7.16 (m, 3H); 7.13 (d, J = 16.4 Hz, 1H); 7.10-6.98 (m, 3H); 3.90 (s, 6H). 13C NMR (acetone-d6, 
100 MHz): δ 156.2; 139.0; 132.5; 132.2; 131.9; 131.1; 129.0; 127.8; 127.6; 127.4; 125.8; 125.7; 
125.6; 125.5; 125.0; 124.1; 119.3; 114.3; 113.9; 56.6; 56.6. 19F NMR (acetone-d6, 375 MHz): δ 
7.62 (s, 3F); 7.60 (s, 3F). IR (neat): 3523.0; 1615.5; 1512.0; 1501.5; 1428.0; 1327.6; 1274.3; 1261.6; 




Following general procedure B, diphosphonate 25 (0.41 g, 1 mmol) was reacted with aldehyde 
38 (0.51 g, 2.5 mmol). After work-up, the crude product was purified by column chromatography 
(0  10% EtOAc/light petroleum) and product 24 was obtained as a bright yellow solid (0.14 g, 
0.27 mmol, 27%). 
1H NMR (DMSO-d6, 400 MHz): δ 7.97-7.83 (m, 3H); 7.81 (dd, J = 7.8 Hz, J = 1.7 Hz, 1H); 7.76 (d, J 
= 1.7 Hz, 1H); 7.65 (d, J = 8.1 Hz, 1H); 7.46 (d, J = 16.8 Hz, 1H); 7.40-7.20 (m, 6H); 3.93 (s, 3H); 3.92 
(s, 3H). 13C NMR (DMSO-d6, 100 MHz): δ  156.1; 137.9; 131.8; 131.5; 130.0; 129.7; 129.2; 128.8; 
127.8; 127.3; 127.0; 126.6; 125.6; 125.1; 122.4; 122.2; 120.7; 119.3; 117.5; 117.2; 114.6; 113.4; 
109.1; 56.3; 56.2. 
19F NMR (DMSO-d6, 375 MHz): δ 17.26 (s, 3F); 17.2 (s, 3F). IR (neat): 1615.6; 1510.4; 1505.8; 
1463.9; 1328.5; 1260.0; 1118.3; 1054.9; 1021.0; 959.3; 818.0; 667.8; 645.5; 541.1. 
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Abstract
Detection of cerebral β-amyloid (Aβ) by targeted contrast agents is of great interest for in vivo 
diagnosis of Alzheimer’s disease (AD). Partly because of their planar structure several bis-
styrylbenzenes have been previously reported as potential Aβ imaging agents. However, these 
compounds are relatively hydrophobic, which likely limits their in vivo potential. Based on their 
structures, we hypothesized that less hydrophobic bis-pyridylethenylbenzenes may also label 
amyloid. We synthesized several bis-pyridylethenylbenzenes and tested whether these 
compounds indeed display improved solubility and lower LogP values, and studied their 
fluorescent properties and Aβ binding characteristics. Bis-pyridylethenylbenzenes showed a 
clear affinity for Aβ plaques on both human and murine AD brain sections. Competitive binding 
experiments suggested a different binding site than Chrysamine G, a well-known stain for 
amyloid. With a LogP value between 3 and 5, most bis-pyridylethenylbenzenes were able to 
enter the brain and label murine amyloid in vivo with overall the bis(4-pyridylethenyl)benzenes 
showing the most favorable characteristics. In conclusion, the presented results suggest that 




Cerebral accumulation of senile amyloid plaques plays an important role in the pathogenesis 
of Alzheimer’s disease (AD), as it is thought to precede the onset of the first clinical symptoms 
by up to two decades.1,2 These typical deposits of fibrillar amyloid-β peptides (Aβ) thereby 
constitute an important target for the development of imaging agents capable of visualizing 
and quantifying them. Much progress has been made in the development of such Aβ-targeting 
imaging ligands suitable for visualization by positron emission tomography (PET), single 
positron emission tomography (SPECT), fluorescence microscopy or magnetic resonance 
imaging (MRI). 
Pittsburgh compound B (PiB, 1, Figure 11.1), a [11C]-benzothiazole derivative, is the best 
characterized in vivo PET radiotracer thus far. The short half-life of 11C however limits its use to 
medical centers with an on-site cyclotron. In addition longer-lived 18F radiofluorinated derivatives 
have been synthesized, like flutemetamol (2)3, florbetapir (3) and florbetaben(4)4, of which the 
first two recently were approved by the U.S. Food and Drug Administration for commercial 
use.5,6 However improved Aβ-targeted imaging agents or backbones that could potentially 
outperform previous agents, bind to specific subtypes of cerebral amyloid or that are suitable 
for other clinical imaging modalities are still warranted.
The precise mechanisms that cause these small molecules to bind specifically to amyloid 
structures are still not completely understood.7 An hypdrophobic planarized π system is 
hypothesized as an important design feature for high binding specificity based on a well-known 
histological amyloid dye, Congo Red (5).8 In vivo application of Congo Red however was not 
feasible due its limited brain entry. Its molecular structure served as backbone for the 
development of bis-styrylbenzene imaging probes for PET, SPECT and 19F MRI, like 6 (Chrysamine 
G), 7 (X-34)9, 8 (ISB)10, 9 (FSB)12and 10 (Methoxy-X04)11. (Figure 1) The acidic functional groups 
appeared to be unnecessary for high affinity Aβ binding, while bis-styrylbenzenes lacking these 
groups showed Kd’s ~300 fold lower compared to 9.
Unfortunately, the use of amyloid targeting bis-styrylbenzenes is limited to preclinical imaging 
studies that exploit their fluorescent properties.15 Despite the promising initial in vivo 19F MRI 
performed with 9 the incorporation of multiple fluorine atoms thus far has not sufficiently 
increased their sensitivity for the use as an MRI contrast agent.13,14 In general, many of these 
compounds are very hydrophobic, their poor aqueous solubility and blood-brain barrier (BBB) 
passage are likely to limit the in vivo imaging potential of these compounds or lead to an 
unfavorable cerebral washout that causes non-specific signal of unbound compound.
We envisioned that replacement of the phenyl outer rings of the (bis)styrylbenzene backbone 
with pyridine rings may overcome some of these hurdles, as the presence of the nitrogen atom 
is expected to improve solubility and lower LogP values. This study therefore aims to investigate 
whether bis-pyridylethenyl benzene may serve as a new backbone for the development of an 
amyloid-β targeting imaging agent. Synthesized compounds were evaluated with respect to 
their in vitro Aβ binding and specificity, and their fluorescent properties. Partition coefficients 
(LogP) were determined to assess hydrophobicity. In vivo affinity for amyloid plaques and 
cerebral entrance was evaluated following intravenous injection of the compound in a transgenic 
AD mouse model. 
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Design
We designed a series of six different bis-pyridylethenylbenzenes (11 – 16) with the amyloid-
targeting compound Methoxy-X04 (10)11 set as starting point for the design and synthesis. 
(Figure 11.2) With an affinity for Aβ plaques in the nanomolar range (Ki = 26.8 nM), this 
fluorescent small molecule is frequently used for intravital microscopy studies in vivo following 
intravenous or intraperitoneal injection.11 Compounds 11 – 13 have no substituents at all and 
can serve to evaluate whether the presence of the two nitrogen atoms can compensate for the 
hydroxy- and methoxy functionalities in Methoxy-X04. Compounds 14 – 16 contain a methoxy-
substituent on the middle ring for a more direct comparison with Methoxy-X04.
Figure 11.1 Previously reported amyloid-β binding ligands
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All these compounds are accessable using the general synthesis route recently separately 
published by ourselves14 and the group of Boländer et al.16, which is depicted in Scheme 11.1 
with the key building blocks being diphosphonate C and an aldehyde D. p-xylene A is subjected 
to radical bromination to yield dibromide B. This dibromide is then treated with triethyl phosphite 
in an Arbuzov reaction to give diphosphonate C. A Horner-Wadsworth-Emmons reaction between 
diphosphonate C and an aldehyde D yields (E,E)-bis-pyridylethenylbenzene E. 
The building blocks needed for the synthesis of compounds 11 – 16 are either easily synthesized 
or commercially available. (Figure 11.3) With all building blocks in hand, compounds 11 – 16 
were synthesized. The synthesis proceeded uneventful, and all compounds were obtained in 
reasonable yields (14 – 45%). 
Figure 11.2 Envisioned bis-pyridylethenylbenzenes
Scheme 11.1 General synthesis route for the envisioned bis-pyridylethenyl benzenes
Reagents and conditions: a) N-bromosuccinimide, benzoyl peroxide, CCl4, reflux, 16 h. b) Triethyl phosphite, 150 ºC, 16 h. 
c) 1. KOtBu, THF, -10 ºC, 20 min. then D, rt, 16 h.




All synthesized compounds are expected to have fluorescent properties based on their 
conjugated ring structures. We therefore determined excitation and emission wavelength 
maxima of 300 nM solutions and the emission intensities were compared to that of Methoxy-X04. 
(Table 11.1) The intrinsic fluorescent intensity was typically higher for the bis(3-pyridylethenyl)
benzenes compared to the bis(2-pyridylethenyl)benzenes.
It has been reported that binding to amyloid may have a significant effect on fluorescence 
properties17, and therefore the fluorescence was also measured in the presence of synthetic 
Aβ fibrils. The parent compound 10 showed the highest fluorescence yield with a 10-fold 
increase in the presence of amyloid fibrils. All tested bis-pyridylethenylbenzenes showed an 
increase of fluorescence after binding, with compound 12 being the brightest. (Table 11.1) 
Several previously reported Aβ-targeting fluorophores have shown a clear red-shifted emission 
spectrum following binding18,19, but such a spectral shift was not observed for any of the tested 
bis-pyridylethenylbenzenes.
Qualitative assessment of human and murine amyloid plaques binding
Fluorescence microscopy was used for a qualitative ex vivo assessment of the amyloid-binding 
properties. A concentration series of each compound (1 – 10 – 100 μM) was applied to brain 
sections of AD patients and of aged APPswe-PS1ΔE9 (APP/PS1) mice, which have a high amyloid 
plaque load. At 100 μM all compounds showed characteristic staining of amyloid plaques on 
murine APP-PS1 brain sections. Although all compounds bound to amyloid plaques at high 
concentration, differences in binding became visible at the lower concentrations. (Table 11.1 
and Figure 11.4) No non-specific background labeling or labeling of neurofibrillary tangles 
(NFTs) was observed at these concentrations suggesting their specificity for amyloid.
As stated in the previous paragraph, the fluorescence intensity with and without amyloid fibrils 
differed significantly for the various compounds. Therefore, the fluorescence intensity in the 
presence of fibrils was calculated and expressed relative to the intensity of Methoxy-X04 (10). 
(Table 11.1) Assuming that the fluorescence yield in the presence of synthetic Aβ is 
representative for that in the presence of amyloid plaques, the staining data was interpreted 
Figure 11.3 The required building blocks
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as follows. With no substitution on the inner ring 
bis-pyridylethenylbenzenes 11 – 13 displayed 
improved amyloid labeling compared to 
Methoxy-X04 (10). This was already shown for a 
similar bis-styrylbenzene lacking additional 
groups, suggesting that planarity indeed plays 
an important role.20 Although compounds 12 
and 15 expressed the highest fluorescent 
intensity after synthetic amyloid binding of all 
tested bis-pyridylethenylbenzenes, their ability 
to depict amyloid plaques on brain sections 
seemed less clear. This would suggest that 
incorporation of a nitrogen atom on the 3rd 
position results in less favorable binding 
characteristics. Incorporation of an additional 
methoxy-group (14 and 16) resulted in a slightly 
reduced binding on the murine sections. 
Compared to Methoxy-X04, however, their 
ability to depict murine amyloid seems better, 
as the fluorescence yield of compounds 14 and 
16 is lower. This suggests that the nitrogen 
alone might be sufficient to replace the hydroxy 
groups present in Methoxy-X04 (10). Similar to 
Methoxy-X04, the affinity of the ligands for 
human plaques appears to be less than for the 
murine plaques. As amyloid plaques in humans 
and mice differ in composition and 
compactness21, this is likely the reason for the 
observed differences in staining between 
human and murine AD sections. Nevertheless, 
staining of human tissue could still be clearly 
observed for compounds 11 – 13, and was 
improved compared to Methoxy-X04 for 
compound 11 and 13.
Affinity for synthetic Amyloid-β fibrils
A competition assay with tritiated amyloid dye 
Chrysamine G (6) was used to determine the 
binding inhibition coefficient (Ki) for the 
compounds.11 Unlike compound 10, none of the 
bis-pyridylethenylbenzenes showed any 
competitive binding to [3H]Chrysamine G using 
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murine brain homogenate. (Figure 11.6) This implies that these compounds use a different 
binding site than Chrysamine G, and most likely Methoxy-X04 (10). Unfortunately, we were 
therefore unable to determine Ki values for the synthesized compounds.
LogP values
The blood-brain barrier (BBB) is formed by a tight layer of endothelial cells in the wall of cerebral 
blood vessels that regulates the exit and entry of blood compounds into the brain. It is 
traditionally stated that for optimal passive BBB passage, compounds should preferably have 
moderately hydrophobicity (LogD or LogP 2.0 - 3.5), although several successful 
radiopharmaceuticals do not meet this requirement.22 Therefore LogD or LogP should be 
Figure 11.4 Staining of human and APP/PS1 murine amyloid plaques
All bis-pyridylethenylbenzenes stained both human and murine amyloid plaques after applying 100 µM (data not shown). 
At 1  µM concentration,  differences in binding between the compounds become apparent compared to each other or the 





 Human AD APP/PS1 mice Human AD APP/PS1 mice 
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carefully considered as selection criterion, but when it is applied within one series of compounds 
it is nonetheless a valid parameter for selection. For each of the compounds 10 – 16, LogP 
values were determined with an HPLC-based method according to Benhaim et al.23-25 
All compounds have a LogP below that of Methoxy-X04, although none of them meets the 
before mentioned criterion. (Table 11.2)
In vivo amyloid plaque labeling in transgenic AD mice
To assess the ability of the compounds to pass the BBB in vivo, solutions of each compound 
were injected at 30 µmol/kg in aged transgenic APP/PS1 mice, which have extensive cerebral 
amyloid plaques. One day after injection the mice were sacrificed, their brains were removed 
and sections were studied according to the fluorescence microscopy set-up used for the stained 
brain sections. All compounds were readily dissolved using a mixture of 0.05 M compound 
dissolved in 1:1 DMSO:Cremophor (volume ratio) diluted up to 200 µl with PBS at pH 7.2. 
Disolving bis(2-pyridylethenyl)benzenes 13 and 16 however resulted in a viscous substance 
that was not well tolerated by the animals. In vivo targeting of amyloid plaque however was 
observed for all compounds, showing their ability to pass the BBB. (Figure 11.7 and Table 11.2) 
No non-specific labeling was detected in the wild type brain. Direct comparison of the in vivo 
amyloid labeling between the different compounds remained difficult, as the amyloid load may 
differ between the transgenic animals and the fluorescence yield of the compounds varies 
considerably. Bis-pyridylethenylbenzene 11 showed a comparable signal intensity in individual 
labeled plaques after intravenous injection compared to Methoxy-X04, while having a 4-fold 
lower fluorescence yield. Also its methoxy variant, compound 14, clearly crossed the BBB in 






































Figure 11.5 Competition binding 
with synthetic Aβ fibrils
Displacement of [3H]ChrysamineG 
binding by Methoxy-X04 (10) (closed 
circles) and compound 11 (open 
circles), on fibrilized synthetic Aβ1-40. 
Data are presented as the mean ± SEM 
of one experiment, conducted in 
triplicate, and replicated three to seven 
independent times. 10 inhibited the 
binding of 5 nM [3H]Chrysamine G with 
a mean Ki value of 24.1 ± 8.0 nM.
PART TWO  |  CHAPTER 11
186  |.
Table 11.2 LogP values and in vivo amyloid labeling
compound LogP LogP In vivo amyloid labeling
(calc)a (determined)
10 5.55 4.84 +
11 3.94 3.93 +
12 3.94 3.73 +
13 4.12 3.75 +
14 3.86 3.73 +
15 4.03 4.32 +
16 4.16 4.25 +
aLogP values were calculated used web-based methods: www.molinspiration.
com and http://intro.bio.umb.edu/111-112/OLLM/111F98/jLogP/test.html. 
The ability to label amyloid plaques in the brains of APP-PS1 mice following 
































































































control Figure 11.6 Binding competition 
with APP/PS1 transgenic brain 
homogenates
Displacement of [3H]Chrysamine G 
binding by Methoxy-X04 (10) (A) and 
compound 11 (B), on brain cortex 
homogenates of 11 months-old APP/
PS1 transgenic and control mice. Data 
are presented as the mean ± SEM of 
one experiment, conducted in 
duplicate and replicated three 
independent times. 10 inhibited the 
binding of 5 nM [3H]Chrysamine G in 
APP/PS1 mice (closed circles) with a Ki 





Several bis-pyridylethenylbenzenes have been prepared and evaluated for their Aβ binding 
properties and ability to pass the BBB. In general, all compounds showed affinity towards both 
human and murine fibrillar amyloid. Independent of the position of the nitrogen atom, the bis-
pyridylethenylbenzenes without any additional groups seemed to show a higher affinity to 
amyloid in comparison with Methoxy-X04 (10). Besides the possible influence of the nitrogen 
atom, this might be due to their planar structure, which was previously suggested to be 
advantageous for a similar (bis)styrylbenzene with no further substituents.20 The methoxy group 
on the inner ring structure seemed to result in a decrease in amyloid binding, particularly for 
human amyloid. However, in contrast to several known bis-styrylbenzenes, like 10, the bis-




Figure 11.7 In vivo amyloid labeling
Shown are thirty micrometer brain sections of APP/PS1 transgenic mice resected injected with compound 10 – 16. None of 
the wild type mice showed amyloid plaques or aspecific labeling. Scale bar = 200 µm
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In addition, all bis-pyridylethenylbenzenes seemed to cross the BBB and label amyloid in vivo. 
Based on the above results, compound 11, (E,E)-1,4-bis(4-pyridylethenyl)benzene, showed the 
most favorable ex and in vivo characteristics and as such might serve as a starting point to 
further explore the potency of bis-pyridylethenylbenzenes.
A direct application of bis-pyridylethenylbenzenes for amyloid targeting would be their use in 
preclinical optical imaging. In addition we believe that the  bis-pyridylethenylbenzene may serve 
as a novel backbone for the development of amyloid targeting PET or SPECT probes. As their 
binding sites may differ from existing amyloid targeting imaging probes, these compounds may 
provide additional information regarding accumulation of cerebral amyloid.
Materials and Methods
Preparation of Aβ1-40 fibrils
Aβ fibrils were prepared by stirring a 0.5 mg/ml solution of Aβ1-40 peptide (RPeptide, Bogart, GA) 
at 37 ºC for 3 days, which resulted in a cloudy solution. The presence of fibrils was confirmed 
by the presence of an emission peak at 482 nm (excitation 440 nm) upon addition of a 5 μM 
solution in PBS of Thioflavin T (Sigma, Germany) to a small amount of fibrils. Aliquots of 10 μl 
were transferred to Eppendorf vials and stored at -80 ºC until the assay was to be performed.
Fluorescence spectra
All compounds were dissolved in DMSO at 0.3 mM and diluted to 300 nM with 10 % ethanol in 
PBS (pH 7.2). Fluorescence spectra were measured on a Varian Cary Eclipse fluorescence 
spectrophotometer to obtain excitation and emission wavelength maxima, which were used to 
select the correct fluorescence filter settings for further microscopic evaluation. All 
measurements were carried out at 20 ºC and in triplicate. 3D emission-excitation spectra were 
obtained by adding 500 μl of the dissolved compounds to previously prepared Aβ aliquots. 
After manual shaking for 30 sec, 300 μl samples were measured (Infinity M1000, Tecan, 
Switzerland). 
Staining of human and transgenic AD brain sections
Stock solutions of 3 mM in DMSO were diluted to 1 – 10 – 100 µM in 2:3 volume ratio PBS:ethanol 
and sonicated for 15 minutes. Paraffin sections (8 µm) of human AD cortex, 14 months old 
transgenic murine APP/PS1 brain and age-matched control cortices were deparaffinized prior 
to staining for 10 minutes in absolute darkness. After gently rinsing with tap water, sections 
were placed in 0.1 % NaOH in 80% ethanol for 2 minutes, air dried and coverslipped using Aqua 
/ Polymount. Fluorescence of the stained sections was analyzed using a whole microscopic slide 
scanner (Pannoramic MIDI, 3DHistech, Hungary) with a DAPI filter cube (Ex 365 nm; Em 445/50 
nm) using the same intensity setting throughout all experiments.
In vivo Aβ plaque labeling in transgenic AD mice
Twelve-to-fourteen-month-old APP/PS1 mice or age-matched wildtype animals (n=2 per 
compound) were injected intravenously with 0.05 M dissolved in 1:1 volume ratio 
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DMSO:Cremophor diluted with PBS (pH 7.2) to a total volume of 200 µl, resulting in a total dose 
of 30 µmol/kg. One day after  injection, animals were sacrificed using 200 µl Euthanasol (AST 
Pharma) prior to transcardial perfusion with 4% paraformaldehyde in PBS (pH 7.2). Brains were 
removed and cryoprotected in 4% PFA with 10% sucrose for 4 hours, followed by immersion 
in 4% PFA with 30% sucrose overnight. Snap-frozen brains were cryosectioned (30 µm) and 
fluorescence images were analyzed as described above.
Brain homogenates
Male, control and transgenic APP/PS1 mice (11 months old) were killed by decapitation. The 
cortices were removed and homogenized using a DUALL tissue homogenizer (20 strokes, 2000 
rpm), in a 20-fold excess (v/w) of ice-cold 0.25 M sucrose. Homogenates were isolated by 
centrifugation (40 min x 250,000 x g) in a refrigerated Beckman ultracentrifuge (rotor 60-Ti). 
The resulting pellet was suspended in 20 volumes of 150 mM Tris + 20 % ethanol buffer (pH 
7.0) for competition binding experiments.  
Competition binding assay
Competition binding experiments were conducted at room temperature, in a final volume of 1 
ml assay buffer (150 mM Tris-HCl, 20% ethanol, pH 7.0). Compounds were dissolved as 3 mM 
stock solutions in DMSO, sonicated for 15 min, and used in a final concentration range of 30 
μM to 30 pM. 10 μl of unlabeled test compounds was combined with 890 μl of assay buffer and 
50 μl of 100 nM [3H]Chrysamine G stock (specific activity 33.8 Ci/mmol). The mixture was 
sonicated for 10 min, and the assay was subsequently started by the addition of 50 μl synthetic 
Aβ1-40 fibrils or by addition of 400 µl of the brain homogenate suspension . Nonspecific binding 
was determined in the presence of 1 μM of 10. Incubations were terminated after 1 h via 
filtration through Whatman GF/B filters (pre-soaked in binding buffer), using a 48-well Brandel 
harvester. The filters were washed two times with 3 ml of ice-cold binding buffer (pH 7.0), and 
radioactivity was determined by liquid scintillation spectrometry in 5 ml of Optiphase-HiSafe 3, 
at an efficiency of 40 %.
Ki values were determined by nonlinear regression analysis using the equation: logEC50 = 
log[10^logKi*(1+RadioligandNM/HotKdNM)] where Kd = 200 nM, and radioligand = 5nM. 
(GraphPad Software Inc., San Diego, CA)
Procedure for LogP determinations
LogP determinations were performed using literature procedures.23 The measurements were 
performed on a Jasco HPLC-system (detection simultaneously at 214 and 254 nm) coupled to 
a Perkin Elmer Sciex API 165 mass instrument with a custom-made Electrospray Interface (ESI). 
An analytical Gemini C18 column (Phenomenex, 50 x 4.60 mm, 3 micron) was used in combination 
with buffers A) phosphate buffer of pH = 7.0 (0.02 M Na2HPO4 adjusted to pH = 7.0 with 
phosphoric acid) and  B) 0.25% octanol in methanol. 
Of all compounds to be evaluated, stock solutions of 0.5 mg ml-1 were prepared in methanol. 
These stock solutions were then diluted with water, making sure that the volume percentage 
of water was such that the compounds did not precipitate (max 40% water). A 0.25 mg ml-1 
solution of NaNO3 in water was used as a non-retaining compound to determine the dead time 
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of the system. For calibration purposes known compounds were taken from the literature. 
(Table 3) Of these compounds, 0.25 mg ml-1 solutions in either 75% H2O/MeOH or 50% H2O/
MeOH were made. 
For each sample, a series of four isocratic runs was performed, (for instance 55, 60, 65, 70% B), 
and the retention times (from UV-detection at 214 nm) thus obtained were converted to the 
retention factor k’ according to the formula k’ = (tR-t0)/t0, with tR being the retention time of the 
compound and t0 being the retention time of NaNO3. The retention factors were extrapolated 
to 0% B, yielding k’w. As there is a linear relationship between LogP and log k’w plotting LogP values 
of known compounds against obtained log k’w values in this system yields a calibration curve. 
From this curve, LogP values of unknown compounds  were calculated from their k’w values.
Synthesis Procedures
General
Reagents and solvents were used as provided, unless stated otherwise. 2-pyridinecarboxaldehyde 
(21) and 4-pyridinecarboxaldehyde (19) were purchased from Acros,  3-pyridinecarboxaldehyde 
(20) was purchased from Sigma-Aldrich. THF was distilled over LiAlH4 prior to use. Reactions 
were carried out under inert conditions and ambient temperature, unless stated otherwise. 
Prior to performing a reaction, traces of water were removed from the starting materials by 
repeated co-evaporation with anhydrous 1,4-dioxane or anhydrous toluene. These solvents 
were stored over 4 Å molsieves. Reactions were monitored by thin layer chromatography on 
aluminum coated silica sheets (Merck, silica 60 F254), using visualization either with iodine, or 
spraying with a solution of 25 g (NH4)2MoO4, 10 g (NH4)4Ce(SO4)4 in 100 ml H2SO4 and 900 ml 
H2O, or a solution of 20% H2SO4 in ethanol, followed by charring at ~150°C. Column 
chromatography was carried out with silica gel (Screening Devices bv, 40-63 μm particle size, 
60 Å), using technical grade solvents. NMR spectra were recorded at 298K on a Bruker AV400 
using deuterated solvents. All carbon spectra are proton-decoupled. Chemical shifts (δ) are 
given in ppm, in 13C spectra relative to the solvent peaks of CDCl3 (77.0 ppm) or CD3OD (49.0 
ppm), in 1H spectra relative to the solvent peak of tetramethylsilane (0.0 ppm) or CD3OD (3.31 
ppm). Coupling constants are given in Hz. LC-MS analysis was performed on a Finnigan Surveyor 








Based on known literature values, the LogP of several reference compounds yield 
a required calibration curve to determine the LogP values of our compounds.23-25
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HPLC system with a Gemini C18 50 × 4.6 mm column (3 micron, Phenomenex, Torrance, CA, 
USA) (detection at 200-600 nm), coupled to a Thermo Finnigan LCQ Advantage Max mass 
spectrometer (Breda, The Netherlands) with electrospray ionization (ESI; system 1), with as 
eluents A: H2O; B: MeCN and C: 1% aq. TFA. For RP-HPLC purification of the peptides, a Gilson 
GX-281 automated HPLC system (Gilson), supplied with a preparative Gemini C18 column 
(Phenomenex, 150 x 21.2 mm, 5 micron) was used. The applied buffers were A: 0.2% aq. TFA 
or 20 mM NH4OAc and B: MeOH. 
IR spectra were recorded on a Perkin Elmer Paragon 1000 FT-IR Spectrometer. High resolution 
mass spectra were recorded by direct injection (2 µL of a 2 µM solution in H2O/MeCN; 50/50; 
v/v and 0.1% formic acid) on a mass spectrometer (Thermo Finnigan LTQ Orbitrap) equipped 
with an electrospray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10, 
capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z = 150-2000) 
and dioctylpthalate (m/z = 391.28428) as a “lock mass”. The high resolution mass spectrometer 
was calibrated prior to measurements with a calibration mixture (Thermo Finnigan). It should 
be noted that we did not obtain the suited HRMS data for every compound. This finding is in 
agreement with related compounds as reported earlier by us.. Based on the other 
characterization data obtained for each compounds we know for sure that our compounds are 
sound. For clarity, we here include the HMRS data that we did find: compound 14: Exact mass: 
Calculated for [C21H19N2O]+: 315.14919. Found: 315.14901 [M + H]+. compound 15 Exact mass: 
Calculated for [C21H19N2O]+: 315.14919. Found: 315.14915 [M + H]+. 
General procedure for the Horner-Wadsworth-Emmons reaction
The diphosphonate (0.95 mmol) was dissolved in THF (20 mL) and cooled to -10º C. KOtBu (0.30 
g, 2.45 mmol) was added and the black mixture stirred for 20 min. A solution of the aldehyde 
(2.37 mmol) in THF (6 mL) was added and the reaction stirred at rt for 16 h. The reaction was 
cooled to 0ºC, quenched with water and extracted five times with EtOAc. The combined organic 
layers were dried (Na2SO4), filtered and concentrated. The crude product was subjected to 
column chromatography to yield the pure product. 
(E,E)-1,4-bis(4-pyridylethenyl)benzene (11) 
According to the general procedure, diphosphonate 17 (0.19 g, 0.5 mmol) was reacted with 
4-pyridinecarboxaldehyde 19 (0.12 mL, 1.25 mmol). After work-up, the resulting yellow solids 
were purified by column chromatography (50  70% EtOAc/light petroleum) and the pure 
compound was obtained as a bright yellow solid (43 mg, 0.15 mmol, 30%). 
1H NMR (CDCl3, 400 MHz): δ 8.59 (d, J = 5.6 Hz, 4H); 7.56 (s, 4H); 7.38 (d, J = 5.7 Hz, 4H); 7.30 (d, 
J = 16.3 Hz, 2H); 7.05 (d, J = 16.3 Hz, 2H). 13C NMR (CDCl3, 100 MHz): δ 150.1; 144.4; 136.5; 132.4; 
127.5; 126.4; 120.8. IR (neat): 3442.0; 1591.6; 1414.1; 1217.5; 1118.9; 973.4; 868.4; 830.6; 595.9; 
556.2. LC-MS retention time: 3.86 min (10  90% MeCN, 15 min run). Mass (ESI): m/z 285.13 
[M + H]+. 
(E,E)-1,4-bis(3-pyridylethenyl)benzene (12)
According to the general procedure, diphosphonate 17 (0.19 g, 0.5 mmol) was reacted with 
3-pyridinecarboxaldehyde 19 (0.12 mL, 1.25 mmol). After work-up, the resulting yellow solids 
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were purified by column chromatography (50  100% EtOAc/light petroleum) and the pure 
compound was obtained as a bright yellow solid (64 mg, 0.23 mmol, 45%). 
1H NMR (CDCl3, 400 MHz): δ 8.73 (s, 2H); 8.49 (d, J = 4.3 Hz, 2H); 7.83 (d, J = 8.0 Hz, 2H); 7.53 (s, 
4H); 7.29 (dd, J = 8.2 Hz, J = 5.1 Hz, 2H); 7.16 (d, J = 16.4 Hz, 2H); 7.09 (d, J = 16.4 Hz, 2H). 13C NMR 
(CDCl3, 100 MHz): δ 148.5; 148.5; 136.5; 132.9; 132.6; 130.1; 127.0; 125.0; 123.5. IR (neat): 
3029.1; 1564.9; 1481.0; 1427.6; 1022.1; 965.9; 823.5; 704.8; 551.7. LC-MS retention time: 3.87 
min (10  90% MeCN, 15 min run). Mass (ESI): m/z 285.13 [M + H]+. 
(E,E)-1,4-bis(2-pyridylethenyl)benzene (13)
According to the general procedure, diphosphonate 17 (0.19 g, 0.5 mmol) was reacted with 
2-pyridinecarboxaldehyde 21 (0.12 mL, 1.25 mmol). After work-up, the resulting yellow solids 
were purified by column chromatography (0  20% EtOAc/light petroleum) and the pure 
compound was obtained as a bright yellow solid (20 mg, 0.07 mmol, 14%). 
1H NMR (CDCl3, 400 MHz): δ 8.62 (d, J = 4.4 Hz, 2H); 7.70-7.64 (m, 2H); 7.65 (d, J = 16.2 Hz, 2H); 
7.60 (s, 4H); 7.40 (d, J = 7.8 Hz, 2H); 7.20 (d, J = 16.0 Hz, 2H); 7.16 (dd, J = 7.0 Hz, J = 5.4 Hz, 2H). 
13C NMR (CDCl3, 100 MHz): δ 155.5; 149.6; 136.7; 136.6; 132.2; 128.0; 127.5; 122.2; 122.1. IR 
(neat): 1634.1; 1581.5; 1559.8; 1467.9; 1431.7; 1333.4; 1205.7; 1145.3; 981.8; 873.8; 829.9; 
763.9; 736.2; 609.6; 547.6. LC-MS retention time: 3.84 min (10  90% MeCN, 15 min run). Mass 
(ESI): m/z 285.13 [M + H]+. 
(E,E)-1-methoxy-2,5-bis(4-pyridylethenyl)benzene (14) 
According to the general procedure, diphosphonate 18 (0.20 g, 0.5 mmol) was reacted with 
4-pyridinecarboxaldehyde 19 (0.12 mL, 1.25 mmol). After work-up, the resulting yellow solids 
were purified by column chromatography (50% EtOAc/light petroleum  2% MeOH/EtOAc) and 
the pure compound was obtained as a bright yellow solid (20 mg, 0.07 mmol, 14%). 
1H NMR (CDCl3, 400 MHz): δ 8.60-8.55 (m, 4H); 7.80 (s, 1H); 7.64 (d, J = 16.3 Hz, 1H); 7.61 (d, J = 
8.1 Hz, 1H); 7.42 (d, J = 6.1 Hz, 2H); 7.40-7.36 (m, 4H); 7.17 (s, 1H); 6.97 (d, J = 16.2 Hz, 1H); 3.98 
(s, 3H). 13C NMR (CDCl3, 100 MHz): δ 156.5; 137.7; 131.7; 130.9; 128.7; 127.7; 127.3; 125.8; 120.9; 
120.8; 119.9; 108.8; 55.9. IR (neat): 1633.9; 1590.5; 1463.7; 1417.6; 1389.6; 1323.3; 1297.7; 
1116.6; 1029.2; 971.4; 819.7; 805.4; 616.0; 582.4; 548.1; 518.4. LC-MS retention time: 4.14 min 
(10  90% MeCN, 15 min run). Mass (ESI): m/z 315.2 [M + H]+. 
(E,E)-1-methoxy-2,5-bis(3-pyridylethenyl)benzene (15)
According to the general procedure, diphosphonate 18 (0.20 g, 0.5 mmol) was reacted with 
3-pyridinecarboxaldehyde 20 (0.12 mL, 1.25 mmol). After work-up, the resulting yellow solids 
were purified by column chromatography (50%  100% EtOAc/light petroleum) and the pure 
compound was obtained as a bright yellow solid (54 mg, 0.17 mmol, 34%). 
1H NMR (CDCl3, 400 MHz): δ 8.79-8.65 (m, 2H); 8.48 (dd, J = 9.3 Hz, J = 4.7 Hz, 2H); 7.88-7.81 (m, 
2H); 7.59 (d, J = 8.0 Hz, 1H); 7.52 (d, J = 16.6 Hz, 1H); 7.31-7.25 (m, 2H); 7.19-7.03 (m, 4H); 3.97 (s, 
3H). 13C NMR (CDCl3, 100 MHz): δ 157.3; 148.6; 148.5; 148.3; 137.7; 133.6; 132.8; 132.6; 132.6; 
130.5; 126.9; 125.9; 125.4; 125.2; 125.1; 123.5; 123.5; 119.5; 115.6; 108.9; 55.6. IR (neat): 1633.7; 
1567.2; 1557.6; 1479.8; 1463.5; 1423.3; 1328.1; 1240.6; 1164.2; 1117.7; 1035.0; 1024.0; 964.2; 
819.8; 799.3; 705.5; 643.8; 627.1; 549.8. 
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LC-MS retention time: 4.14 min (10  90% MeCN, 15 min run). Mass (ESI): m/z 315.2 [M + H]+. 
(E,E)-1-methoxy-2,5-bis(3-pyridylethenyl)benzene (16)
According to the general procedure, diphosphonate 18 (0.20 g, 0.5 mmol) was reacted with 
2-pyridinecarboxaldehyde 21 (0.12 mL, 1.25 mmol). After work-up, the resulting yellow solids 
were purified by column chromatography (0%  30% EtOAc/light petroleum) and the pure 
compound was obtained as a bright yellow solid (42 mg, 0.13 mmol, 27%). 
1H NMR (CDCl3, 400 MHz): δ 8.61 (s, 2H); 7.93 (d, J = 16.3 Hz, 1H); 7.70-7.58 (m, 4H); 7.45 (d, J = 
8.2 Hz, 1H); 7.41 (d, J = 7.9 Hz, 1H); 7.31-7.08 (m, 6H); 3.95 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 
157.6; 156.2; 155.5; 149.7; 149.5; 137.9; 136.6; 136.4; 132.4; 128.8; 128.2; 127.5; 127.4; 125.9; 
122.1; 122.1; 121.8; 121.8; 119.9; 109.2; 55.5. IR (neat): 1584.0; 1562.5; 1467.9; 1430.5; 1248.3; 
1036.0; 970.7; 769.3; 668.0. LC-MS retention time: 4.10 min (10  90% MeCN, 15 min run). 
Mass (ESI): m/z 315.07 [M + H]+. 
Tetraethyl 1,4-xylylene diphosphonate (17)
As described previously by Kikuchi et al.26, a solution of NaBrO3 (12.1 g, 80 mmol) in H2O (40 mL) 
was added to a solution of p-xylene (2.47 mL, 20 mmol) in EtOAc (40 mL) and the mixture was 
vigorously stirred. A solution of NaHSO3 (8.3 g, 80 mmol) in H2O (80 mL) was added dropwise 
within 15 min and the reaction was stirred for 5 h. After the reaction mixture was poured out in 
Et2O (300 mL), the layers were separated and the aqueous layer extracted twice with Et2O. The 
combined organic layers were washed with 2 M Na2S2O3, dried (Na2SO4), filtered and concentrated. 
The resulting white solids were subjected to column chromatography (0  5% EtOAc/light 
petroleum) and the product was obtained as a white solid (5.4 g), but not completely pure. 
1H NMR (CDCl3, 400 MHz) δ 7.37 (s, 4H); 4.47 (s, 4H). 13C NMR (CDCl3, 100 MHz) δ 129.5; 32.8. 
The impure 1,4-di(bromomethyl)benzene (5.4 g) was dissolved in triethyl phosphite (8.6 mL, 50 
mmol) and the mixture was heated to reflux for 16 h. After cooling, the crude product was 
applied to a silica column and purified (50% EtOAc/light petroleum  2% MeOH/EtOAc). The 
pure product was obtained as white fluffy powder (5.6 g, 14.8 mmol, 74% over two steps). 
1H NMR (CDCl3, 400 MHz) δ 7.25 (s, 4H); 4.07-3.95 (m, 8H); 3.13 (d, J = 20.2 Hz, 4H); 1.24 (t, J = 
7.1 Hz, 12H). 13C NMR (CDCl3, 100 MHz) δ 130.2; 130.1; 130.1; 129.9; 129.8; 129.7; 62.0; 62.0; 
61.9; 34.0; 33.0; 16.3; 16.3; 16.2. 31P NMR (CDCl3, 162 MHz): δ 26.7 (s). 
Tetraethyl 2-methoxy-1,4-xylylene diphosphonate (18)
As described previously by Kumar et al.27, 2,5-dimethylanisole (1.36 g, 10 mmol) was dissolved 
in CCl4 (22 mL). N-bromosuccinimide (3.92 g, 22 mmol) and benzoyl peroxide (20 mg) were 
added and the mixture heated to reflux for 2 h. After cooling to rt, the reaction mixture was 
filtered over Celite and concentrated. The resulting solids were purified by column 
chromatography (0  5% EtOAc/light petroleum). The dibromide was obtained as white solid 
(1.71 g, 5.8 mmol, 58%). 
1H NMR (CDCl3, 400 MHz): δ 7.27 (d, J = 7.7 Hz, 1H); 6.92 (dd, J = 7.6 Hz, J = 1.2 Hz, 1H); 6.89 (s, 
1H); 4.52 (s, 2H); 4.44 (s, 2H); 3.88 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 157.4; 139.7; 131.0; 126.3; 
121.1; 111.5; 55.6; 33.2; 28.3. 
Next, the 2,5-di(bromomethyl)-methoxybenzene (1.71 g, 5.8 mmol) was dissolved in triethyl 
phosphite (2.5 mL, 14.5 mmol) and the mixture was heated to reflux for 16 h. The mixture was 
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cooled, and directly applied to a silica column (50% EtOAc/PE   4% MeOH/EtOAc). 
The pure product was obtained as a yellowish solid (1.55 g, 3.8 mmol, 66%). 
1H NMR (CDCl3, 400 MHz): δ 7.25 (dd, J = 7.6 Hz, J = 2.9 Hz, 1H); 6.86 (s, 1H); 6.83 (d, J = 7.6 Hz, 
1H); 4.07-3.95 (m, 8H); 3.84 (s, 1H); 3.21 (d, J = 21.4 Hz, 2H); 3.13 (d, J = 22.2 Hz, 2H); 1.27-1.20 
(m, 12H).  13C NMR (CDCl3, 100 MHz): δ 157.2; 131.5; 131.1; 121.9; 121.900; 118.85; 112.1; 55.5; 
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Alzheimer’s disease (AD) is the predominant form of dementia in the aging population and its 
increasing incidence represents an important socio-economic and public health concern.  The 
hallmarks of this disease, amyloid plaques and neurofibrillary tangles,  are thought to develop 
early in the disease pathogenesis, up to decades before first clinical symptoms occur. However, 
these pathological hallmarks are still difficult to detect in vivo, and therefore a definitive diagnosis 
can only be made post-mortem. A clinical imaging technique or biomarker capable of visualizing 
and quantifying amyloid plaques and associated early changes thus may enable an earlier 
diagnosis, better understanding of the pathophysiology and eventually aid therapy development. 
The work presented in this thesis aimed to develop innovative diagnostic imaging techniques 
to detect the histological signatures of AD using emerging ultra-high field MRI technologies 
(Part One) and molecular imaging strategies (Part Two).
Detection of Aβ plaques by MRI has previously been demonstrated both in vivo in several 
transgenic AD mouse models and in ex vivo human AD brain tissue. The high magnetic field 
strengths needed to obtain these results only recently became available for in vivo human use. 
These high field human MRI systems (≥7 Tesla) offer new possibilities to specifically detect these 
neuropathological hallmarks, perhaps even at an earlier stadium than the traditional MRI 
biomarker of brain atrophy. 
Part One of this thesis explores the correlation between intrinsic AD-induced MRI contrast 
changes and the underlying neuropathological changes, which is an essential step in the 
development of native contrast MRI techniques for diagnostic purposes.
After a brief general introduction into MRI (Chapter 2), we addressed the usability and limitations 
of post-mortem brain tissue for the development of novel MRI methods for AD (Chapter 3). 
Although post-mortem brain tissue is often exploited for this purpose, we strongly advise the 
use of formalin fixed brain tissue with fixation times less than two years, because prolonged 
fixation times induced destruction of normal brain tissue visible as hypointense imaging artifacts 
on MRI. 
Correlating MRI contrast changes at high magnetic field strength to its underlying pathologic 
substrate is not straight-forward, due to the intrinsic differences in resolution between the 
techniques, and tissue deformation during processing. To solve these issues we designed a 
simple inductively-coupled microcoil setup that allowed us to obtain MRI images directly from 
a single 60 µm thick histological section that could be stained histologically afterwards, thereby 
allowing a direct comparison between the MRI and histological data (Chapter 4). The design 
can easily be integrated into any MRI system using existing commercial hardware while improving 
the signal-to-noise ratio. Initial application on human AD brain tissue demonstrated that human 
Aβ deposits indeed correspond to signal hypo-intensities on T2*-weighted MRI.
Previous studies in the literature had suggested that Aβ deposits, irrespective of associated 
iron, might induce detectable MRI contrast. The direct MR microscopy of histological sections 
offered a valuable tool to investigate the MR properties of the different forms of human cerebral 
Aβ deposits (Chapter 5).  We demonstrated that only when Aβ is deposited in its fibrillar amyloid 
conformation,  a decreased signal can be observed on T2* and T2-weighted MRI. In addition, 
direct visualization of cerebral amyloid angiopathy (CAA) is possible, although signal attenuation 
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was not observed in all CAA-affected vessels. With regard to the cerebral presence of Aβ, this 
would imply that MRI would depict the cerebral fibrillar amyloid load rather than the amount 
of cerebral Aβ peptides.
In Chapter 6 we examined changes in cortical appearance of AD patients using susceptibility 
weighted 7T MRI in vivo. Similar changes on MRI were found in post-mortem tissue of AD patients 
versus controls, which could be correlated to the histological changes found in the same tissue. 
On MRI, diffuse hypointense bands were frequently found in the cortex of the frontal lobes of 
AD patients (57%), but they were not observed in healthy age matched control subjects. Further 
histologic correlation revealed that the pattern of the susceptibility-weighted contrast in the 
cortex of AD patients does not primarily co-localize with amyloid plaques or neurofibrillary 
tangles, but with microglia- and myelin-associated iron accumulation and with an altered myelin 
cytoarchitecture. The current findings show great promise for the in vivo detection of the 
underlying pathological changes in AD. Nevertheless, future work should focus on the specificity 
of these findings for AD versus other neurodegenerative diseases.
Part Two is focused on the development of targeted contrast agents to allow the specific in 
vivo detection and visualization of different Aβ deposits. In general in vivo application of these 
molecular imaging strategies to study or diagnose neurodegenerative diseases, especially with 
regard to MRI, depends on the ability to enter the brain as well as the characteristics of the 
available imaging ligand, as is explained in Chapter 7.
Previously, we have selected heavy chain antibody fragments (VHH) with high affinity specific for 
either cerebral amyloid angiopathy (CAA) or all types of human Aβ deposits. Derived from the 
Camelid heavy chain antibody repertoire, which completely lack light chains, their single 
N-terminal domain (VHH) is fully capable of antigen binding with affinities comparable with those 
of conventional antibodies. The potential of VHH as in vivo imaging agent to assess CAA and 
cerebral amyloid load hinges on their ability to enter the brain, and in Chapter 8 we tested 
their ability to cross the blood-brain barrier (BBB) using an in vitro BBB system. VHH ni3A showed 
the highest transmigration efficiency, which is to a large extent due to 3 different amino acid in 
its N-terminal domain, and occurred by means of active transport. 
As a next step, in Chapter 9 the in vivo properties of two VHH, ni3A and pa2H, were assessed 
in transgenic APPswe/PS1delta9 mice. Following rapid renal clearance only 99mTc-pa2H showed 
a small yet significant higher cerebral uptake in the APP/PS1 animals one day post-injection. 
After circumventing the BBB, the in vivo specificity for Aβ was confirmed for both fluorescently 
labeled VHH, where pa2H remained readily detectable for 24 hours or more after injection. Both 
VHH showed affinity for parenchymal and vascular deposits, this in contrast to human tissue, 
where ni3A specifically targeted only vascular Aβ. Brain uptake as yet is too low for direct in vivo 
imaging, however this study provided evidence that VHH detect Aβ deposits in vivo making them 
promising tools for further development.
A completely different approach is presented in Chapter 10 in which we synthetized several 
novel fluorinated bis-styrylbenzenes to serve as potential 19F MRI contrast agents and studied 
their fluorescent and Aβ binding characteristics. Ideally these small organic molecules carrying 
normal fluorine might allow direct MR imaging of the amyloid binding compound, without any 
endogenous background signal. Most compounds showed a high affinity for both murine and 
human amyloid. Interestingly, they bind to a different binding site than chrysamine G, one of 
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the parent compounds from which our bis-styrylbenzenes were derived. Despite their high logP 
values, many bis-styrylbenzenes were able to enter the brain and label murine amyloid in vivo. 
Initial post-mortem 19F NMR studies using the most promising compound unfortunately showed 
that these compounds as yet do not warrant further MRI studies, mainly due to the severe 
reduction of the 19F signal in the environment of the brain.
Chapter 11 presents a similar study in which we synthesized six bis-pyridylethenylbenzenes 
based on the assumption that the incorporation of nitrogen might lower the hydrophobicity of 
the previous compounds and perhaps thereby further improve their amyloid binding 
characteristics. These compounds did also not share a binding site with chrysamine G. With a 
logP value in between 3 and 5, most bis-pyridylethenylbenzenes were able to enter the brain 
and label murine amyloid in vivo. Based on its in and ex vivo binding characteristics and its 
solubility, bis(4-pyridylethenyl)benzene showed the most promise to serve as a novel amyloid-




The current view on Alzheimer’s disease (AD) is that the neuropathological changes start two 
decades before the clinical symptoms occur.1 The cognitive decline associated with AD, 
represents a late stage of the disease when neurodegeneration is extensive and therapeutic 
interventions may be too late. The search for new imaging methods is driven by the promise 
that earlier diagnosis, preferably before overt dementia is present, may help to identify patients 
early enough to benefit from future treatments. 
Diagnostic biomarkers: Current status
Divided into two main categories, the most extensively characterized biomarkers for AD reflect 
either cerebral amyloid load or neuronal injury and degeneration. (Table 12.1) It is due to the 
increasing knowledge and understanding of the disease obtained by biomarker research that 
only recently, almost thirty years after its first publication, the clinical diagnostic criteria of AD 
as set by the NINDS-ADRDA have finally been revised. According to these new criteria a possible 
diagnosis of AD is no longer one of exclusion, solely based on clinical symptoms of dementia 
or mild cognitive impairment (MCI). The new criteria include the presence of one or more of 
the following five biomarkers: medial temporal lobe atrophy, abnormal cerebrospinal fluid levels 
of Aβ1-42 or tau, or specific patterns of glucose metabolism or Aβ ligands as detected by PET 
neuroimaging. Furthermore, a new set of criteria has been added to stage pre-clinical AD only 
based on positive biomarkers, but without clinical symptoms.2
The revised criteria are based on the hypothetical dynamic biomarker model for AD, as initially 
proposed by Jack et al.1 With new biomarker data continuously being gathered this model 
requires constant revision. According to this model the different biomarkers change in a specific 
temporal order and it is assumed that the accumulation of cerebral amyloid is one of the earliest 
and leading events. Many independent cross-sectional observations are in line with this model. 
However, the exact order in which biomarkers change over time and the relationship of these 
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changes with the clinical outcome is currently the main topic of many ongoing longitudinal 
studies. Recently, the initial results of one of the largest prospective biomarker studies, the 
Australian Imaging, Biomarkers & Lifestyle Study of Ageing (AIBL), again affirmed the model.3 
In this study, researchers retrospectively compared cerebral atrophy and amyloid load at 
baseline with respect to the revised clinical criteria for (pre)clinical AD. Based on amyloid imaging 
as a predictor for AD its outcome again suggested a disease onset of twenty years or more 
before noticeable clinical symptoms. 
Meanwhile a recent revision of the model by Jack and his colleagues confirmed the typical 
sigmoid shape of the changes of each marker over time but also adjusted their temporal order. 
CSF-Aβ now is the first biomarker to change prior to amyloid detected by PET imaging. 
Subsequently, tau can be detected in CSF, and finally FDG PET changes and cerebral atrophy 
appear simultaneously.4 (Figure 12.1) In addition, an initial attempt was taken to include 
cognitive or so-called brain reserve based on intelligence, education, occupation and leisure 
activities into the model to highlight the existing individual differences in clinical presentation 
with respect to the level of their biomarkers. Although Aβ is still considered to be the major 
hallmark as well as an important initiating factor in the progression of the disease, there is 
increasing evidence that other primary or interacting causes exist, e.g. the accumulation of tau 
or changes in myelin and iron metabolism.5-7 As these mechanisms may act alongside Aβ 
accumulation or even further upstream in the disease process, it is important to continue 
improving Aβ biomarkers but also to investigate new possible biomarkers that may project 
brain reserve or any of the aforementioned alternative mechanisms of disease, such as tau-
targeting PET agents or novel MRI techniques. 
In this thesis, we aimed at developing improved imaging biomarkers for AD following two 
approaches: development of novel techniques to detect AD pathology using MRI (Part One: 
Chapter 3 - 6), and development of new Aβ- or amyloid-binding imaging probes (Part Two) 
based on either llama antibody fragments (Chapter 8 and 9) or small amyloid binding molecules 
(Chapter 10 and 11). 
MRI-based biomarker research
Table 12.1 Classification of AD biomarkers (adapted from Jack et al.16)
Biomarker Type
Amyloid accumulation
CSF Aβ1-42 CSF Analysis
Amyloid PET Imaging
Neurodegeneration





In AD patients structural MRI studies revealed specific patterns of regional cerebral atrophy.8 
Severity of atrophy was observed to correlate well with loss of cognitive function as well as with 
post-mortem Braak staging. Of all putative biomarkers, volumetric measures of hippocampal 
and medial temporal lobe atrophy showed the best correlation with the severity of clinical 
symptoms, and has therefore been incorporated as one of the five biomarkers in the revised 
diagnostic criteria. According to the dynamic marker model, however, brain atrophy is a late 
stage event, and therefore structural MRI may not be the method of choice for early or pre-
symptomatic diagnosis. 
As for other neuropathological hallmarks of AD, the development of MRI-based biomarkers has 
mainly focused on the detection of cerebral amyloid. Initial pre-clinical studies were able to 
detect individual amyloid plaques, as they induce a detectable decrease in T2* or SWI signal 
due to the accumulation of iron or the protein aggregate itself.9-11 The work in this thesis not 
only replicated these findings, but also showed that only the functionally relevant fibrillar amyloid 
induces detectable changes in MRI signal, and not just the presence of Aβ peptide. A good 
understanding of the neuropathological substrate of changes on MRI is important for further 
development and interpretation of novel MRI biomarkers for AD. However, despite the arrival 
of novel high magnetic field (≥7 Tesla) human MRI systems, it is not to be expected that direct 
detection of individual amyloid plaques by MRI is feasible in the near future. This is due to 
imaging artifacts based on physiological movements of patients, limited scan time, and the 
resulting limited resolution that can be obtained when scanning patients in vivo. As discussed 
in Chapter 5, although for the time being individual plaques may remain beyond in vivo detection 
the early and subtle changes in MRI signal due to cerebral amyloid accumulation might be 
Figure 12.1 The revised dynamic biomarker model (reproduced from Jack et al.4) 
Pathophysiological changes that are below the detection threshold are visualized by the grey area. At a subthreshold level 
tau pathology is thought to precede Aβ deposition. Based on the current diagnostic techniques the detection of Aβ rises 
above the threshold first (purple and red arrows). As this accelerates tauopathy then comes CSF tau (light blue arrow). Later 
still, functional and metabolic biomarkers appear abnormal as seen by FDG PET and MRI (dark blue arrow). At last, a wide 
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exploited by quantitative MRI methods. However, quantitative parameters reflecting bulk T2 and 
T2* signal in a region of interest will not only reflect cerebral amyloid, but also other tissue 
changes. In addition to amyloid, brain iron not directly associated with plaques and myelin also 
generate local variations in magnetic susceptibility, especially at high magnetic field strengths.12 
High-field (≥ 7 Tesla) human MRI systems therefore show great promise in visualizing new iron- 
and myelin-driven contrasts in the human brain.
The findings in Chapter 6 provide convincing evidence that myelin structure and iron distribution 
in the cortex are disturbed in AD patients. Furthermore, our findings suggest that these changes, 
detected on SWI images at 7 Tesla, may allow distinguishing “probable AD” subjects and healthy 
age-matched controls. Interestingly, changes in iron metabolism and myelin breakdown have 
both been mentioned as potential upstream mechanisms for AD.5,13 The ability to visualize these 
changes in vivo by MRI thus creates a putative novel biomarker with the potential to reflect a 
yet underappreciated change that may accompany the progression of AD. As discussed 
previously, further studies are required, comprising larger patient series as well as patients with 
different types of dementia. And also several additional questions should be answered, such 
as whether the presence of cortical changes is associated with cognitive dysfunction, whether 
the changes appear early in the course of AD, and whether the frontal lobes are the best location 
to detect these changes. 
An important but still poorly understood mechanism that also requires further investigation is 
the influence of the normal ageing process on SWI images at 7 Tesla. Previous histopathological 
studies already pointed out that the cortical distribution of myelin not only differed between 
cortical regions but it was also subject to changes during life.5 Whether a similar relationship 
exists between cortical iron and age has not yet been shown, but given its effect on MRI signal 
it has become essential to gain a better understanding of the role of cortical iron accumulation 
in normal brain aging. Full characteristics of cortical myelin and iron distribution over the lifespan 
starting from as early as the mid-twenties serves as a solid basis for the comparison between 
normal brain ageing or alterations of cortical myelin and iron due to AD or other 
neurodegenerative diseases.
Besides its novel in vivo finding, our work described in Chapter 6 also demonstrates a new 
approach to study neurodegenerative diseases using post-mortem material. Thus far most 
neuropathological MRI studies have attempted to investigate the histopathological substrate 
corresponding the observed MRI contrast using MR images with almost microscopic resolution 
to allow direct and detailed comparison of the histology, similar to the work described in 
Chapters 3 - 5. Although full understanding of this relationship is of crucial importance for 
further development of clinical techniques, the direct translation of these microscopic findings 
to clinical MR images that are acquired at a much lower resolution remains however difficult 
and understudied. 
In Chapter 6 we started with a comparison of the post-mortem MR images acquired at a low 
or almost clinical resolution alongside their histological sections on a mesoscopic scale rather 
than directly focusing on the microscopic MRI-histology correlation using the high resolution 
images. Based on visual inspection we aimed to examine whether any of the applied stainings 
expressed a pattern or distribution similar to that observed on the clinical and low resolution 
MRI. In contrary to normal pathological examination, this analysis of the histological data 
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required a helicopter view to allow a more mesoscopic pattern recognition before diving into 
the exact underlying microscopic details. This approach provided crucial information that 
otherwise might have been lost in the details. It for instance revealed the difference in cortical 
distribution of the myelin-related iron observed throughout the neuropil, which by normal 
microscopic evaluation would have been difficult to discriminate.
Molecular imaging strategies
Since the mid-1990s, molecular imaging has gained interest as it attempts to detect non-
invasively cellular and molecular signatures of disease processes by means of imaging. Crucial 
to molecular imaging is the availability of an imaging probe that targets a specific disease 
process, ideally allowing for an early and specific diagnosis.14,15 For AD, thus far two molecular 
imaging strategies are used in the revised criteria: the detection of glucose hypometabolism 
using 18FDG-PET, and visualization of cerebral amyloid load by radioactive PET ligands. (Table 
1) The cerebral pattern of glucose hypometabolism is considered to be an indicator of synaptic 
loss that accompanies neurodegeneration, and has demonstrated to be a sensitive and specific 
indicator for conversion of MCI to AD.16 However, currently, the most sensitive methods for 
early detection of AD are based on detection of cerebral amyloid.3,4 According to the dynamic 
biomarker model, amyloid plaque accumulation is the first change to be present, and thereby 
constitutes a well-defined specific target for the development of in vivo molecular imaging 
strategies as highlighted in Part Two. It is important, however, to realize that the presence of 
cerebral amyloid might allow an early diagnosis, but it does not allow to follow disease 
progression due to its early plateau level.3,4
Based on preclinical research on the modification of existing amyloid-binding dyes like Congo 
Red and Thioflavin into imaging agents, the initial in vivo breakthrough came with the 
development of Pittsburgh Compound B, a neutral 11C derivative of Thioflavin.17 Despite many 
in vivo human studies its broad applicability is hampered by its short radioactive half-life 
(<20min), requiring the availability of a cyclotron, and therefore it has been mainly used for 
research purposes. Recently Amyvid, a novel amyloid-binding PET probe, has been the first 
probe to receive approval for clinical use to image amyloid plaque burden by the American 
Food and Drug Administration (FDA).18 This 18F-containing stilbene derivative does not need the 
presence of a cyclotron in the vicinity due to its long half-life of 109 minutes. When this first 
FDA approved amyloid imaging probe will prove both its clinical and commercial value this may 
push the development of different or more specific AD imaging probes, like those presented 
in this thesis.
For molecular imaging tracers based on small molecular compounds, such as Amyvid and our 
bis-pyridylethenyl- and fluorinated bis-styrylbenzenes thus far PET, and not MRI, remains the 
imaging modality of choice due to its higher sensitivity.19 If possible MR-based Aβ targeting 
imaging agents are still desirable despite all the difficulties for the design of MR-based AD 
imaging probes as described in Chapter 7. Such agents could be used in one scan session 
comprising a comprehensive structural and functional scan protocol as well as a scan to detect 
the molecular imaging tracers, whereas one PET examination only provides one biomarker. 
Furthermore, the availability of MRI tracers would lower the threshold for performing amyloid 
scans given the wider availability of MRI systems as compared to PET systems, the lack of ionizing 
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irradiation and the lower costs involved in performing MRI as compared to PET. However, 
although existing PET-based amyloid tracers can be modified for MRI, e.g. by. addition of 19F, 
current clinical MRI setups require an administration of such a high dose that it might create 
potential toxicity issues. Novel advances in brain delivery systems combined with AD targeting 
backbones, like VHH, may perhaps overcome these hurdles in the future. Additionally, the 
recently introduced hybrid PET-MRI systems may be instrumental since they allow for acquiring 
PET and MRI data in one diagnostic imaging session. 
Theragnostics
The integration of diagnostic and therapeutic components into a single compound or so-called 
theragnostic agent holds great promise for future drug development. The incorporation of an 
imaging moiety to a possible drug or drug delivery system enables the precise monitoring of in 
vivo temporal and spatial bioavailability and target engagement of the drug, and also treatment 
outcome.20 During the development of the drug, crucial information can be obtained regarding 
the possible pharmacological challenges that have to be addressed to further enhance its 
efficacy, such as biodistribution, pharmacokinetics, fast metabolism, limited specificity and 
severe adverse effects.
With regard to AD, amyloid plaques have not only been an obvious target for diagnostics but 
the break-down or inhibition of these Aβ deposits has also attracted attention as a possible 
target for therapeutic intervention. Compounds that were initially probed for diagnostic 
purposes may also have a therapeutic effect. The development of anti-Aβ antibodies for 
therapeutic purposes initially faced the same restrictions that are met in the development of 
diagnostic agents. Despite almost no cerebral uptake, however, both passive and active 
immunization studies using animal models showed a decrease in cerebral amyloid and improved 
cognitive performance.21 Their effect was partly attributed to the so-called “peripheral sink” 
mechanism that assumes that the removal of Aβ from the bloodstream leads to a lower 
concentration of Aβ in the circulation which then leads to the efflux of the peptide from the 
brain. Unfortunately translation of these findings into the clinic was less successful as therapeutic 
human anti-Aβ studies were stopped either due to unwanted side effects or because no 
significant clinical improvements were detected.21 Besides their inability to gain sufficient entry 
into the brain, the general consensus on the reason for the therapeutic failure of these 
antibodies is that the trials started too late in the course of the disease. Several new trials, such 
as DIAN and A4, are starting this year with groups of pre-symptomatic, but amyloid-positive 
patients.22 These drug development trials are only possible because of the progress that has 
been made over the last years in new diagnostic biomarkers, particularly PiB-PET. 
Although initially designed for diagnostic purposes the llama antibody fragments or VHH that 
we studied have many unique characteristics that make them especially interesting for 
theragnostics, as pointed out in Chapter 9. Several VHH have already shown their potential 
therapeutic value in vitro, preventing aggregation of amyloid fibrils or oligomeric forms of Aβ 
and thus inhibiting formation of or disentangling amyloid plaques.23 Compared to the 
conventional monoclonal antibodies or antibody fragments (Fab’) used for clinical trials, like 
those described above, VHH express a similar high level of specificity and affinity, but because 
of their single domain production and modification is relatively easy and cost-efficient.24 
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Possible immunologic reactions are easily avoided by humanization. Their selective binding to 
different Aβ species, like CAA or oligomeric Aβ, could shift Aβ brain efflux in the favored direction, 
which could be used to tailor anti-Aβ therapy, thereby further reducing therapy induced 
complications. 
Although in this thesis a proof of principle is given regarding the specific brain uptake of VHH, 
their full therapeutic effect may be hampered by a limited ability to enter the brain. Similar to 
the adaptations needed to improve their value as a diagnostic marker, novel strategies will have 
to be addressed to improve their therapeutic value.
Concluding remarks
In the next decade biomarker studies will play a crucial role in developing strategies for early 
detection and treatment of AD. It remains doubtful whether eventually one single biomarker 
will be able to give a final diagnosis, but the incorporation of biomarkers in the revised NINDS-
ADRDA criteria mean an important step forward, and confirm the importance of AD biomarker 
research in general. Further evaluation and standardization of the included biomarkers may 
provide more insight on the yet unknown pathogenesis of AD and contribute to the development 
of effective treatment. 
Finally, it should be noted that due to the current absence of an effective treatment the impetus 
to develop methods for early diagnosis for AD, particularly for the asymptomatic individual, is 
limited and creates a Catch 22 situation. However, as discussed earlier in this thesis, the ability 
to detect the early phases of the disease is expected to provide improve our understanding of 
the pathophysiology of the disease, which then sets the stage for developing more effective 
treatment. Once more effective treatment will be available, the same tools for early disease 
detection will become relevant to individual patients by opening the therapeutic window to the 
early phases of the disease they are suffering from. 
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Synthesis of phosphonate building blocks
General synthetic procedures
All phosphonate building blocks were prepared according to the general synthesis scheme 
below (Scheme I.1) starting from either commercially available dimethylbenzenes, or 
dimethylbenzenes prepared according to literature procedures. 
General procedure for bromination (A  B): To a solution of the dimethyl compound (10 mmol) 
in CCl4 (22 ml) were added N-Bromosuccinimide (3.92 g, 22 mmol) and benzoyl peroxide (20 
mg) and the mixture was heated to reflux for 16 h. After cooling to room temperature, the 
mixture was filtered over Celite, the filtrate concentrated and the residue applied to column 
chromatography (0  5% EtOAc/light petroleum) to yield the pure product. 
General procedure for Arbuzov (B  C): To the dibromide (1 mmol) was added triethyl phosphite 
(0.42 ml, 2.5 mmol) and the mixture was heated to reflux (150 °C) for 16 h. After cooling to room 
temperature, the mixture was directly applied to a silica column (50% EtOAc/light petroleum  
10% MeOH/EtOAc) to yield the pure product. 
Synthesis of dimethylbenzene precursors
The dimethylbenzene precursors 40 - 42 for phosphonates 29, 31 – 32  were not commercially 
available and were prepared from 2,5-dimethylaniline as depicted in Scheme I.2.  
Diazonium salt 39 was prepared according to literature procedures.1 To a solution of HBF4 (50% 
in H2O, 25.5 ml, 200 mmol) in water (25.5 ml), 2,5-dimethylaniline (12.5 ml, 100 mmol) was added 
and the reaction mixture was cooled to 0º C. A solution of NaNO2 (6.9 g, 100 mmol) in water (6 
ml) was added dropwise and the reaction mixture warmed to room temperature. The solids 
were filtered off and washed with 5% aq. HBF4, EtOH and Et2O and dried under vacuum. The 
resulting pinkish powder was dissolved in acetone and precipitated with Et2O. After filtration, 
this procedure was repeated two times and after drying under vacuum, the product was 
Scheme I.1 General procedure for preparation of phosphonates
Scheme I.2 Preparation of fluorinated dimethylbenzene precursors
Reagents and conditions: a) HBF4, NaNO2, H2O, 0ºC  rt, 47%. b) fluorinated alcohol, reflux, 18 h.
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obtained as an off-white powder (10.4 g, 47.4 mmol, 47%).  1H NMR (acetone-d6, 400 MHz):  δ 
8.54 (s, 1H); 8.03 (d, J = 8.2 Hz, 1H); 7.78 (d, J = 8.0 Hz, 1H); 2.86 (s, 3H); 2.51 (s, 3H). IR (neat): 
2275.8; 1506.6; 1303.6; 1210.7; 1029.3; 847.8; 521.4.
Fluorethers 40 – 42  were synthesized form diazonium salt 39 according to literature 
procedures.1 Diazonium salt 39 (2.2 g, 10 mmol) was dissolved in the appropriate fluorous 
alcohol (25 ml) and the mixture was heated to reflux for 18 h. After cooling to room temperature, 
2 N NaOH and Et2O were added and the layers separated. The organic layer was dried (Na2SO4); 
filtered and concentrated (careful: product is volatile!). The crude product was purified by flash 
column chromatography (light petroleum) to yield the fluorous ether as a colorless fluid. As the 
products are volatile, care needs to be taken during evaporation after work-up and column 
chromatography. 
Following the general procedure above, 40 was obtained from reaction of 39 with 
2,2,2-trifluoroethanol as a colorless liquid (1.14 g, 5.6 mmol, 56%). 1H NMR (CDCl3, 400 MHz): δ 
7.03 (d, J = 7.5 Hz, 1H); 6.75 (d, J = 7.5 Hz, 1H); 6.58 (s, 1H); 4.30 (q, J = 8.2 Hz, J = 8.2 Hz, 2H); 2.31 
(s, 3H); 2.20 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 155.5; 136.8; 130.9; 124.9; 124.4; 122.8; 122.1; 
112.8; 66.7; 66.3; 66.0; 65.6; 21.2; 15.4. 19F NMR (CDCl3, 375 MHz): δ 3.36 (t, J = 8.1 Hz, 3F).
Compound 41 was obtained from reaction of 39 with 1,1,1,3,3,3-hexafluoroisopropanol as a 
colorless liquid (1.79 g, 6.6 mmol, 66%). 1H NMR (CDCl3, 400 MHz): δ 7.07 (d, J = 7.6 Hz, 1H); 6.85 
(d, J = 7.6 Hz, 1H); 6.72 (s, 1H); 4.91-4.80 (m, 1H); 2.33 (s, 3H); 2.24 (s, 3H). 13C NMR (CDCl3, 100 
MHz): δ 155.6; 137.3; 131.4; 125.5; 124.7; 122.6; 122.6; 119.8; 114.6; 76.2; 75.9; 75.6; 21.2; 15.3. 
19F NMR (CDCl3, 375 MHz): δ 3.90 (d, J = 5.7 Hz, 6F). IR (neat): 1511.8; 1368.9; 1250.5; 1218.2; 
1192.2; 1155.7; 1134.3; 1104.1; 886.8; 809.9; 686.2.
Following the general procedure above, 42 was obtained from reaction of 39 with nonafluoro-
tert-butanol as a colorless liquid (2.22 g, 6.5 mmol, 65%).
1H NMR (CDCl3, 400 MHz): δ 7.00 (s, 1H); 6.94 (d, J = 7.7 Hz, 1H); 6.81 (d, J = 9.0 Hz, 1H); 2.30 (s, 
3H); 2.24 (s, 3H). 19F NMR (CDCl3, 375 MHz): δ 8.23 (s, 9F).
Synthesis of phosphonates 25 – 32 
Phosphonate 25 was prepared as described previously.2 2,5-dimethylanisole (1.36 g, 10 mmol) 
was brominated according to the general procedure for bromination. The dibromide was 
obtained as white solid (1.71 g, 5.8 mmol, 58%). 
1H NMR (CDCl3, 400 MHz): δ 7.27 (d, J = 7.7 Hz, 1H); 6.92 (dd, J = 7.6 Hz, J = 1.2 Hz, 1H); 6.89 (s, 
1H); 4.52 (s, 2H); 4.44 (s, 2H); 3.88 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 157.4; 139.7; 131.0; 126.3; 
121.1; 111.5; 55.6; 33.2; 28.3. 
The dibromide (1.71 g, 5.8 mmol) was subjected to the Arbuzov reaction according to the general 
procedure. The pure product was obtained as a yellowish solid (1.55 g, 3.8 mmol, 66%). 
1H NMR (CDCl3, 400 MHz): δ 7.25 (dd, J = 7.6 Hz, J = 2.9 Hz, 1H); 6.86 (s, 1H); 6.83 (d, J = 7.6 Hz, 1H); 
4.07-3.95 (m, 8H); 3.84 (s, 1H); 3.21 (d, J = 21.4 Hz, 2H); 3.13 (d, J = 22.2 Hz, 2H); 1.27-1.20 (m, 
12H). 13C NMR (CDCl3, 100 MHz): δ 157.2; 131.5; 131.1; 121.9; 121.900; 118.85; 112.1; 55.5; 34.4; 
33.0; 27.0; 25.6; 16.3. 31P NMR (CDCl3, 162 MHz): δ 27.39 (d, J = 9.0 Hz), 26.77 (d, J = 9.1 Hz). 
To synthesize phosphonate 26 1,4-bis(chloromethyl)-2,5-dimethoxybenzene (0.24 g, 1 mmol) 
was added to triethyl phosphite (0.42 ml, 2.5 mmol) and the mixture was heated to reflux for 
16 h. After cooling to room temparature, the solids were filtered off, washed with light petroleum 
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and dried under vacuum, yielding the pure product as a white solid (0.37 g, 0.85 mmol, 85%). 
1H NMR (CD3OD, 400 MHz): δ 6.95 (d, J = 1.8 Hz, 2H); 4.03 (m, 8H); 3.82 (s, 6H); 3.24 (s, 2H); 3. 
22 (s, 2H); 1.25 (t, J = 7.1 Hz, 12H). 13C NMR (CD3OD, 100 MHz): δ 152.5; 120.5; 115.3; 63.6; 56.6; 
27.7; 26.3; 16.7. IR (neat): 1520.1; 1476.4; 1415.0; 1265.3; 1221.0; 1026.7; 963.8; 881.0; 837.8; 
819.8; 768.0; 725.8; 700.2; 632.7; 518.4. LC-MS retention time: 6.70 min (10  90% MeCN, 13.5 
min run). Mass (ESI): m/z 439.0 [M + H]+; 876.9 [2M + H]+. Exact mass: Calculated for 
[C18H33O8P2]+: 439.16452; [C18H32O8P2]+: 461.14646. Found: 439.16446 [M + H]+; 461.14583 
[M + Na]+.
Phosphonate 27 was prepared as described previously.2 2,5-dimethylphenol (6.1 g, 50 mmol) 
was dissolved in DMF (30 ml), imidazole (3.4 g, 50 mmol) was added and the reaction mixture 
stirred for 10 min. Subsequently, TBDPS-Cl (15.6 ml, 60 mmol) was added. After stirring for 22 
h, the mixture was poured out in water (250 mL) and the aqueous layer extraced three times 
with DCM. The combined organic layers were washed with water, dried (Na2SO4), filtered and 
concentrated. The resulting yellow oil was purified by column chromatography (0  2% EtOAc/
light petroleum) to yield the pure product as a pale yellow oil (16.0 g, 44.3 mmol, 89%). 
1H NMR (CDCl3, 400 MHz): δ 7.76-7.64 (m, 4H); 7.45-7.33 (m, 1H); 7.01 (d, J = 7.6 Hz, 1H); 6.59 (d, 
J = 7.4 Hz, 1H); 6.22 (s, 1H); 2.33 (s, 3H); 1.94 (s, 3H); 1.10 (s, 9H). 13C NMR (CDCl3, 100 MHz): δ 
153.6; 150.2; 135.4; 133.1; 130.4; 129.8; 127.7; 121.4; 119.3; 26.6; 16.7. 
The protected phenol (16.0 g, 44.3 mmol) was subjected to the general bromination procedure 
to yield the pure product as a white solid (9.2 g, 17.8 mmol, 40%). 
1H NMR (CDCl3, 400 MHz): δ 7.76-7.66 (m, 4H); 7.47-7.35 (m, 6H); 7.29 (d, J = 7.8 Hz, 1H); 6.85 
(dd, J = 7.8 Hz, J = 1.7 Hz, 1H); 6.39 (d, J = 1.7 Hz, 1H); 4.69 (s, 2H); 4.04 (s, 2H); 1.15 (s, 9H). 13C 
NMR (CDCl3, 100 MHz): δ 135.4; 131.1; 130.1; 130.0; 128.0; 121.7; 119.8; 32.7; 26.5; 26.5. 
The dibromide (9.2 g, 17.8 mmol) was converted to the diphosphonate according to the general 
procedure and the pure product obtained as a viscous yellow oil (6.6 g, 10.4 mmol, 58%). 
1H NMR (CDCl3, 400 MHz): δ 7.76-7.69 (m, 4H); 7.45-7.30 (m, 7H); 6.82 (d, J = 7.8 Hz, 1H); 6.33 (s, 
1H); 4.16-3.98 (m, 8H); 3.39 (d, J = 21.7 Hz, 2H); 2.74 (d, J = 21.5 Hz, 2H); 1.11 (s, 9H); 1.26 (t, J = 
7.1 Hz, 6H); 1.04 (t, J = 7.1 Hz, 6H). 13C NMR (CDCl3, 100 MHz): δ 153.1; 153.0; 135.3; 132.206; 
131.2; 131.0; 129.9; 127.7; 122.4; 120.3; 120.3; 120.2; 120.2; 120.1; 120.0; 120.0; 120.0; 119.9; 
61.7; 61.7; 61.7; 33.8; 32.5; 27.4; 26.4; 26.0; 16.4; 16.3; 16.2; 16.2. 31P NMR (CDCl3, 162 MHz): 
δ 27.24 (d, J = 8.5 Hz); 25.77 (d, J = 8.5 Hz). 
The dibromide precursor of 28 was prepared according to literature procedures.3 To a solution 
of NaBrO3 (0.15 g, 1 mmol) in water (0.5 ml), a solution of 4-methyl-3-trifluoromethyl benzyl 
bromide (0.13 g, 0.5 mmol, in EtOAc (1 ml) was added and the mixture stirred vigorously. A 
solution of NaHSO3 (0.1 g, 1 mmol) in water (1 ml) was added dropwise and the deep-orange 
solution was stirred for 77 h. The mixture was poured out in Et2O and the layers were separated. 
The aqueous layer was extracted two times with Et2O and the combined organic layers were 
washed with 2 M Na2S2O3, dried (Na2SO4); filtered and concentrated. The resulting brown oil 
was subjected to column chromatography (0  4% EtOAc/light petroleum) and the product 
was obtained as an off-white solid (0.11 g, 0.33 mmol, 66%). 
1H NMR (CDCl3, 400 MHz): δ 7.66 (s, 1H); 7.58 (s, 2H); 4.61 (s, 2H); 4.48 (s, 2H).  13C NMR (CDCl3, 
100 MHz): δ 138.5; 136.2; 133.3; 132.8; 126.7; 124.4; 122.3; 31.3; 27.8. IR (neat): 1319.7; 1297.0; 
1224.7; 1197.7; 1169.2; 1144.5; 1122.0; 1055.7; 914.3; 908.2; 848.9; 776.2; 746.1; 667.7; 615.4; 
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583.4.  The dibromide (0.96 g, 2.89 mmol) was treated with triethyl phosphite according to the 
general procedure, yielding diphosphonate 28 as a yellow oil (0.66 g, 1.47 mmol, 51%).  1H NMR 
(CDCl3, 400 MHz): δ 7.64  (dd, J = 7.9 Hz, J = 1.4 Hz, 1H); 7.58 (s, 1H); 7.47 (d, J = 8.0 Hz, 1H); 4.09-
3.98 (m, 8H); 3.35 (d, J = 22.6 Hz, 2H); 3.18 (d, J = 21.6 Hz, 2H); 1.25 (dd, J = 15.6 Hz, J = 7.1 Hz, 
12H). 13C NMR (CDCl3, 100 MHz): δ 132.8; 132.3; 130.9; 128.8; 127.3; 125.2; 122.4; 62.1; 62.0; 
33.7; 32.3; 30.3; 28.9; 16.1.
19F NMR (CDCl3, 375 MHz) δ 18.38 (s, 3F). IR (neat): 1320.6; 1246.7; 1145.4; 1118.5; 1047.3; 
1019.5; 958.9; 898.9; 856.8; 819.1; 730.0; 667.8; 641.7; 589.0; 556.2; 522.4.   LC-MS retention 
time: 7.34 min (10  90% MeCN, 13.5 min run). Mass (ESI): m/z 447.1 [M + H]+; 892.8 [2M + 
H]+. Exact mass: Calculated for [C17H28F3O6P2]+: 447.13077. Found: 447.13058 [M + H]+.  
Following the general procedure for bromination, the dibromide was obtained from 40 (0.85 
g, 4.18 mmol) as a yellow solid (0.64 g, 1.76 mmol, 42%). 
1H NMR (CDCl3, 400 MHz): 7.35 (d, J = 7.7 Hz, 1H); 7.06 (dd, J = 7.7 Hz, J = 1.5 Hz, 1H); 6.88 (s, J = 
1.2 Hz, 1H); 4.53 (s, 2H); 4.45 (s, 2H); 4.46 (q, J = 8.0 Hz, J = 8.0 Hz, 2H). 13C NMR (CDCl3, 100 MHz): 
δ 155.1; 140.0; 131.7; 127.4; 124.4; 123.2; 121.7; 113.0; 66.7; 66.3; 66.0; 65.6; 32.5; 27.1. 19F 
NMR (CDCl3, 375 MHz): δ 3.79 (t, J = 8.0 Hz, 3F). IR (neat): 1611.8; 1582.2; 1508.7; 1423.7; 1289.7; 
1259.7; 1224.4; 1204.4; 1158.2; 1099.9; 1068.0; 974.4; 855.9; 746.4; 663.3; 556.4; 539.8. 
Following the general procedure for the Arbuzov reaction, 29 was obtained from the dibromide 
(0.64 g, 1.76 mmol) as a yellow oil (0.41 g, 0.86 mmol, 49%). 
1H NMR (CDCl3, 400 MHz): δ 7.32 (dd, J = 7.8 Hz, J = 2.4 Hz, 1H); 6.94 (d, J = 7.8 Hz, 1H); 6.88 (s, 1H); 
4.41 (q, J = 8.2 Hz, J = 8.2 Hz, 2H); 4.08-3.96 (m, 8H); 3.23 (d, J = 21.0 Hz, 2H); 3.12 (d, J = 21.0 Hz, 
2H); 1.25 (dt, J = 7.1 Hz, J = 2.2 Hz, 12H). 13C NMR (CDCl3, 100 MHz): δ 154.9; 132.0; 132.0; 131.9; 
131.9; 131.6; 131.6; 131.6; 131.6; 124.6; 124.0; 124.0; 123.9; 123.9; 121.8; 120.1; 120.1; 120.0; 
120.0; 113.9; 113.9; 113.9; 66.9; 66.6; 66.2; 65.9; 62.1; 62.0; 61.8; 61.8; 34.1; 32.7; 26.8; 25.4; 
16.3; 16.2; 16.2; 16.1. 31P NMR (CDCl3, 162 MHz): δ 26.58 (d, J = 8.7 Hz); 26.27 (d, J = 8.3 Hz). 
19F NMR (CDCl3, 375 MHz): δ 3.61 (t, J = 11.3 Hz, 3F). IR (neat): 1615.8; 1581.8; 1429.8; 1393.3; 
1243.0; 1158.0; 1019.8; 957.2; 845.9; 670.0; 624.4; 512.2. LC-MS retention time: 7.38 min (10 
 90% MeCN, 15 min run). Mass (ESI): m/z 477.0 [M + H]+; 952.8 [2M + H]+. Exact mass: 
Calculated for [C18H30F3O7P2]+: 477.14134; [C18H30F3O7P2Na]+: 499.12328. Found: 
477.14118 [M + H]+; 499.12261 [M + Na]+.
To obtain compound 30 a chilled (0°C) solution of 2,5-dimethylphenol (1.22 g, 10 mmol) in DMF 
(50 ml) NaH (60% wt. dispersion in mineral oil, 0.8 g, 20 mmol) was prepared and the mixture 
was stirred for 10 min. A solution of 1-bromo-4,4,4-trifluorobutane (2.28 g, 12 mmol) in DMF 
(25 ml) was added and the mixture was stirred at room temperature for 16 h. After cooling to 
0°C and quenching with water, the reaction mixture was extracted thrice with EtOAc and the 
combined organic layers were dried (Na2SO4); filtered and concentrated. The resulting yellow 
oil was subjected to column chromatography (0  10% EtOAc/light petroleum) and the pure 
product was obtained as a yellow fluid (2.13 g, 9.2 mmol, 92%).
1H NMR (CDCl3, 400 MHz): δ 7.01 (d, J = 7.5 Hz, 1H); 6.68 (d, J = 7.5 Hz, 1H); 6.61 (s, 1H); 3.99 (t, J = 
5.9 Hz, 2H); 2.31 (s, 3H); 2.39-2.25 (m, 2H); 2.17 (s, 3H); 2.10-2.00 (m, 2H). 13C NMR (CDCl3, 100 
MHz): δ 156.5; 136.6; 130.4; 128.6; 125.8; 123.5; 121.1; 111.8; 65.8; 31.2; 31.0; 30.7; 30.4; 22.4; 
21.3; 15.7. 19F NMR (CDCl3, 375 MHz): δ 11.26 (t, J = 10.9 Hz, 3F). IR (neat): 1615.9; 1586.1; 1508.8; 
1385.3; 1337.0; 1285.9; 1248.6; 1231.1; 1149.9; 1128.0; 1026.7; 804.7; 661.7; 598.8; 586.4; 553.3. 
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Following the general procedure for bromination, this dimethyl compound (0.2 g, 0.86 mmol) 
was converted into the dibromide, which was obtained as a yellow solid (0.26 g, 0.66 mmol, 77%). 
1H NMR (CDCl3, 400 MHz): δ 7.27 (d, J = 7.7 Hz, 1H); 6.95 (dd, J = 7.7 Hz, J = 1.3 Hz, 1H); 6.87 (s, 
1H); 4.50 (s, 2H); 4.44 (s, 2H); 4.10 (t, J = 5.9 Hz, 2H); 2.48-2.31 (m, 2H); 2.19-2.06 (m, 2H). 13C NMR 
(CDCl3, 100 MHz): δ 156.5; 139.9; 131.1; 128.5; 126.4; 121.4; 112.1; 66.3; 33.1; 30.9; 30.6; 28.2; 
22.2. 19F NMR (CDCl3, 375 MHz): δ 11.4 (t, J = 10.6 Hz, 3F). IR (neat): 1685.6; 1607.6; 1496.0; 
1450.6; 1383.7; 1337.9; 1249.6; 1230.4; 1149.1; 1025.9; 835.7; 663.2; 626.2; 553.0. 
Following the general procedure for the Arbuzov reaction, 30 was obtained from the dibromide 
(0.26 g, 0.66 mmol) as a yellow oil (0.23 g, 0.45 mmol, 68%). 
1H NMR (CDCl3, 400 MHz): δ 7.26 (dd, J = 7.5 Hz, J = 2.7 Hz, 1H); 6.86 (s, 1H); 6.84 (d, J = 9.8 Hz, 
1H); 4.08-3.95 (m, 10H); 3.20 (d, J = 21.6 Hz, 2H); 3.11 (d, J = 21.5 Hz, 2H); 2.44-2.30 (m, 2H); 2.14-
2.04 (m, 2H); 1.24 (dd, J = 12.8 Hz, J = 6.9 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ 156.0; 156.0; 
155.9; 155.9; 131.6; 131.6; 131.5; 131.5; 131.1; 131.0; 131.0; 131.0; 128.3; 125.6; 122.1; 122.1; 
122.1; 122.0; 118.8; 118.8; 118.7; 118.7; 112.8; 112.8; 112.7; 112.7; 66.1; 61.9; 61.9; 61.7; 61.6; 
34.1; 32.8; 30.6; 30.3; 30.0; 29.5; 27.1; 25.7; 22.0; 22.0; 16.2; 16.1; 16.1. 19F NMR (CDCl3, 375 
MHz): δ 11.28 (t, J = 10.9 Hz, 3F). IR (neat): 1612.1; 1581.7; 1511.6; 1431.2; 1391.5; 1248.9; 
1149.2; 1050.8; 1019.6; 954.9; 819.9; 627.5; 518.1. LC-MS retention time: 8.01 min (10  90% 
MeCN, 15 min run). Mass (ESI): m/z 505.07 [M + H]+; 1008.87 [2M + H]+. Exact mass: Calculated 
for [C20H34F3O7P2]+: 505.17264; [C20H33F3O7P2Na]+: 527.15458. Found: 505.17254 [M + H]+; 
527.15411 [M + Na]+.
Compound 31 was prepared as follows. Following the general procedure for bromination, the 
dibromide was obtained from 41 (1.36 g, 5  mmol) as a yellow solid (0.97 g, 2.25 mmol, 45%). 
1H NMR (CDCl3, 400 MHz): δ 7.40 (d, J = 7.8 Hz, 1H); 7.14 (d, J = 7.8 Hz, 1H); 6.99 (s, 1H); 5.11-4.95 
(m, 1H); 4.52 (s, 2H); 4.44 (s, 2H). 13C NMR (CDCl3, 100 MHz): δ 154.5; 140.3; 132.2; 128.2; 124.9; 
122.3; 119.4; 114.0; 75.9; 75.6; 75.2; 75.0; 74.6; 74.2; 73.9; 32.0; 26.0. 19F NMR (CDCl3, 375 MHz): 
δ 4.47 (d, J = 5.6 Hz, 6F). IR (neat): 1616.7; 1578.9; 1507.6; 1425.5; 1368.6; 1256.1; 1193.7; 1147.8; 
1103.3; 890.7; 758.3; 686.3; 662.9; 532.8. 
Following the general procedure for the Arbuzov reaction, 31 was obtained from the dibromide 
(0.97 g, 2.25 mmol) as a yellow oil (0.76 g, 1.48 mmol, 66%). 
1H NMR (CDCl3, 400 MHz): δ 7.40 (dd, J = 7.8 Hz, J = 1.6 Hz, 1H); 7.04 (d, J = 7.8 Hz, 1H); 7.00 (s, 
1H); 5.13-5.02 (m, 1H); 4.09-3.97 (m, 8H); 3.23 (d, J = 20.6 Hz, 2H); 3.14 (d, J = 20.5 Hz, 2H); 1.24 
(t, J = 7.1 Hz, 12H). 13C NMR (CDCl3, 100 MHz): δ 155.8; 155.8; 155.8; 155.7; 133.8; 133.8; 133.7; 
133.7; 133.0; 132.9; 126.5; 126.4; 126.4; 126.4; 124.1; 121.4; 121.3; 121.3; 116.7; 116.6; 75.4; 
75.0; 74.7; 63.8; 63.7; 63.6; 63.5; 34.2; 32.8; 27.4; 26.0; 16.7; 16.6; 16.5. 31P NMR (CDCl3, 162 
MHz): δ 25.77 (d, J = 1.45 Hz). 19F NMR (CDCl3, 375 MHz): δ 4.25 (d, J = 7.5 Hz, 6F). 
Phosphonate 32 was obtained similarly. Following the general procedure for bromination, the 
dibromide  was obtained from 42 (0.34 g, 1  mmol) as a yellow solid (0.31 g, 0.62 mmol, 62%). 
1H NMR (CDCl3, 400 MHz): δ 7.47 (d, J = 2.4 Hz, 1H); 7.28 (d, J = 1.4 Hz, 1H); 6.58 (s, 1H); 4.49 (s, 
2H); 4.42 (s, 2H). 13C NMR (CDCl3, 100 MHz): δ 150.7; 143.6; 132.2; 130.7; 127.1; 124.1; 121.45; 
116.5; 31.7; 25.8.
Following the general procedure for the Arbuzov reaction, 32 was obtained from the dibromide 
(0.34 g, 0.68 mmol) as a yellow oil (0.10 g, 0.16 mmol, 24%). 
1H NMR (CDCl3, 400 MHz): δ 7.47 (dd, J = 7.9 Hz, J = 1.8 Hz, 1H); 7.22 (s, 1H); 7.15 (d, J = 8.0 Hz, 
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1H); 4.06-3.97 (m, 8H); 3.20 (d, J = 20.9 Hz, 2H); 3.12 (d, J = 20.6 Hz, 2H); 1.24 (t, J = 7.0 Hz, 12H). 
13C NMR (CDCl3, 100 MHz): δ 150.7; 150.7; 150.7; 132.2; 132.1; 132.1; 132.1; 131.7; 127.5; 127.5; 
123.6; 123.6; 123.5; 123.5; 121.3; 121.1; 118.2; 61.8; 61.8; 61.7; 61.7; 33.7; 32.3; 27.0; 25.6; 16.0; 
15.9; 15.9; 15.8; 15.8. 31P NMR (CDCl3, 162 MHz): δ 25.57 (q, J = 7.8 Hz, J = 7.8 Hz). 19F NMR 
(CDCl3, 375 MHz): δ 8.71 (s, 9F). IR (neat): 1506.3; 1425.1; 1393.4; 1250.4; 1135.7; 1022.1; 999.7; 
965.7; 849.4; 816.5; 727.5; 629.2; 524.4. LC-MS retention time: 8.85 min (10  90% MeCN, 15 
min run). Mass (ESI): m/z 613.07 [M + H]+; 1224.73 [2M + H]+. Exact mass: Calculated for 
[C20H28F9O7P2]+: 613.11611; [C20H28F9O7P2Na]+: 635.09805. Found: 613.11622 [M + H]+; 
635.09790 [M + Na]+.
Synthesis of aldehyde building blocks 33 and 34
Aldehyde 33
The silyl-protected aldehyde was prepared according to literature procedures.4 
4-hydroxybenzaldehyde (1.22 g, 10 mmol) was dissolved in DMF (25 ml), imidazole (0.95 g, 14 
mmol) was added and the reaction mixture cooled to 0 ⊥C. A solution of TBDMS-Cl (1.8 g, 12 
mmol) in DMF (5 ml) was added dropwise and the reaction stirred at room temperature for 4 
h. After removal of the solvent, the residue was taken up in EtOAc and washed with sat. aq. 
NaHCO3 and sat. aq. NaCl, dried (Na2SO4), filtered and concentrated. The crude product was 
subjected to column chromatography (0  5% EtOAc/light petroleum) and obtained as a pale 
yellow oil (2.12 g, 9.0 mmol, 90%). 
1H NMR (CDCl3, 400 MHz): δ 9.89 (s, 1H); 7.79 (d, J = 8.6 Hz, 2H); 6.95 (d, J = 8.5 Hz, 2H); 1.00 (s, 
9H); 0.25 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 190.8; 161.4; 131.9; 130.3; 120.4; 25.5; 18.2; -4.4. 
Aldehyde 34
p-hydroxymethylbenzaldehyde was prepared following literature procedures.5 
Terephtaldicarboxaldehyde (6.71 g, 50 mmol) was dissolved in THF (50 ml). The mixture was 
cooled to 0°C, NaBH4 (0.66 g, 17.5 mmol) was added and the reaction stirred for 4 h. After 
concentration of the reaction mixture, the residue was taken up in EtOAc, water was added 
and the layers separated. The organic layer was washed with water, sat. aq. NaCl, dried (Na2SO4), 
filtered and concentrated. The residue was purified by column chromatography (10  40% 
EtOAc/light petroleum) and the pure compound was obtained as an off-white solid (1.88 g, 13.8 
mmol, 28%). 
1H NMR (CDCl3, 400 MHz): δ 9.99 (s, 1H); 7.87 (d, J = 8.1 Hz, 2H); 7.53 (d, J = 8.0 Hz, 2H); 4.80 (s, 
2H). 13C NMR (CDCl3, 100 MHz): δ 192.1; 147.8; 135.6; 129.9; 126.9; 64.5. 
p-hydroxymethylbenzaldehyde (1.88 g, 13.8 mmol) was protected with the TBDMS functionality 
as described for 33, yielding 34 as a yellow fluid (3.0 g, 12.0 mmol, 87%). 
1H NMR (CDCl3, 400 MHz): δ 10.00 (s, 1H); 7.85 (d, J = 8.3 Hz, 2H); 7.49 (d, J = 8.0 Hz, 2H); 4.82 (s, 
2H); 0.96 (s, 9H); 0.12 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 192.0; 148.6; 135.3; 129.8; 126.2; 




1.  Canning, PSJ, Maskill, H, McCruddem, K, et al.  A product analytical study of the thermal and photolytic 
decomposition of some arenediazonium salts in solution. Bull Chem Soc Jpn. 2002; 75:789-800.
2.  Kumar, P, Zheng, W, McQuarrie, SA, et al.  18F-FESB: Synthesis and automated radiofluorination of a novel 
18F-labelled PET tracer for beta-amyloid plaques. J Labelled Comp Radiopharm. 2005;983-996.
3.  Kikuchi, D, Sakaguchi, S, and Ishii, Y. An Alternative Method for the Selective Bromination of Alkylbenzenes Using 
NaBrO(3)/NaHSO(3) Reagent. J Org Chem. 1998; 63:6023-6026.
4.  Azuma, H, Miyasaka, K, Yokotani, T, et al.  Lipase-catalyzed preparation of optically active 1'-acetoxychavicol 
acetates and their structure-activity relationships in apoptotic activity against human leukemia HL-60 cells. 
Bioorg Med Chem. 2006; 14:1811-1818.
5.  Mak, CC, Bampos, N, Darling, SL, et al.  A strategy for the assembly of multiple porphyrin arrays based on the 













De ziekte van Alzheimer (AD) is de meest prevalente vorm van dementie met veroudering als 
belangrijkste risicofactor. De toenemende vergrijzing gaat dan ook gepaard met een stijgende 
incidentie van AD en drukt hierbij een zware stempel op zowel sociaaleconomisch vlak als op 
de volksgezondheid. De precieze etiologie van deze aandoening is echter onbekend en helaas 
ontbreekt een adequate therapie. Histologisch kenmerkt deze ziekte zich door de ophoping 
van een tweetal eiwitten in de cortex van het brein, namelijk gehyperfosforyleerd τ in 
neurofibrillary tangles en amyloid-β (Aß) peptiden in amyloid plaques. Deze eiwitophoping lijkt 
zich al te voltrekken tientallen jaren voordat de eerste klinische symptomen merkbaar zijn. 
Detectie van deze accumulatie in vivo in een preklinisch stadium is echter nog niet mogelijk. 
Het stellen van de definitieve diagnose is daarom tot op heden afhankelijk van obductie. 
Een diagnostische methode die in staat is de specifieke accumulatie van amyloid plaques en 
de bijbehorende vroege corticale veranderingen te visualiseren of kwantificeren heeft niet alleen 
de potentie voor vroegdiagnostiek, maar leidt daarnaast ook tot een beter begrip van de 
pathofysiologie. Daarnaast kan zo’n methode uiteindelijk zelfs bijdragen tot de ontwikkeling en 
follow-up van een therapie. In dit proefschrift heb ik me dan ook gericht op het ontwikkelen 
van nieuwe diagnostische beeldvormende technieken om de specifieke histologische kenmerken 
van de ziekte van Alzheimer te kunnen detecteren. Daarvoor zijn enerzijds de nieuwe 
mogelijkheden van ultra-hoogveld MRI verkend (Deel Eén) en zijn anderzijds nieuwe molecular 
imaging strategieën ontwikkeld (Deel Twee).
Dat MRI in staat is om individuele amyloid plaques te detecteren is reeds aangetoond in zowel 
transgene AD muismodellen in vivo als in post-mortem humaan hersenweefsel. Recentelijk zijn 
de hiervoor benodigde hoge magnetische veldsterktes (≥ 7 Tesla) beschikbaar gekomen voor 
klinisch gebruik. Door de verhoogde gevoeligheid voor veranderingen in magnetische 
susceptibiliteit en toegenomen resolutie bieden deze ultra hoogveld MRI-systemen nieuwe 
mogelijkheden om AD neuropathologie op te sporen, en wellicht zelfs eerder dan de huidige 
MRI biomarker van atrofie van de hersenen.
In Deel Eén wordt de relatie tussen optredende veranderingen in MRI-contrast of wel natief 
contrast met bijbehorende neuropathologische veranderingen tot op microscopisch niveau 
bestudeerd. Dit begrip is van essentieel belang voor de verdere ontwikkeling van klinisch 
toepasbare MRI-technieken.
Na een korte uitleg over de werking van MRI (hoofdstuk 2), onderzochten we allereerst de 
toepasbaarheid en beperkingen van post-mortem formaline gefixeerd hersenmateriaal voor 
de ontwikkeling van nieuwe MRI-technieken voor het diagnosticeren van AD. (hoofdstuk 3) 
Langdurige fixatietijden veroorzaakte destructie van het normale hersenweefsel zichtbaar als 
hypo-intense gebieden op verscheidene MRI-sequenties. Aangezien vaak formaline gefixeerd 
post-mortem hersenmateriaal voor dit doel wordt gebruikt, raden wij aan alleen met 
hersenweefsel te werken dat minder dan twee jaar gefixeerd is met regelmatige verversing van 
de formaline ter voorkoming van deze artefacten.
De verschillen in resolutie tussen microscopie en MRI evenals de vervormingen die optreden 
tijdens de histologische bewerking bemoeilijken het precies correleren van het MRI contrast 
met het bijbehorende verantwoordelijke pathologische substraat. Om deze 
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registratieproblemen te minimaliseren hebben we een inductie-gekoppelde microcoil 
ontworpen die het mogelijk maakt om rechtstreeks MRI-beelden te vervaardigen van een 
histologische coupe van 60 µm. (hoofdstuk 4) Achtereenvolgens kan deze coupe zonder 
verdere bewerking direct aan de gewenste histologische kleuring worden onderworpen. 
Aangezien zowel de MRI als de histologie op precies dezelfde coupe plaatsvinden is directe 
vergelijking mogelijk. Het ontwerp kan eenvoudig worden geïntegreerd in elke MRI-systeem 
met behulp van bestaande commerciële hardware waarbij een evidente verbetering van de 
signaal-ruisverhouding kan worden bereikt. Initiële toepassing op humaan AD hersenweefsel 
bevestigde voornoemde studies waarbij de accumulatie van Aß in het brein gepaard gaat met 
een focale hypointensiteit op T2*-gewogen MRI.
Eerder onderzoek suggereerde dat louter de neerslag van Aß-peptiden in het hersenparenchym 
in plaques al zou kunnen leiden tot een signaal reductie op MRI onafhankelijk van de mogelijk 
gepaard gaande ijzeraccumulatie. Middels de bovenstaande MR-microscopie setup hebben wij 
getracht de MRI-karakteristieken van de verschillende vormen Aß-deposities in het brein in 
kaart te brengen. (hoofdstuk 5) Alleen de fibrillaire aggregatie in amyloid en niet de diffuse 
plaques leidde tot een signaalverandering in T2* en T2-gewogen MRI. Tevens bleek ook cerebrale 
amyloid angiopathie (CAA) een negatief effect op het MRI signaal te hebben, alhoewel niet voor 
alle soorten CAA een zelfde signaalreductie werd waargenomen. De consequentie van deze 
resultaten is dat MRI in principe in staat is om niet zo zeer de totale cerebrale Aß-load te 
bepalen, maar het Aß-gerelateerde signaalverandering alleen samen hangt met aanwezigheid 
van amyloid plaques, één van de belangrijkste markers van AD.
In hoofdstuk 6 hebben we veranderingen in corticale patronen van gezonde ouderen en AD-
patiënten in vivo onderzocht middels susceptibiliteit gewogen 7T MRI. Tegelijkertijd werden 
soortgelijke corticale patronen eveneens waargenomen bij MRI verricht op post-mortem AD 
hersenmateriaal. Dit materiaal bood tevens de mogelijkheid tot correlatie met de onderliggende 
corticale pathologie verantwoordelijk voor deze signaal veranderingen. De frontale cortex van 
AD-patiënten presenteerde zich in vivo met een diffuse hypointense corticale band (57%), terwijl 
deze niet werden geobserveerd bij gezonde controles van dezelfde leeftijd. Uit de histologische 
studie bleek dat het corticale patroon op MRI niet primair overeenkwam met de distributie van 
amyloid plaques of neurofibrillaire tangles, maar het liet een duidelijk correlatie zien met 
microglia- en myeline-geassocieerde ijzer ophoping alsmede een veranderde corticale myeline 
cytoarchitectuur. Deze resultaten zijn veelbelovend voor de in vivo detectie van de onderliggende 
pathologische veranderingen in AD middels MRI. Toekomstig onderzoek dient uit te wijzen of 
dit corticaal patroon specifiek is voor AD.
Deel Twee beschrijft de ontwikkeling van doelgerichte contrastmiddelen voor de specifieke in 
vivo detectie en visualisatie van verschillende Aß-aggregaten, zoals CAA en amyloid plaques. In 
vivo implementatie van zulke moleculaire imaging strategieën voor het bestuderen of 
diagnosticeren van neurodegeneratieve ziekten is in sterkte mate afhankelijk van de 
karakteristieken van de gekozen imaging ligand, zoals de detectielimiet  en het vermogen om 
de bloed-hersen barrière (BBB) te passeren. In dit kader bespreekt Hoofdstuk 7 de 
mogelijkheden met betrekking tot moleculaire neuro-imaging middels MRI. 
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Voorafgaand aan deze thesis hebben we heavy chain antilichaamfragmenten (VHH) geselecteerd 
die zich uitsluitend binden aan CAA versus verscheidene VHHs die zowel CAA als alle 
parenchymateuze humane Aß-deposities herkennen. Afkomstig uit het antilichaamrepertoir 
van de Camelidae ontbreekt bij deze klasse antilichamen de licht ketens, maar desondanks heeft 
het N-terminale domein ofwel het VHH-fragment een vergelijkbare hoge en specifieke affiniteit 
als die van conventionele antilichamen. De potentie van VHH om als in vivo contrastmiddel CAA 
en/of cerebraal Aß te detecteren hangt af van hun vermogen om in het brein te geraken. In 
Hoofdstuk 8 is de mogelijke BBB passage getest met een middels een in vitro BBB systeem. 
De CAA-specifieke VHH ni3A transmigreerde het meest efficiënt over deze barrière via een actief 
transport mechanisme.  Het verschil in transmigratie ten opzichte van andere VHH lijkt 
grotendeels te berusten op aanwezigheid van een drietal specifieke aminozuren in het 
N-terminale domein.
Als volgende stap, zijn in hoofdstuk 9 de in vivo eigenschappen onderzocht van een tweetal 
radioactief of fluorescent gelabelde VHH, ni3A en pa2H, na toediening in transgeen AD 
muismodel. Na een initiële snelle renale klaring liet 99mTc-pa2H een dag na de injectie een 
significant hogere opname zien in het brein van de transgene AD muizen. Na het omzeilen van 
de BBB werd voor beide fluorescent gelabelde VHH de in vivo specificiteit voor Aß bevestigd, 
waarbij pa2H zelfs 24 uur na toediening goed zichtbaar bleef. Opvallend echter was dat beide 
VHH affiniteit vertoonden voor zowel het parenchymale als het vasculaire Aß in het muizenbrein, 
dit in tegenstelling tot eerdere toepassing op humaan hersenweefsel, waarbij ni3A uitsluitend 
CAA detecteerde. Ondanks dat de cerebrale accumulatie zich nog ver beneden de detectielimiet 
bevindt nodig voor in vivo beeldvorming, laat deze studie zien dat VHHs in staat zijn om cerebraal 
Aß te detecteren en vormt hiermee een basis voor verdere ontwikkeling en verbetering.
Hiernaast is een geheel andere strategie gekozen voor de detectie van amyloid plaques, namelijk 
door het ontwikkelen van kleine organische amyloid bindende moleculen. Hoofdstuk 10 
beschrijft de synthese van gefluorineerde bis-styrylbenzenes als mogelijke 19F-MRI 
contrastmiddelen alsmede hun fluorescente en Aß bindingskarakteristieken. Idealiter passeren 
deze kleine organische moleculen de BBB en binden daar aan amyloid waarbij het 
geincorporeerde fluor direct detecteerbaar is middels MRI zonder enig endogeen 
achtergrondsignaal. De meeste verbindingen vertoonden een hoge affiniteit voor Aß plaques 
van zowel muizen als mensen. Ze bleken echter een andere bindingsplaats te hebben dan 
chrysamine G, één van de oorspronkelijke verbindingen waarvan onze bis-styrylbenzenes zijn 
afgeleid. Ondanks een hoge logP waarde waren bijna alle gefluorineerde bis-styrylbenzenes in 
staat om in vivo de BBB te passeren en aan amyloid te binden in de transgene AD muizen. 
Initiële post-mortem 19F nuclear spin resonantie (NMR) verricht voor de meest veelbelovende 
verbinding toonde echter aan dat verder MRI studies nog niet te rechtvaardigen zijn gezien de 
significante reductie van de 19F-signaal , welke voornamelijk een direct gevolg lijkt te zijn van 
samenstelling van het hersenweefsel.
Om de farmacokinetiek mogelijk ter verbeteren wordt in Hoofdstuk 11 de synthese en 
karakteristieken van zes bis-pyridylethenylbenzenes beschreven met het idee dat het 
incorporeren van een stikstofatoom dergelijke structuren meer hydrofiel zou kunnen. Ook deze 
verbindingen delen geen bindingsplaats met chrysamine G. Met een logP waarde tussen 3 en 
5 waren alle verbindingen in staat om in vivo de BBB te passeren en het amyloid in het brein 
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te labelen. Op basis van de in en ex vivo eigenschappen en de oplosbaarheid toonde bis-(4-
pyridylethenyl)benzene de meeste potentie om als backbone te dienen voor verdere 
ontwikkeling tot een amyloid imaging biomarker, bijvoorbeeld als mogelijke PET-tracer. 
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